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Abstract 
Skin cancer is reported to incur the highest treatment costs of all cancers. The treatment 
cost of non-melanoma skin cancer (NMSC) was purported to be around AUD$264 million, 
and AUD$30 million for melanoma in 2001. Conventional skin biopsy techniques are 
performed to identify histopathological signs of malignancy. Suspicious lesions are often 
present on cosmetically sensitive areas and may be present in large numbers, making 
biopsies unfeasible. As a result, many atypical lesions are left untreated (leaving patients 
with early cancerous lesions) or needlessly removed (unnecessary scars). Prognostic 
biomarkers are useful for assessing borderline cases to facilitate early detection of skin 
cancer. The development of a novel microbiopsy device (Figure 1.1) from this Thesis 
enables quick, simple, minimally invasive and suture-free sampling of tiny skin samples 
sufficient for molecular assays.  
Laser cutting technologies have enabled rapid prototyping of microbiopsy devices made 
from medical-grade stainless steel. Through optimisation of the laser parameters, a two-
dimensional microbiopsy that assembles to form a three-dimensional cutting tip with a 
hallow chamber was successfully constructed. A quick and safe method to facilitate 
repeated collection over time in human patients is now possible with the microbiopsy-
based approach. 
Characterisation studies revealed approximately 1000 to 3000 cells from each velocity-
aided microbiopsy with an average DNA and RNA yield of 5.9 ± 3.4 ng and 9.0 ± 10.1 ng, 
respectively.  Human volunteer studies have shown that the microbiopsy application 
Figure 1.1: Diagrams of a conventional punch biopsy and three-dimensional Microbiopsy 
cutting tip. 
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velocity, channel width, edge surface roughness and geometries were important aspects 
to achieve reproducible tissue sampling.  
Genomic profiling of an individual can now be done using microbiopsy sampling approach 
instead of conventional blood or saliva samples. The limitation of small sample size can be 
overcome by using high-fidelity amplification technologies for amplifying nucleic acids. The 
defects left by microbiopsy application observed in histopathological sections were similar 
to artefacts arising from routine tissue processing. This opens up opportunities for the 
possibility of in vivo sampling and enables molecular diagnosis without the risk of 
damaging the lesion - which will help to improve patient care by reducing unnecessary 
excision. Proof-of-concept studies have established the potential of the guided skin 
microbiopsy device to study in vivo molecular changes within a targeted area over time, 
which was impossible in the past. 
Other than clinical applications, the microbiopsy device also offers a novel approach for 
live cell assays. Current approaches, in particular those related to the cosmeceutical arena 
are limited to restrictive regulations on animal testing, and the fact it is often not deemed 
ethical or practical to use conventional biopsy techniques to assess the effect of 
cosmetics. One debatable topic in this arena is the likelihood of nanoparticles to infiltrate 
the viable epidermis and cause cell toxicity. Human volunteers treated with common 
nanoparticle UV-filters showed that no metabolic changes occurred in the viable cells even 
when the skin barrier was disrupted.  
In the final exploratory studies of this Thesis, various downstream omics technologies 
were used to analyse the microbiopsy samples. The key take-home message from these 
studies was the technical variations observed for small sample input. Moving forward, it is 
of priority to address how this issue can be overcome to validate the accuracy of biological 
information the microbiopsy sample represents.  
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 Chapter 1
Introduction and Literature Review 
 Introduction 1.1
Australia has the highest skin cancer burden compared to the rest of the western world. 
The total cost for treating non-melanoma skin cancer (NMSC) and melanoma in 2001 was 
$264 million and 30 million (Goss J. and Mann N., 2005), ranking skin cancer the most 
expensive treatment among all cancers (Fransen et al., 2012). Conventional biopsy 
techniques can provide accurate prognosis of the disease occurrence and progression but 
they are painful, often require suture, and render the area unsuitably damaged for further 
scientific study. Patients may be present with many questionable lesions and removing 
that many lesions is impractical. The development of a minimally invasive biopsy device 
could prove to be useful in detecting skin cancer earlier and resolving some difficult 
differential diagnoses. Furthermore, molecular fingerprinting of skin disease has the 
potential to dramatically improve diagnostic sensitivity and open the door for personalised 
medicine. 
Animal testing of cosmeceutical ingredients have been banned in many countries including 
the European Union, Norway, Israel and India. Association of Southeast Asian Nations, 
United States (USA) and South Korea are also moving forward to introduce this legal 
prohibition. The closest alternative to animal testing for toxicity screening is done in vitro. 
Toxicology and efficacy studies of drug candidates and chemicals can be performed in live 
cells acquired by the Microbiopsy devices. Accordingly, it provides a more relevant system 
to execute these assessments. The Microbiopsy is developed for skin tissue sampling in 
human adults for molecular analysis and toxicology assessment, but its application can 
also be extended into paediatrics and animal studies. This Thesis discusses the 
development and validation processes of the first minimally invasive micro sampling tool 
for the skin. 
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 Conventional skin sampling for diagnostics in dermatology 1.2
Skin biopsy is one of the most essential techniques that results in accurate diagnosis of 
melanomaand NMSC through histopathological assessment. This technique is performed 
under local anaesthetic by trained personnel, normally a dermatologist, to remove a small 
skin sample (2 - 4 mm) that is then sent to a pathologist for histopathological examination. 
Pathological examination using skin biopsy often complements and/or confirms the 
diagnosis of common neoplastic skin diseases where clinical appearance of lesions is 
insufficient to obtain an accurate diagnosis (Sina et al., 2009). Incisional (Figure 1.1a and 
1.1b) and excisional biopsies are the two main types of skin biopsies. Incisional biopsy 
involves partial removal of a lesion, and is preferred when a wider or deeper portion of the 
skin is needed. An excisional biopsy is performed when the entire tumour is needed for 
histopathological examination, or when melanoma is suspected (Pickett, 2011b).   There 
are six key biopsy techniques to perform biopsy of the skin. The selection to the type of 
Figure 1.1: Skin biopsy techniques. 
Diagrams and clinical photographs of different skin biopsy procedures including incisional 
biopsy (a – b), snip biopsy (c – d), punch biopsy (e – f), shave biopsy (g – h), saucerisation 
biopsy (i – j), and curettage biopsy (k – l). Figure modified with permission from (Bolognia et al., 
2012) Copyright © 2012, Elsevier.  
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technique employed depends on the type and size of lesion (Bolognia et al., 2003).  
1.2.1 Snip biopsy  
Snip or scissors biopsy are used to remove extruding elongated (i.e. pedunculated) lesions 
(Figure 1.1c and 1.1d). Lesions with very narrow neck can be quickly biopsied without the 
need for local anaesthetic. The tissue is held by a toothed forceps and the lesion is 
detached from the base of the skin using a pair of fine iris or sharp gradle scissors. This 
method of biopsy produces small and often hypo-pigmented macule that may be hard to 
identify (Bolognia et al., 2003). 
1.2.2 Punch biopsy 
Punch biopsy is the primary procedure physicians use to obtain full-thickness skin samples 
of inflammatory skin lesions (Figure 1.1e and 1.1f). The size of punch biopsy available 
ranges from as small as 0.35 mm and up to 12 mm. The standard of care is to take a 
biopsy for conventional histopathological examination but a 0.35 mm punch biopsy is too 
small for such analysis. Typically, a cylindrical piece of tissue is obtained by rotating and 
pressing the circular blade into the skin’s topmost subcutaneous fat. The skin specimen 
must be carefully removed using a fine needle to avoid artefacts. Punch biopsy is 
potentially useful for diagnosis of inflammatory lesions and is also often used for neoplastic 
skin conditions. This simple technique can be taught easily and gives similar cosmetic 
outcome for 1 to 4 mm biopsies. On the down side, this procedure may not provide 
sufficiently wide skin specimen depending on the lesion, given the narrow and deep nature 
of biopsy. This might affect prognosis and tumour staging but the error can be minimized 
by taking multiple biopsies. Depending on the size of the skin lesion, the most common 
sizes of punch biopsy that are routinely used in the clinics are 2-4 mm. Other limitations 
include the need for local anaesthetic, bleeding, need for suture, and possible damage to 
arteries, veins or nerves on thin skin areas (e.g. face or dorsum of hand) (Australian 
Cancer Network Melanoma Guidelines Revision Working Party, 2008, Pickett, 2011b, Sina 
et al., 2009, Zuber, 2002).  
1.2.3 Shave biopsy 
Shave biopsies are shallow removal of lesions confined to the depth of the dermis (Figure 
1.1g and 1.1h). The technique is performed using a scalpel, dermablade, a razor blade, or 
scissors. Shave biopsies are most commonly performed because it is a low cost 
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procedure, easy to perform, and have simple post-biopsy wound care. Shave biopsies are 
commonly used for lesions that are mainly epidermal, such as warts, papillomas, skin tags, 
superficial basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), and seborrheic 
or actinic keratoses (AK) and not melanomas (Pickett, 2011b, Swanson et al., 2002).  
1.2.4 Saucerisation (deep scoop shave) 
A saucerisation or deep scoop shave, as the name implies, is a biopsy that involves 
excision through viable dermis and into the reticular dermis or even sub-cutis (Figure 1.1i 
and 1.1j). The procedure is quick and easy to perform, and leaves an oval scar. This 
technique provides adequate tissue for histopathological examination. The disadvantage 
of saucerisation is the occurrence of scoop scars that reform over many years that may 
include residual melanocytic lesions left over by an incomplete excision. These recurring 
naevi resemble the appearance of a melanoma that is hard to distinguish, and may result 
in a second excision causing distress to the patient (Swanson et al., 2002).    
1.2.5 Curettage biopsy 
Curettage biopsy (Figure 1.1k and 1.1l), also known as the broad superficial shave 
biopsy, provides a larger area of epidermis for histology. However, this technique usually 
does not remove sufficient dermis for full assessment of invasion. Hence, curettage biopsy 
is limited to lesions that are likely to be confined to the epidermis. This biopsy method 
involves applying pressure under or through the lesion using a curette that is 3 – 5 mm in 
diameter. The benefit of curettage biopsies is that the patient will heal with little or no 
scaring, with resulting good cosmesis (i.e. biopsies can be performed on sensitive areas 
such as the face) (Australian Cancer Network Melanoma Guidelines Revision Working 
Party, 2008, Bolognia et al., 2003).  
1.2.6 Excisional biopsy 
This technique is commonly performed by dermatologists as well as family physicians for 
removal of full-thickness lesions. Excisional biopsy has been previously referred to as an 
elliptical biopsy because of the biconcave appearance of the wound. The incision area 
should have a three to one length-to-width ratio which will give an angle of less than 30 
degrees at the ends of the wound. Typically, doctors who are experienced in skin surgery 
can often perform the procedure unsupervised after two to five guided sessions. It is a 
technique that offers cosmetic and diagnostic advantages in certain clinical situations. The 
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excisional technique is recommended for obtaining biopsy samples of any pigmented 
lesions that is suspected as melanoma (Zuber, 2003). 
 Emerging skin sampling techniques for biomolecular diagnostics 1.3
Histopathological assessment is the reference standard for many inflammatory and 
neoplastic skin diseases but it is limited by the qualitative nature and analytical variability 
(Taylor, 2000). The changes in skin biochemistry have been widely observed in various 
skin diseases. These biomolecular changes can provide opportunities for disease 
diagnosis and to assess therapeutic responses. Conventional skin biopsy is one of the 
common methods to sample the skin’s biomolecular information as it allows collection of 
partial to full thickness of skin. This method, however, is unsuitable as a routine approach 
due to its invasive nature (Schrolnberger et al., 2001), and the biomolecular extraction 
approaches from these samples are usually multi-step and technically involved.  
Less invasive techniques are necessary as alternative diagnosis if monitoring of the 
lesions over time is required. Techniques such as tape-stripping, iontophoresis, 
ultrasound, suction-blister, microneedle, electroporation are some of the less invasive or 
minimally invasive methods to sample skin tissue or constituents. The pros and cons of 
these techniques are summarised in Table 1. Most of these techniques are developed to 
sample small molecules including drugs, protein and peptides (Rao et al., 1995, Benfeldt 
et al., 1999, Schmelz et al., 1997, Kost et al., 2000, Mukerjee et al., 2004, Escobar-
Chavez et al., 2008, Paliwal et al., 2010, Nair et al., 2014) to study pharmacokinetics and 
monitoring of therapeutic drugs etc. Conventional skin biopsy and tape-stripping are the 
only two methods that enable collection of skin cells for extraction of molecular materials 
(Morhenn et al., 1999, Schrolnberger et al., 2001).  
Starting in the late 1990s, tape-stripping has been employed as a non-invasive approach 
to sample messenger RNA (mRNA) to study cytokine expression profiles to differentiate 
irritant from immunological reactions (Morhenn et al., 1999). Wachsman et al. have 
recently also demonstrated the non-invasive method of tape-stripping, together with a 
gene classifier, as an alternative method to detect genomic biomarkers for melanoma 
(Wachsman et al., 2011). The group utilised a patented non-invasive method, epidermal 
genetic information retrieval (EGIR™), to sample RNA from stratum corneum using four 
pieces of custom adhesive tapes that successfully identified 312 differentially expressed 
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genes related to melanoma. With the use of a data mining algorithm, they subsequently 
developed a 17-gene classifier from the microarray dataset based on 39 melanomas and 
89 naevi that provides 100% sensitivity and 88% specificity in melanoma detection.  
Table 1: Sampling techniques to collect skin tissue or constituents. Modified from (Paliwal 
et al., 2013), Copyright © 2013, Elsevier B.V. 
Sampling 
methods Advantages Disadvantages 
Skin biopsy Morphology, gold standard for 
skin diagnostics. 
Most invasiveness, potential 
recovery problems, need of 
liquefying to assess native 
chemistry. 
Tape-stripping Rapid, convenient, minimally 
invasive. 
Lack of standardised protocol and 
heterogeneous sampling. 
Iontophoresis Minimally invasive, 
administration for skin vessel 
reactivity. 
Local irritation. 
Ultrasound Minimally invasive and 
bioreactive protein harvesting 
method with detergent mixture. 
Potential denaturation of 
biomarkers, complex device. 
Microdialysis Minimally invasive and 
continuous method without 
contamination. 
Time-consuming, long recovery 
time, not for large molecules and 
proteins, detection sensitivity. 
Suction-blister Simple and possible proteomic 
analysis. 
Topical anaesthesia, time-
consuming. 
Electroporation Minimally invasive. Complex device, limited clinical 
data. 
Microneedles Minimally invasive and simple to 
use. 
Possible irritation, limited data on 
extraction. 
Submillimetre 
biopsy  
Rapid, simple to use, minimally 
invasive, may not require local 
anaesthetic. 
Insufficient sample for 
histopathological analysis. 
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Concurring with Wachsman et al., a minimally invasive sampling approach to discriminate 
benign from neoplastic lesions may provide more objective diagnosis than clinical 
assessment or optical diagnostics. It also improves patient care by subjecting reduced 
discomfort and possible risk of complications. These are the driving force behind the 
minimally invasive microbiopsy device that was described in this Thesis (Lin et al., 2013). 
Unlike the tape-stripping technique where non-nucleated cells (stratum corneum) are 
collected, the conventional skin biopsy device samples into the dermis. Thus, samples 
from this device can be processed for both DNA and RNA to analyse not only gene 
expression but also mutational profiling, DNA profiling and copy number variations. In 
addition, the noise-to-signal ratio in gene expression profiles of mRNA samples from tape-
stripping will be higher than microbiopsy due to high content of corneocytes/keratinocytes 
within the samples. Therefore, skin biopsy samples can provide more robust detection. 
Other than the use of molecular analyses for facilitating diagnosis of suspicious lesions, 
the majority of current medical procedures to provide diagnosis and prognosis are 
performed using non-invasive tools and techniques. Other than clinical examinations, 
diagnostic imaging is the other non-invasive technology that is commonly carried out by 
physicians to assess states of health and disease.  
 Non-invasive tools and techniques for skin diagnostics 1.4
Conventional biopsy for histopathology assessment may be the gold standard for skin 
lesion diagnosis. However, it can be time-consuming, painful, and can be disfiguring in 
cosmetically sensitive areas. Given when 26.6% of assumed premalignant and malignant 
lesions were benign (Hallock and Lutz, 1998), this may lead to non-compliance in patients. 
Non-invasive imaging modalities were developed to provide examination and visualisation 
of the skin and its organisational structure without the need of conventional skin biopsy.  
These modalities have shown to increase diagnostic accuracy by improving the clinical 
examination and reducing variability between physicians (Goodson and Grossman, 2009), 
particularly in the pigmented lesions. The utility of these imaging modalities were 
established mostly in screening and diagnosis of melanoma (Ferrari et al., 2014, Salerni et 
al., 2014, de Giorgi et al., 2005). Dermoscopy and reflectance confocal microscopy (RCM) 
are one of the few imaging modalities which have shown promising results for accurate 
diagnosis of non-melanoma skin cancer (Longo et al., 2014a, Ulrich et al., 2008, Rishpon 
et al., 2009, Peppelman et al., 2014).  
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1.4.1 Dermoscopy 
Along with training and experience, the use of dermoscopy can significantly increase 
clinical diagnosis of non-invasive clinical diagnosis of pigmented (melanocytic and non-
melanocytic) and non-pigmented lesions. The dermatoscope (Figure 1.2a) is a magnifier 
that enables improved visualisation of colour and structures of skin that cannot be 
perceived by the naked eye (Soyer et al., 2011). The use of liquid interface conventional 
(non-polarised) or cross-polarised light dermoscopy phases out light reflection, increases 
the transparency of the stratum corneum and facilitates visualisation of the skin structure 
in deeper layers. In polarised dermoscopy, cross-polarisation of light as achieved with two 
filters (Figure 1.2b). Part of polarised light penetrates the skin and the rest is reflected at 
the stratum corneum. The penetrated light is backscattered and loses its polarisation after 
numerous scatterings. The superficially reflected light at the stratum corneum is selectively 
blocked by the second filter that is placed between the skin and the detector, while 
capturing the backscattered light from deeper layer of the skin to reach the eyes 
(Anderson, 1991). 
The capabilities of conventional and polarised dermoscopy were different but comparable 
in patterns, colours and structures to varying extents (Benvenuto-Andrade et al., 2007). An 
example in the capability differences of conventional and polarised light dermoscopy is 
shown in Figure 1.2c-d.  Better visualisation of the red areas such as the vessels was 
seen with the polarised dermoscopy. In addition, melanin that is seen as dots and streaks 
appeared darker and the blue naevi had more shades of blue. Other features like milia-like 
cysts, peppering, comedo-like openings, blue-white areas and lighter colours were 
enhanced with conventional dermoscopy (Benvenuto-Andrade et al., 2007).  
Dermoscopy has been integrated with different non-invasive platforms including digital 
imaging system, computer-based analysis and laser-based technologies. The use of 
dermoscopy in combination with total body photography was proven beneficial in early 
diagnoses of skin cancer (Salerni et al., 2014). 
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1.4.2 Total body photography 
Total body photography (TBP) (Figure 1.3) uses a series of high resolution digital 
photographs taken from different body sectors to screen for melanoma in high-risk 
patients.  It was shown that patients with high total body naevi counts of more than 100 
compared to those who had less than 10 naevi had increased risk of melanoma by 12 
times (Grulich et al., 1996).  A surveillance study over the course of 13 - 120 months was 
conducted to evaluate the value of two-step digital follow-up procedures (total body 
photography followed by dermoscopy) for early diagnosis of melanoma with 618 high risk 
patients (Salerni et al., 2012). A total of 11,396 lesions were monitored, and of which 1152 
were excised and assessed for histopathology. Of the patients, 556 had moderate to 
severe atypical mole syndrome, where 57.6% had more than 100 naevi. Approximately 
44.8% had personal history of melanoma and 28.8% had a familial history of melanoma. In 
total, 53 melanoma in-situ (0.05%) and 45 invasive melanomas (0.04%) with less than 1 
Figure 1.2: Cross-polarised light dermoscopy in melanoma diagnosis. 
Panel (a) shows a commercially available hand-held polarised dermoscopy. Polarised light is 
formed when part of the non-polarising light passes through the first filter and emerged. Cross-
polarised light is achieved when polarised light beam is blocked when passing through a second 
filter that is perpendicular to the first filter (b).  Example of a seborrheic keratosis documented 
with a non-polarised dermoscopy and a polarised dermoscopy are shown in Panels (c) and (d) 
respectively. Figure modified with permission from (3Gen, 2014), Copyright © 2015, 3Gen and 
(Wang et al., 2008), Copyright  © 2008, Blackwell Publishing Ltd. 
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mm Breslow index were diagnosed from the 1152 excised lesions. Salerni et al. (2012) 
concluded that the dual modality allowed detection of early stage melanoma that had few 
dermatoscopic features or were new or had arisen from monitored existing naevi.  
 
Majority of the pigmented lesions are stable and do not undergo significant changes, while 
some regressed and new ones can appear over a course of time. This technique facilitates 
sequential comparison of lesions, enabling physicians to identify new and/or changing 
lesions (Feit et al., 2004). Out of the 93 biopsied melanocytic lesions, 43 of them (56%) 
were excised due to changes in color or size from baseline photographs. Twenty of these 
43 (47%) melanocytic lesions were histologically diagnosed as malignant melanoma. A 
total of 18 lesions (23%) were newly identified lesions from baseline and of which, five 
(28%) were diagnosed as malignant melanoma. Feit et al. have concluded from their study 
that TBP has faciliated detection of melanoma by monitoring subtly changing lesions and 
identifying newly appeared ones. They concluded that TBP provided valuable information 
to prevent unncessary biopsy of suspicious but stable melanocytic lesions (Feit et al., 
2004).  
Figure 1.3: Total body photography system from Dermagraphix™ imaging software. 
A series of body sectors in standard poses are documented from an individual to accurately 
map and track lesions, especially in pigmented lesions. Dermoscopy and close-up photographs 
are linked to individually marked lesions. Figure reproduced with permission from (Feit et al., 
2004), Copyright © 2004, John Wiley & Sons, Inc. 
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Risser et al. compared the number of biopsies in 128 patients who received either total 
body examination alone to those who were assessed in combination with TBP to 
determine the impact of this technique on the rate of biopsy (Risser et al., 2007).  The 
average number of biopsy was similar for patients who only had total body examination 
and those who received TBP (0.82 vs. 0.8, respectively). They did not observe an effect of 
TBP on the number of biopsies and on the number of dysplastic naevi based on the chart 
review analysis. Unlike Feit et al., they had a control patient group to determine whether 
TBP has any impact of the biopsy rate. The limitation of their study was the lack of 
information on the reason for biopsy due to the study design and the number of patients 
reviewed were also smaller. However, they did support that TBP allowed detection of 
changes in melanocytic lesions and this has changed the physicians’ behavior in biopsy 
decision-making (Risser et al., 2007). The downside of this technology is the variable cost 
involved as it is dependent on the sophistication of the equipment used.  
1.4.3 Reflectance confocal microscopy 
Reflectance confocal microscopy (RCM) or confocal scanning laser microscopy (CSLM) 
enables real-time in vivo examination of the skin using the visible or near-infrared range 
low power laser. The first rapid RCM prototype that had the capacity to provide high-
resolution and good correlation compared to conventional histology was built by 
Rajadhyaksha and his colleagues in 1995 (Rajadhyaksha et al., 1995). RCM is the only 
technique that has the necessary resolution for histological analysis. The low power laser 
creates a small beam spot that is focused at the skin. Light that is reflected from the focal 
point towards the objective lens that is then focused through a pinhole spatial filter and 
detected by the photodetector at the back (Figure 1.4a). The cellular organisation and 
structure details that can be seen within the dermoscopy image (Figure 1.4b and d) are 
translated into a two to 5 µm thick optical section (Figure 1.4c and e).  
Different epithelial tissues such as skin and oral mucosa in their healthy and diseased 
states have been characterised with RCM (Contaldo et al., 2013, Gonzalez et al., 1999, 
Wurm et al., 2012, Rishpon et al., 2009). This imaging platform has been proven as a 
useful diagnosis tool to detect melanoma and non-melanoma skin lesions, particularly 
BCC (Nori et al., 2004, Pellacani et al., 2014, Rishpon et al., 2009, Ulrich et al., 2008).  
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Nori et al. completed a multicenter, retrospective study where they aimed to determine the 
sensitivity and specificity of RCM images for BCC diagnosis (Nori et al., 2004). 
Additionally, they combined photography-based clinical assessment and RCM to 
determine if this approach will provide more accurate diagnosis of BCC. Out of the 152 
skin lesions, 83 BCCs were clinically detected and confirmed by histopathology. Blinded 
retrospective analysis based on 5 selected diagnosis criteria that were previously identified 
(Gonzalez and Tannous, 2002) was performed to assess the correlation of these 
characteristics in BCC lesions. The sensitivity and specificity for presence of ≥2 criteria 
was 100% and 53.6%, respectively. Increasing the number of criteria to 4 ≥ decreased the 
sensitivity to 82.9% but increased the specificity for BCC to 95.7%. Two dermatologists 
categorised the likelihood of BCC diagnosis based on high quality clinical images alone 
and when used in combination with RCM analyses. The addition of RCM analyses 
increased the diagnosis from 58.72% to 90.74% in the high probability category while the 
accuracy was increased to 90.00% from 47.06% in the low probability category. The study 
concluded that diagnosis of BCC using presence of 4 or more RCM criteria provided the 
Figure 1.4: Set-up of reflectance confocal microscopy. 
Panel (a) illustrates the optical set-up of the reflectance confocal microscopy. Figure modified 
with permission from (Piston et al., 2013) Copyright © 2013 Nikon and (Longo et al., 2014b) 
Copyright © 2014 Elsevier B.V. 
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most ideal compromise, enabling accurate detection with high sensitivity and specificity 
(Nori et al., 2004). 
Pellacani and his colleagues also found that the use of RCM provided a second-level 
examination that improved diagnostic accuracy in equivocal lesions and can prevent 
unnecessary excisions (Pellacani et al., 2014). This conclusion has also been established 
in other studies (Pellacani et al., 2007, Guitera et al., 2009, Segura et al., 2009, Gerger et 
al., 2008). They have shown that RCM had recommended excision for 23 melanomas and 
19 BCCs, 121 Clark naevi eight Spitz naevi and 12 benign non-melanocytic lesions. 
Eighty-three percent of 23 melanomas and 95% of 19 BCCs of same diagnosis that was 
confirmed with histopathology was made using RCM. RCM was proven to provide 76.3% 
diagnostic accuracy for melanomas and 89.4% for BCCs. The number of benign lesions 
that was excised for every melanoma (NNE) reduced from 14.6 to 6.8 with RCM 
examination (Pellacani et al., 2014). The ability of RCM to distinguish precancerous from 
malignant lesions is also true for an SCC model. RCM features such as presence of 
architectural disarray in the viable epidermis and nest-like structures in the dermis resulted 
in significant odd ratios for SCC (11.0 to 24.0). The presence of architectural disarray in 
stratum granulosum alone in combination of all three features provided diagnosis accuracy 
between 84.6% to 88.5% (Peppelman et al., 2014).  
One of the limitations RCM faces is the penetration depth of the technology. The maximum 
imaging depth is between 150 to 200 µm and images past this become unclear. This limits 
the usefulness of RCM to only non-thickened skin area. Another limitation is pathology 
diagnosis as the images are presented in black and white, depending on the reflective 
index of the cellular structures, while conventional histopathology has colour and 
immunohistochemistry information. This requires training and experience in order to 
competently make a diagnosis. 
1.4.4 Optical coherence tomography 
Optical coherence tomography (OCT) is based on low coherence interferometry to 
generate two- or three-dimensional cross-sectional images by detecting the intensity of 
backscattered light and echo delays. This technique is similar to that of high frequency 
ultrasound (HFU) imaging only that the latter measures acoustic waves instead. Maximum 
imaging depth is achieved by targeting the window of transmission where the absorption 
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and scattering in the specimen is minimised. In the case of tissue imaging, this window of 
transmission is attained with a wavelength between 700 and 1300 nm (Gambichler et al., 
2011).  
OCT has been widely used in the field of ophthalmology to measure retinal thickness 
(Massin et al., 2001, Lim et al., 2005, Alamouti and Funk, 2003). This technology was then 
introduced in dermatology in the late 1990s. The OCT has an optical resolution of 3-15 
mm and can image up to 1 mm in depth (Kardynal and Olszewska, 2014). Hinz et al. have 
shown that OCT has a stronger correlation with histopathology than HFU (Spearmen 
correlation, r = 0.734) (Hinz et al., 2011). They compared the tumor thickness of 26 
melanocytic lesions measured from histopathology to OCT and HFU. The median tumor 
thickness on histopathology was 0.25 mm while OCT and HFU were 0.31 mm and 0.44 
mm, respectively. The concluded that OCT provides more accurate tumour depth than 
HFU that is frequently used for surgical planning for cutaneous melanocytic lesions (Hinz 
et al., 2011). OCT may have a lower resolution compared to RCM but it can provide real-
time imaging to detect gross alteration in skin structure that can be easily correlated to 
conventional histopathology (Figure 1.5). Others have also demonstrated that OCT has 
potential to discriminate benign from malignant skin lesions (Gambichler et al., 2007, 
Boone et al., 2015). This may be one explanation for the rapid gain of popularity of this 
technology for clinical diagnostics. Despite the advances made in optical imaging for 
clinical diagnosis, all these technologies are limited either by the imaging penetrance 
depth, optical resolution and/or the need of training/experience. The lack of objective 
diagnosis also applies to optical diagnoses. Therefore, there is a need of a suitable 
sampling tool that can be used routinely for molecular diagnosis. This drives the invention 
of minimally invasive micro-devices in many medical fields.  
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 Novel minimally invasive tools for micro-sampling 1.5
There is an emergence of micro devices for minimally invasive tissue biopsy since mid-
1990s.  Experimental diagnostic devices are evolving towards miniaturised version of their 
predecessors. This miniaturisation trend is supported by improved micro-manufacturing. 
The results of these efforts are usually first published as patents and patent applications. 
One of the earliest micro-devices developed to obtain biopsy was patented by Krulevitch et 
al. (Krulevitch et al., 1999). Their invention involves microbiopsy/precision cutting devices 
Figure 1.5: Capacity of OCT images compared to histopathology to detect structural 
changes. 
Examples of OCT images compared to corresponding histopathology sections in various tissue 
engineered skin models: oral mucosa (a and b), D20 model of invasive carcinoma (c and d), 
severely dysplastic skin (e and f) and Cal27 model of invasive carcinoma.  Reproduced  with 
permission from (Smith et al., 2011), Copyright © 2011, SPIE. 
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fabricated by conventional machining, silicon micromachining, precision machining and 
injection moulding. 
Pflueger and Capistrano filed a patent in 2004 for claims of a novel micro-invasive breast 
biopsy device. The device contains a handpiece coupled with motorised tissue removal 
mechanism. Part of the tissue removal mechanism includes a cannula with a rotatable 
element to allow extension of an open distal tip with an outer diameter of > 5mm. The 
extension of the distal tip past the rotating element will facilitate tissue biopsy samples to 
prolapse with each turn of the helical threading (Pflueger, 2002). 
Another research group from Korea in 2005 published findings of their micro-scale biopsy 
tool prepared using crystal silicon. The tool is a single planar micro-spike with a dimension 
of 3 mm (length) by 0.250 mm (width) by 0.100 mm (thickness). Their findings concluded 
that the micro-scale biopsy tool requires protruding barbs to facilitate successful tissue 
biopsy as those features help to tear off and retain tissue samples. The team effectively 
obtained biopsy samples from small intestine of the anaesthetised rabbit and pig (Byun S., 
2005). Seven years after publishing their first data on the device, they filed a patent to 
introduce the device as a micro-electromechanical system-based (MEMS) micro-biopsy 
catheter that includes a disposable micro-biopsy tool (Cho D., 2011).  
Over the years since this patent, there have been many similar patents that report a 
variety of devices. These micro-scale biopsy devices were all developed to biopsy non-
stratified epithelium tissue, and none for stratified epithelium tissue such as the human 
epidermis. The advances in rapid prototyping technologies over the last two decades have 
enabled significant development of micro- and nano-size devices using laser-based rapid 
prototyping methods (Gittard and Narayan, 2010, Lu and Chen, 2004). These small scale 
devices are mostly used in drug delivery and regenerative medicine. However, these rapid 
prototyping technologies can also be used to fabricate small medical devices for other 
biological applications (Henry et al., 2009, Martinez et al., 2008, Lin et al., 2013, Gomaa et 
al., 2012). 
 Fabrication of micro devices 1.6
Rapid prototyping (RP), also known as solid freeform fabrication, is the physical creation or 
assembly of a three-dimensional (3D) object using computer-aided design (CAD), 
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computer-aided manufacturing (CAM) or computer numerical control (CNC) technologies. 
It was first developed in the 1980s to enable the fabrication of a model or prototype parts 
without the need of conventional manufacturing tools and processes. In this present time, 
the advances from RP technologies can create not only prototypes in plastic materials but 
also good quality finished products.  
There are three fundamental rapid prototyping processes: additive, subtractive and 
formative. Most RP processes are based on additive manufacturing or fabrication. Additive 
RP involves depositing of sequential layers until the desired object is formed. Examples of 
these processes include stereolithography apparatus (SLA) and solid ground curing 
(SGC). On contrary, the subtractive prototyping process starts off with a block of material 
and material is cut out until the desired form is achieved. They are mostly in the form of 
automated machining processes by CNC such as milling, laser cutting and water-jet 
cutting etc. The formative prototyping process requires application of mechanical or 
restrictive force to the portions of the material to create the desired form. These processes 
include bending, forging and injection moulding. Most of the current RP processes are 
based on additive operations. There are several means of classifying RP technologies and 
one common type of classification is by the form of the starting material: 1) solid-based, 2) 
liquid-based and 3) powder-based (Chua et al., 2010, Gene, 2007). 
 Solid-based RP processes 1.6.1
1.6.1.1 Fused deposition modelling 
Fused deposition modelling (FDM) is a type of extrusion-based additive fabrication 
process (Figure 1.6) (Gene, 2007). The dimensions of the part is translated into x, y and z 
coordinates that is controlled by a computer system to direct the nozzle and build platform. 
It uses a thin filament of polymer that is fed through an extrusion nozzle. The polymers 
used in this process are known as thermoplastics that are mouldable when heated to a 
specific temperature and solidifies when cooled. The nozzle melts the filament of polymer, 
extrudes and deposits thin beads of molten materials onto the build platform. The nozzle 
moves in the XY axes and prints the cross-sectional layer, which has a typical thickness of 
0.25 mm, of the part using the melted polymer (Wong and Hernandez, 2012). Each layer 
goes through a cooling period where the polymer hardens and binds to the layer beneath 
it. 
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Table 2: Advantages and disadvantages of different rapid prototyping technologies.  
Rapid prototyping technologies Advantages Disadvantages 
Fused deposition modelling No post processing required. 
No curing of build parts. 
Materials are stable and do not change with 
time or environmental exposures. 
Materials are non-toxic.  
Low z-axis resolution of 0.25 mm. 
Rough surface finish. 
Relatively slow fabrication process. 
Laminated object manufacturing Build is self-supported. 
Build parts do not warp, deform or shrink. 
Not suitable for making parts with complex internal 
cavities. 
Requires installation of a chimney or filtration 
system to remove fumes. 
Stereolithography apparatus Ability to build parts with multiple materials. 
Mass manufacturing is quick and inexpensive. 
Fully automated process. 
Good dimensional accuracy (± 0.1 mm). 
High z-axis resolution of < 0.01 mm available 
with microstereolithography. 
Good surface finish. 
Warping of thin areas. 
Incomplete curing in most areas of build parts. 
Labour intensive. 
High maintenance cost for optical sensors. 
Liquid may be trapped in parts with enclosed and 
hollow structures if cleaning or draining is not 
feasible. 
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Ability to produce parts of any geometry. 
High quality end product comparable to CAD 
data. 
Solid ground curing High-throughput process enabled by 
concurrent printing of multiple parts. 
Build parts do not warp, deform or shrink. 
Ability to reverse wrong operation. 
Complicated fabrication process. 
High operation cost due to set-up and the need to 
monitor fabrication process. 
PolyJet™ High-throughput process enabled by 
concurrent printing of multiple parts. 
No post processing required. 
Ability to build wide range of materials. 
Simple operation process. 
Materials are non-toxic. 
High quality end product comparable to CAD 
data. 
Good surface finish. 
Relatively good dimensional accuracy (≤ 0.6 
mm). 
Unsuitable for an office environment due to need 
of water access for post processing. 
Thin or delicate parts may be damaged during 
cleaning. 
Wastage of support material as they are non-
reusable. 
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Selective laser sintering Ability to build wide range of materials. 
Relatively fast fabrication process. 
No curing of build parts. 
Good surface finish. 
Build parts can shrink by 3-4%. 
Post processing required. 
Collection of excess powder on parts’ surface. 
Potential porosity of build parts. 
Density of build parts may be variable. 
Requires the access of nitrogen gas. 
Electron beam melting Does not require support structures. 
Ability to prototype complex shapes. 
Relatively low maintenance and installation 
costs. 
Finishing is improved with vacuum 
environment. 
Potential porosity of build parts. 
 
Water jet cutting Ability to cut any materials and particularly 
suitable for processing materials that are 
difficult to cut. 
Does not have any thermal effect on 
workpiece. 
Inflicts minimal stresses to workpiece. 
Water usage is very low and can be reused 
Slower processing time than plasma cutting 
technology. 
Abrasive material is relatively expensive. 
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using a closed looped system. 
Flexible and versatile with wide usage 
applications. 
Comparatively low installation and 
maintenance costs. 
 
22 
 
 
The advantages of this process as summarized in Table 2 include no post processing, no 
curing process, stable material properties that do not change with time or environmental 
exposures such as moisture and no exposure to toxic materials thus it can be set-up in an 
office environment. Low z-axis resolution (0.25 mm), rougher surface finish that may 
require manual sanding to smooth surface, and slower fabrication process compared to 
stereolithography (SLA) and selective laser sintering (SLS) are some of the disadvantages 
of this RP process (Grimm, 2003, Wong and Hernandez, 2012). 
1.6.1.2 Laminated object manufacturing 
This is a form of contour-cutting process that combines both additive and subtractive 
manufacturing techniques for RP. Laminated object manufacturing (LOM) construct parts 
by layering sheets of thermoplastics such as paper, plastics or composites to form the 
object. The z-axis resolution is dependent on the material used that can range between 
0.025 to 0.13 mm. The set-up of this process is based on feed mechanism system where 
the material (in sheet) is positioned on the building platform and pressure is applied by a 
heated roller to bind the top and bottom layers. The profile of the part is cut out by a CO2 
laser reflected by the XY moving optic head. The laser settings are adjusted such that only 
a single layer of material is cut at a time. Crosshatch pattern surrounding the profile of the 
part is laser cut to facilitate its removal when the build is complete (Figure 1.7) (Wong and 
Hernandez, 2012, CustomPartNet, 2008, Gene, 2007).  
Figure 1.6: Illustrations of fused deposition modelling process. Reproduced from (Wong 
and Hernandez, 2012).  
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One of the advantages of this process is that the build is self-supported by the excess 
material surrounding the part profile. As the complete parts are constructed by applied 
heat and pressure to bond the stacks of materials, they do not warp, deform or shrink. The 
disadvantage is given that build is form by subtracting the excess materials around it, 
hence making this technique not feasible to fabricate complex internal cavities.  The 
process also generates considerable amount of fumes, thus it requires a chimney or a 
filtration system (Wong and Hernandez, 2012, Gene, 2007). 
 Liquid-based RP processes 1.6.2
Majority of the liquid-based RP processes involve a heat source such as UV light or laser 
to cure or harden a photosensitive liquid resin. The general advantages are evenness of 
liquid surface in a steady state and quality surface finish. However, this process can be 
limited by the type of materials that can be cured. 
Figure 1.7: Illustrations of laminated object manufacturing process. Reproduced with 
permission from (CustomPartNet, 2008), Copyright © 2009 CustomPartNet. All rights 
reserved. 
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1.6.2.1 Stereolithography apparatus 
Stereolithography is the first technique developed for RP and is the benchmark for later 
technologies. The principle of stereolithography apparatus (SLA) is based on the 
solidification of photosensitive polymer classified as an epoxy, vinylether or acrylate with 
the use of the UV laser light.  A 3D object is built layer-by-layer based on a CAD data that 
is converted into thin cross-sections or layers during the SLA process. Each layer is 
constructed by the laser beam that traces a single layer or cross-section on the surface of 
the photosensitive resin (Figure 1.8a-b). The liquid monomer or polymer hardens 
precisely at the point where the UV laser (the catalyst) selectively hits the surface (Figure 
1.8b) and is converted into a solidified polymer. This process is known as 
photopolymerisation. Another layer of the resin is recoated on the platform by a sweeper 
and the tracing of the UV laser is repeated until the object is completed (Figure 1.8c-d). 
Small structures known as the support materials (Figure 1.8e) are constructed in some 
Figure 1.8: Schematics of step-by-step stereolithography process. 
The process starts off by single layer of photosensitive resin on the platform (a) and the UV laser 
selectively hits on the surface of the resin to harden the material (b). The tracing of the UV laser 
is performed on the second layer (c) and repeated to construct the remaining layers of the build 
(d). Support materials for ‘bridging’ purpose are built into the object (e) and can be removed after 
the final part is completed (f). Reproduced with permission from (Gene, 2007) Copyright © 
(2007), CRC Press. 
25 
 
cases where a ‘bridge’ is needed to raise the part off the platform. Excess liquid resin is 
drained off and supports are removed after the build is complete (Figure 1.8f) (Gene, 
2007). Excess liquid resin that is drained off can be reused for the next build.  
An improved version of stereolithography process that can achieve a higher resolution of 
less than 0.01 mm layer thick, known as microstereolithography, has been developed 
using photopolymerizable suspensions (Halloran et al., 2011).  It is possible to build parts 
with multiple materials using stereolithography. This process requires a software 
scheduling system and the use of low viscosity resins where a change in material between 
layers can be done without the need to sweep post recoating (Kim et al., 2010).  This 
technology is a fully automated process that enables round-the-clock and unattended 
operations. The process of mass fabrication is also quick and inexpensive, and has the 
ability to produce parts of any geometry. The resolution of the end product compared to 
the CAD data is relatively close, with dimensional accuracy within ± 0.1 mm.  The 
problems of this technology are the high maintenance cost for optical sensors and the 
need for post processing and curing of the build parts. Build parts with enclosed and 
hallow structures can trap liquid if cleaning and draining is not feasible and most areas 
may have incomplete curing due to the cone shape energy properties of the UV laser. 
Lastly, the thinner areas of the parts may warp over time due to water absorption. The 
pros and cons of SLA are summarised in Table 2. 
1.6.2.2 Solid ground curing 
A form of mask-based process is the solid ground curing (SGC) technology. This 
technology works on a similar principle as the SLA process wherein build parts are 
fabricated based on solidification of photosensitive resin by an UV source. In contrast to 
SLA, there is no need to construct support materials within the build part as wax is used as 
a secondary material to support the build (Chua et al., 2010, Liou, 2007). This technology 
also uses an electron gun to print a charged, cross-sectional image pattern on the glass 
(mask). A black electrostatic toner is applied and adhered to the charged pattern on the 
glass. The glass mask is placed over the layer of resin and moved to an exposure cell 
consisting of a UV source. UV light is exposed to resin that is not covered by the glass 
mask to cure part of the material. Uncured resin is removed and discarded and a thin layer 
of wax is applied on top of the solidified resin and fills in the space that formerly held the 
uncured resin. The layer of wax goes through a cooling process and hardens. The harden 
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wax provides support for the part. The surface of the build is evened out by a milling cutter 
to the precise thickness. Additional curing by a longitudinal UV source is repeated after the 
milling step to ensure complete curing of the build. Hence, no post-curing step is required 
after the build is completed. The layering and curing process is repeated. Similar to SLA, a 
post processing step is required for SGC to dissolve the wax (Chua et al., 2010). 
The advantage of this technology is the high-throughput process where many different 
parts can be constructed at once without compromising the vertical accuracy due to the 
large volume capacity of the system and the addition of milling step. The fabrication 
process of this system allows construction of parts that do not warp or curl and the 
inclusion of the milling step enables the reversal of incorrect operations. The downside of 
this technology is the relative high operating cost as it is a complicated process, which 
requires monitoring by a skilled worker (Chua et al., 2010, Gene, 2007).  
1.6.2.3 PolyJet™ 
PolyJet™ technology patented by Objet Geometries Ltd. is a type of inject-based 
technology that can produce high resolution 3D modelling in an office environment. This 
technology works on the same principle as a normal inkjet printing method and is capable 
Figure 1.9: Diagrams of the Objet’s PolyJet™ technology process. Reproduced with 
permission from (Gene, 2007), Copyright © 2007, CRC Press. 
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of producing end-product with good surface finish similar to those from SLA processes  
(Figure 1.9) (Liou, 2007). The resolution of the PolyJet™ technology, depending on the 
type of models, can range between 42 to 84 µm for both X and Y axes and 16 to 30 µm for 
Z axis and a printing accuracy of 0.1 to 0.3 mm (Chua et al., 2010, Gaynor et al., 2014). 
Current systems in the market allow printing of single or multi-materials within each print 
job. This technology is the only additive fabrication process that has the capacity to use 
stiff and flexible materials within a single build. Thus, enabling fabrication of complex and 
multi-material parts (Gaynor et al., 2014). The jetting heads print both the part and gel-like 
support materials at the same time in each layer by moving along the xy-axes. The layer is 
then cured by the UV light with multiple passes once the material is deposited on the build 
tray. The build tray moves down by 16 µm in the z-axis upon the completion of each cross-
sectional layer in preparation for the next layer. The printing and curing processes are 
repeated until the build is finished. The removal of the support materials is then completed 
either by hand or with a water jet.  
Similar to any other rapid prototyping technologies, PolyJet™ also has several advantages 
and disadvantages (Table 2). The process is simple as it uses cartridge systems and 
replacement of material cartridges is easy without the risk of material contact. The 
technology is suitable for wide choices of material ranging from durable acrylic-based 
polymer to rubber-like Tango materials. Multiple models can be concurrently printed, 
enabling fast production time. This technology can achieve relatively good dimensional 
accuracy of less than or equal to 0.6 mm depending on the type of materials and the 
geometry of the build part. High quality end product with reduced stair effect and smooth 
surfaces can be achieved without the need of post processing. It is possible to set this 
process in an office environment as users are not exposed to photosensitive resin during 
modelling process and the support material is non-toxic but may be limited by the lack of 
water access that is required for post processing. Other weaknesses of PolyJet™ include 
possible damage to thin or delicate parts during water jet cleaning and wastage of material 
as support material cannot be recycled. 
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 Powder-based RP processes 1.6.3
1.6.3.1 Selective laser sintering 
Selective laser sintering (SLS) employs a similar operation principle as SLA but instead of 
using photosensitive resin, this process involved fine powder material that can be fused 
when heat is applied. There are a wide range of materials suitable for SLS including 
polymer, ceramics and numerous composites. Powders with low fusion properties can add 
a sacrificial binder material to enable the sintering effect (Kruth et al., 2003). Three-
dimensional built is created by fusing the layers of thermoplastic powder together. The 
sequence of the operation is illustrated in Figure 1.10. The set-up of SLS is made up of a 
powder supply system, a fabrication powder bed, a build cylinder and a moving piston that 
are contained within a sealed chamber. This chamber is maintained at a constant 
temperature just below the melting point of the material and filled with nitrogen to prevent 
potential explosion from handling of large powder quantities (Gene, 2007).  
Given that the chamber is completely sealed, very little heat from the laser is required for 
fusion effect to take place, thus the processing time is greatly reduced. There is no need 
for final curing like in FDM and SGC processes and post processing as part is supported 
by the fabrication powder bed.  The downside of SLS technology is that the part can shrink 
Figure 1.10: Illustrations of selective laser sintering operations.  
The cycle is started by spreading a thin layer of power that is coated on the roller. The laser 
selectively etched the shape of the part to melt and fuse the powder with the layer below. The 
platform lowers to allow coating of next layer. These cycles repeat until the part is    completed. 
Reproduced with permission from (Lee et al., 1995), Copyright © 1995, Emerald Group 
Publishing Limited.   
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by three to four percent (Kruth et al., 2003) unlike SGC technology. Other disadvantages 
include collection of excess powder on part surface, potential porosity of parts, variable 
part density and the need of cleaning before changing materials (Table 2) (Gene, 2007).  
1.6.3.2 Electron Beam Melting 
The process of electron beam melting (EBM) (Figure 1.11) is similar to that of SLS except 
that the heating source is a scanned 4 kW electron beam. Electron beam is required for a 
more energy efficient approach to melt conductive metal powder and produced fully dense 
part. The kinetic energy of the electrons that are projected at half the speed of light melts 
the powder surface. Pre-heating is first applied to the layer of powder to reduce the level of 
residual stress that can cause distortion of the part. The filament within the electron beam 
gun is then heated over 2500oC to accelerate the electrons through the anode to half the 
Figure 1.11: Illustrations of electron beam melting process.  
A fine layer of metal power that is distributed across the building platform, and the layer of 
material is selectively melted by an electron beam controlled by a CAD file. The building platform 
lowers and the process repeats until the part is complete (a). Panel b is a prostatic hand that is 
built using EBM. Figure modified with permission from (Greenemeier, 2013), Copyright © 2013, 
Nature Publishing Group.   
30 
 
speed of light. The beam is focus by a magnetic lens while another is used to deflect the 
direction. The kinetic energy from the emitted electrons is transferred to heat when they hit 
the surface of the metal powder, which then melts the material. Selective melting of the 
layer is controlled by increasing beam power or decreasing the speed.  
This additive process is completed within a vacuum environment to provide a clean 
environment that will improve the metal finishing characteristics. Unfused powder acts as 
material support for the parts hence support structures are not required in this operation. 
The dimensional accuracy for EBM is ± 0.4 mm and the thickness of each layer is between 
0.05 to 0.2 mm. The advantage of this technology is the ability to prototype complex 
shapes with overhangs and undercuts. This technology produces higher energy efficiency 
that results in lower power consumption, thus lowering maintenance and installation costs. 
On the other hand, the limitation of EBM is the potential porosity of part due to the nature 
of sintering process (Table 2) (Gene, 2007). 
 Water-Jet cutting – a subtractive manufacturing process 1.6.4
Water-jet cutting is a form of subtractive machining process as materials are eroded from a 
single block of workpiece by high-pressure water jets to create 2D or 3D objects. This 
method can be classified as abrasive (AWJ) or plain water-jet cutting (PWJ), depending if 
fine abrasive particles are used during the process. It can essentially cut any kind of 
material if the device has an ultrahigh-pressure pump and the flexibility in positional 
movement. Abrasive particles like aluminium oxide are entrained and accelerated to high 
speed (200 to 800 m/s) when high-pressure water-jet (up to 6200 bar) is forced through a 
small orifice of 0.1 to 0.3 mm. This technology was first explored in the 1950s to look for a 
new approach for slicing trees to lumber. PWJ is used for cutting soft and light materials 
such as plastics, paper and food while AWJ has the capacity to cut glass, metallic sheets 
and composites (Kulekci, 2002). The development of PWJ in commercial systems was 
slower than AWJ due to its relatively limited applications. The formation of the high speed 
AWJ is illustrated in Figure 1.12. 
AWJ does not cause machine chattering hence it’s less sensitive to material properties. It 
also has no thermal effects (minimum heat generation) and inflicts minimal stresses to 
workpieces (Azmir and Ahsan, 2009). Water-jet machining is a highly flexible and versatile 
technology and hence has wide applications including cutting, controlled depth milling, 
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coat removal, surface polishing, and micromachining etc. (Kong, 2014). It is a key enabling 
machinery to process materials that are difficult to cut (Wang, 2003, Axinte et al., 2009, 
Kong et al., 2011).  
 
 Rapid prototyping applications in medicine and biomedical fields 1.6.5
The application of RP in the field of medicine was first practise in the 1990s by Mankovich 
et al. to produce a 3D cranial bone anatomy model using a computed tomography image 
data (Mankovich et al., 1990). Bone models and implants were fabricated exclusively for 
various medical specialities in the initial years of medical RP (Minns et al., 2003, Winder 
and Bibb, 2005, Sailer et al., 1998, D'Urso et al., 1999a). The medical models constructed 
using medical imaging modalities and RP technologies provided a new approach for 
Figure 1.12: Schematics showing the formation of high velocity in water-jet cutting head.  
The water passes through the ultrahigh-pressure pump into the tiny orifice to form PWJ in the 
first phase. The highly pressurised PWJ then travel through the jet body, consisting of the cutting 
head and focusing nozzle, and this process creates a partial vacuum to draw in the abrasive 
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planning and pre-operative simulation of complex surgery (Anderl et al., 1994). The 
advancement of RP technologies over the years have also facilitated fabrication of 
anatomical models of the brain (D'Urso et al., 1999b), heart (Kim et al., 2008) and vascular 
systems (Schuller-Ravoo et al., 2014). These prototyping technologies were not only 
useful for producing anatomical models but also widely applied in many biomedical 
science fields, including the fabrication of microneedles (Robison and Finkelstein, 2014, 
Rasooly et al., 2013, Weibel et al., 2007, Walzik et al., 2015, Gittard et al., 2010). 
Two-photon polymerisation is an emerging laser-based microfabrication method that is 
compatible with numerous photosensitive resins. The compatibility of the materials 
depends on 1) the ability to polymerise by two-photon absorption in its original form or with 
the help of a photoinitiator, and 2) the wavelength of the laser is within the window of 
transparency. The advantage of two-photon polymerisation (near-infrared light) is that it 
enables three-dimensional processing of the resins unlike in traditional stereolithography 
processes, the polymerisation occurs at the surface of the material due to the source of 
laser (UV light). 
The choice of fabrication techniques depends on a few factors including whether there is 
requirement of a cleanroom facilities, the need of hazardous waste services for toxic 
chemical handling, the dimensional accuracy of the technique and the cost of microneedle 
precursors and equipment etc. Gittard et al. have provided a review covering different 
methods for microneedle fabrication, the advantages and disadvantages of each method 
as shown in Table 3 (Gittard et al., 2010). The choice of material and technique selected 
for the production of the microbiopsy device will be discussed in Chapter 3 of this Thesis. 
  
33 
 
Table 3: Advantages and disadvantages of current microneedle fabrication methods. 
Production 
technique 
Advantages Disadvantages 
Reactive Ion 
Etching 
High resolution High operation cost, the need of a 
clean room, low throughput 
manufacturing, only compatible with 
silicon, restrictions on geometry 
Photolithography High resolution High operation cost, the need of a 
clean room, geometry restrictions 
Cutting and 
bending 
Low operation cost, 
cleanroom not required, 
strong materials 
Limited to two dimensions control, 
limited to solid microneedles 
Two-photon 
Polymerisation 
Cleanroom not required, 
good geometry control, 
resolution is scalable, 
Limited to photosensitive materials 
Electroplating Low operation cost, high 
throughput manufacturing 
Geometry is dependent on master 
structure, biocompatibility issues, thin 
walls of parts resulting in poor 
mechanical properties  
Casting Low operation cost, high 
throughput, compatible with 
numerous materials 
Geometry is dependent on master 
structure 
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 Literature review summary and Scope of thesis 1.7
The invasive nature of the conventional biopsy and the diagnostic variability from 
histopathology supported the need for new tools for skin research and a different approach 
to provide more accurate diagnosis of skin diseases. Optical imaging can provide alternate 
and non-invasive means of detecting malignancy in skin lesions but like histopathology, 
this method does not provide objective diagnoses. Molecular changes observed in 
progressive lesions advocated an opening for alternative analysis. This led to the 
development of many microbiopsy tools for the detection of tissue abnormality in the 
breast, intestine, brain and other non-stratified epithelial tissue. Yet, none have been 
developed for the skin. The concept and establishment of rapid prototyping has 
revolutionised the manufacturing industry. These technologies are facilitating 
microfabrication in the field of medicine and biomedical sciences. The goal of this Thesis is 
to describe the development of a minimally invasive skin sampling technology and explore 
its analytical potential.  The following aims outline the Thesis structure. 
 
Aim 1: Establish rapid microneedle prototyping.  
Aim 2: Microbiopsy geometry and application refinement. 
Aim 3: Genetic analysis of melanocytic and non-melanocytic skin lesions. 
Aim 4: Develop live cell assay for microbiopsy. 
Aim 5: Explore the high-throughput technologies for microbiopsy samples. 
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Figure 2.1: Folding of two-dimensional microbiopsy cutting die. 
Two-dimensional laser cut microbiopsy cutting die was removed from stainless steel sheet and 
folded along the engraved lines (dotted lines) to assemble into a three-dimensional sampling 
device. 
 Chapter 2
General Materials & Methods 
 Microbiopsy device fabrication 2.1
 Fabrication of in-house standard microbiopsy cutting die 2.1.1
In-house standard microbiopsy cutting die were fabricated using the LaserPro S290-20 
laser system (GCC World, Taiwan). The laser parameters were set at 100% power, 0.016 
m/s speed and 300 kHz frequency. Two-dimensional microbiopsy cutting die were laser 
cut on 0.05 mm medical grade 304L stainless steel sheet (Mastercut Technologies, 
Australia). CorelDRAW Graphics Suite X5 (Corel, Canada) was used to draft the 
microbiopsy designs. A Dremel® rotary tool (Model 225, Mount Prospect, USA) attached 
with a 428 carbon steel polishing brush was used to polish the microbiopsy cutting die to 
remove oxidised metal and excess slag. The cutting die were polished while they were still 
affixed within the stainless steel sheet. Sterilisation was performed with either the Steri 
Inotech 350 glass bead sterilizer (Inotech Biosystems International Inc., Switzerland) or 
with 70% ethanol and air-dried prior to folding (Figure 2.1). Alignment of the three cutting 
element plate was checked under stereo microscopy (Stemi 2000, Carl Zeiss Microscopy 
GmbH, Germany). Microbiopsy cutting die that were not aligned or flush after assembly 
were discarded.  
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 Mass fabrication of standard microbiopsy cutting die 2.1.2
Mass fabrication of the standard microbiopsy cutting die was done by Mastercut 
Technologies with a fibre laser system. Five by 20 microbiopsy cutting die were cut on 210 
mm x 297 mm x 0.05 mm 304L stainless steel shim. The laser has a standard tolerance of 
± 0.5 mm and precision can be as low as 0.01 mm. Fabrication optimisation was 
conducted by the company according to defined specifications. Tabs on the side of the 
base and tip were created to ensure that the cutting die remains attached to the sheet 
during shipment. The tab was broken by gentle twisting of the cutting die.  Sterilisation and 
folding of the cutting die was done according to protocol described in Section 2.1.1. 
 Fabrication of loader cap 2.1.3
The loader cap was designed and drafted using Autodesk Inventor Professional software 
(Autodesk, USA) by Ross Flewell-Smith. The cap was fabricated using either the V-flash 
FTI 230 3D printer (3D Systems, Australia) or the MakerBot Replicator (MakerBot, USA). 
Caps that were 3D-printed by the V-flash FTI 230 were cured and rinsed according to 
supplied instructions before use. 
 Assembling of single-use microbiopsy device 2.1.4
Commercialised single-use blood sampling device, Unistik® 2 (Owen Mumford, UK, # 
08470-0702-01) was modified for use as the microbiopsy applicator. The original 2.4 mm, 
21-gauge blood sampling needle was removed from the device plunger and replaced with 
the microbiopsy cutting die (Figure 2.2a). A polymer loader-cap was capped over the 
opening of the applicator to hold the microbiopsy in position (Figure 2.2b). Each 
assembled microbiopsy device was packed individually in Stericlin® Tyvex® pouch 
(Medcon, Australia, #801976) and sealed using a heat impulse sealer. Individually 
packaged microbiopsy devices were sent to a sterilisation and decontamination contractor 
(Steritech, Australia) for gamma radiation sterilisation at 25,000 Grays. An International 
Organization of Standardization protocol (AS/NZS ISO 11137:2006) was followed for 
sterilising the microbiopsy devices by gamma radiation. Single-use microbiopsy devices 
were only used on volunteer studies described in Chapters 5, 6 and 7. 
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Figure 2.2: Assembly of microbiopsy cutting die.  
Folded microbiopsy cutting die was fitted onto a modified Unistik® 2 plunger (a) and an 
in-house loader cap fabricated by a 3D printer attached to the assembled device. 
 Preparation of excised human skin  2.1.5
Excised human skin was collected from patients who had undergone abdominoplasty 
surgery. All patients were consented with written consent approved by the Metro South 
Human Research Ethics Committee in Princess Alexandra Hospital (HREC/12/QPAH/217) 
and The University of Queensland Human Research Ethics Committee (Approval no. 
2012001094/2008001342). The subcutaneous fat was removed and skin tissue containing 
the epidermis and dermis was kept. Any residual layer of fat tissue was carefully scrap 
using a scalpel blade to avoid damage to the skin. The tissue was then rinsed with saline 
or distilled water to remove residual blood. The tissue was packed into a clean ziplock bag 
and stored at -30°C. 
 Microbiopsy tissue collection from volunteers 2.1.6
The volunteer’s skin was disinfected using an alcohol swab prior to microbiopsy device 
application. The microbiopsy device was removed from the individual package and loaded 
by pushing in the loader cap. The device was applied after removing the loader-cap by 
pressing the spring-loaded applicator onto the skin and releasing the button. No local 
anaesthetic was required prior to microbiopsy application. Volunteers’ skin was cleaned 
with a new piece of alcohol swab post microbiopsy application and volunteers were 
advised to keep the biopsied area clean for the next 24 hours to eliminate any potential 
risk of infection. Simple dressing was made available for the volunteers if required. 
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Microbiopsy device containing tissue sample was kept in an empty 1.5 ml DNAse-/RNAse-
free microfuge tube and/or immersed in 80 µl of RNAlater® RNA Stabilization Solution 
(Life Technologies, USA, #AM7024) on ice. Samples kept in RNAlater® solution were 
stored at 4°C for up to 7 days and transferred to a -80°C freezer if they were not 
processed immediately. All volunteer studies carried out in this Thesis were conducted 
under the approval of the Metro South Human Research Ethics Committee in Princess 
Alexandra Hospital (HREC/12/QPAH/082 & HREC/13/QPAH/551) and The University of 
Queensland Human Research Ethics Committee (Approval no. 2012000648 & 
2013001551). 
 Microbiopsy tissue collection from excised skin 2.1.7
Excised skin was placed on top of gauze soaked with saline and foam tape. Clinical and/or 
dermoscopic photography were documented before microbiopsy application. The 
microbiopsy device was placed on top of the region of interest and applied by releasing the 
button on the modified applicator. The microbiopsy tissue sample was kept in an empty 1.5 
ml DNAse-/RNAse-free microfuge tube and/or immersed in 80 µl of RNAlater® solution on 
ice. Samples kept in RNAlater® solution were stored at 4°C for up to 7 days and 
transferred to a -80°C freezer if they were not processed immediately. 
 DNA Processing 2.2
 DNA extraction from microbiopsy sample 2.2.1
QIAamp DNA Micro Kit (QIAGEN GmbH, Germany, #56304) was used to carry out DNA 
extraction from microbiopsy samples. Microbiopsy devices containing the tissue samples 
were opened up and immersed in 180 µl of Buffer ATL and 20 µl of proteinase K.  
Samples were lysed overnight at 56°C in a thermomixer (Eppendorf, Germany) while 
mixed constantly at 800 rpm. Tissue lysis was completed by adding and mixing 200 µl of 
Buffer AL into the solution after overnight incubation. DNA in lysed sample solution was 
concentrated using 200 µl of 96-100% ethanol. The tube containing the device was briefly 
centrifuged for ten seconds to remove the solution adhering to the cap of the tube before 
transferring the lysate into a QIAamp MinElute column. The tube containing the device 
was centrifuged again at 6000 x g for 30 seconds to remove any lysate adhering to the 
device. The lysates were combined and the remaining procedure followed the 
manufacturer’s supplied instructions. Twenty to 25 µl of Buffer AE or nuclease-free water 
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was added to the middle of the membrane and incubated at room temperature for up to 
five minutes before elution to increase the yield of DNA. 
 DNA extraction from lesional sample 2.2.2
Excised lesion was weighed to ensure that the tissue was not more than 25 mg in weight. 
Tissue that weighed more than 25 mg was cut into appropriate sizes and extracted in 
separate reactions. The tissue was cut up into finer pieces using a single-use surgical 
blade prior to DNA extraction.  Finely cut up tissue was immersed in 180 µl of Buffer ATL 
and 20 µl of proteinase K from QIAamp DNA Mini Kit (QIAGEN GmbH, Germany, #51304). 
Tissue lysis involved overnight incubation at 56°C in a thermomixer (Eppendorf, Germany) 
while mixed constantly at 800 rpm and was completed with an additional ten minutes 
incubation of 200 µl of Buffer AL at 70°C. If visible tissue was present after overnight 
incubation, the sample was incubated for a longer period until no visible tissue could be 
seen prior to addition of Buffer AL. The entire lysate was transferred to QIAamp Mini spin 
column and the remaining procedure followed the manufacturer’s supplied instructions. 
Buffer AE or nuclease-free water was incubated at room temperature for up to five minutes 
before elution to increase the yield of DNA. 
 DNA quantification 2.2.3
The Qubit® dsDNA HS assay (Life Technologies, USA, #Q32854) and dsDNA BR assay 
kits (Life Technologies, USA, #Q32853), a quantitative fluorometer-based assay were 
used to determine the concentration of DNA from the microbiopsy samples and excised 
lesions, respectively, with the instructions provided by the manufacturer. Depending on the 
selection of the downstream application and the type of sample (microbiopsy or lesion), a 
typical sample volume of 2-20 µl was used to quantify the concentration of the sample. For 
amplified DNA samples, a 10- to 15-fold dilution was performed using 1-2 µl of the 
samples prior to quantification.  
 DNA whole genomic amplification 2.2.4
DNA from the microbiopsy samples was concentrated using Thermo Scientific™ DNA 
SPD111V SpeedVac Concentrator (Thermo Fisher Scientific Inc., Australia) for 1.5 hours 
at 55°C. If the DNA samples dried up during the concentration process, three microliters of 
nuclease-free water was added to resuspend DNA at the bottom of the tube. Whole 
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genomic amplification procedure was then carried according to the manufacturer’s 
instructions (REPLI-g Single Cell Kit, QIAGEN, Australia, #150345). 
 DNA quality control 2.2.5
Agilent DNA 12000 DNA kit (Agilent Technologies, USA, #5067-1508) was used to 
determine the integrity and quality of DNA after whole genomic amplification of isolated 
DNA from microbiopsy samples. Alternatively, the quality and integrity of amplified DNA 
was verified using a 2% agarose gel electrophoresis with the 1 Kb Plus DNA Ladder (Life 
Technologies, USA, #10787-018) when the 2100 Bioanalyzer instrument (Agilent 
Technologies, USA) was not available. Samples were diluted to the level within the 
quantitative range prior to quality analysis.   
 RNA Processing 2.3
 RNA extraction from microbiopsy samples 2.3.1
The microbiopsy device was opened up and checked under stereo microscopy for 
presence of tissue prior to RNA extraction. The microbiopsy device containing the tissue 
sample was then transferred to a clean tube containing 100 µl Extraction Buffer. The tube 
was briefly vortex and centrifuged before incubating at 42°C for 30 minutes. Subsequent 
RNA extraction procedures were performed according to the instructions from Arcturus® 
PicoPure® RNA Isolation kit (Life Technologies, USA, #KIT0204) as provided by the 
manufacturer, with modification to Step b wherein 100 µl of 70% ethanol was added. 
DNAse treatment was included in the extraction process using the RNase-DNase Set 
(QIAGEN GmbH, Germany, #79254) according to the instructions provided by the 
manufacturer. Minimum volume of 11 µl Elution Buffer was added to the column and 
incubated for 2-5 minutes before RNA was eluted from the column. 
 RNA extraction from lesional sample 2.3.2
Excised lesion was weighed to ensure that the tissue was not more than 30 mg in weight. 
Tissue that weighed more than 30 mg was cut into appropriate sizes and extracted in a 
separate reaction. The tissue was cut up into finer pieces using a single-use surgical blade 
prior to RNA extraction and transferred to a 2 ml screw cap plastic vial half filled with 1.4 
mm ceramic spheres or a pre-packed Lysing Matrix D tube (MP Biomedicals, Australia, 
#116913050), containing 350 µl of Buffer RTL Plus lysis buffer from RNeasy Plus Mini kit 
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(QIAGEN GmbH, Germany). The tissue sample was disrupted using the FastPrep® FP 
120 instrument (Q-biogene,) at a speed of 6.5 for 45 seconds per cycle. Four to six cycles 
of disruption to the tissue was performed, and the sample was cooled on ice for 1 minute 
and briefly centrifuged between each cycle. Subsequent RNA extraction steps were 
performed according to the instructions provided by manufacturer. An additional 
centrifugation step was performed to eliminate any possible carryover of Buffer RPE by 
adding nuclease-free water and incubating at room temperature for 2-5 minutes before 
eluting the RNA. 
 RNA quantification 2.3.3
The Qubit® RNA HS assay (Life Technologies, USA, #Q32855) and RNA BR assay kits 
(Life Technologies, USA, #Q10211), were used to determine the concentration of RNA 
from the microbiopsy samples and excised lesions, respectively, with the instructions 
provided by the manufacturer. Depending on the selection of the downstream application 
and the type of sample, a typical volume of 2-20 µl was used to quantify the concentration 
of the sample.  
 RNA quality control 2.3.4
Agilent RNA 6000 Pico kit (Agilent Technologies, USA, #5067-1513) was used according 
to the manufacturer’s instructions to determine the integrity and quality (RIN number) of 
RNA. Samples with concentration outside kit’s range were diluted prior to quality analysis.   
 Image data collection 2.4
 Optical and clinical photography 2.4.1
Stemi 2000C stereo microscope (Car Zeiss Microscopy GmbH, Germany) with an external 
five megapixel camera (ZEISS Axiocam ERc 5s, Carl Zeiss Microscopy GmbH, Germany) 
was used to acquire optical photographs. The magnifications of this microscope range 
between 6.5x to 50x. Photographs are acquired by AxioVision LE64 imaging software 
(Carl Zeiss Microscopy GmbH, Germany) that has basic image processing and 
measurement functions. Clinical photographs were acquired using a 14.7 megapixel 
Canon Power Shot G10 digital camera (Canon, USA) using automatic shooting mode.  
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 Reflectance confocal microscopy 2.4.2
Non-invasive real-time visualisation of the microbiopsy site in volunteers 
(HREC/12/QPAH/082) or in excised skin (UQ Human Ethics approval no.: 2008001342) 
was carried out with a Vivascope 1500 Multilaser (Lucid, Inc., USA). The multilaser is a 
reflectance confocal microscope (RCM) coupled with fluorescent confocal laser scanning 
microscopy. The fluorescence imaging can be carried out in three different excitation 
wavelengths: 488 nm, 658 nm and 785 nm. This imaging system has an integrated 
dermoscopic imaging modality. The horizontal and vertical optical resolution of the system 
within the tissue is < 1.25 μm and < 5.00 μm at the center of field of view. Optimum 
reflectance confocal images were collected through the microscope head, integrated with 
a water immersion objective, at a near-infrared wavelength of 785 nm. Block and/or single 
stack images were acquired at the microbiopsy sampling site. Block images were made up 
of 0.5 mm by 0.5 mm single frame images that were stitched together. 
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 Chapter 3
Fabrication of the Microbiopsy device 
 Introduction 3.1
The focus of this Chapter was the development of protocols to enable rapid fabrication of 
microbiopsy prototypes. The aims of this Chapter were to: 
• Optimise fibre laser parameters (power, frequency and speed) using straight lines 
• Reproducibly cut single needle microbiopsy using optimised parameters 
• Assess the mechanical integrity of the prototype during application  
Stainless steel is an essential component in medical devices and has a wide application in 
the medical device industry. There are many types of metal machining processes and one 
of the most common industrial cutting systems is laser cutting. This is because there are 
numerous benefits that an industrial laser cutting system has over other material 
machining technologies (Table 4), especially in the context of micromedical device 
prototyping. In the context of mass manufacturing, the ability to automate the process and 
manufacture at high volumes are vital.  Laser cutting was ideal for manufacturing of 
stainless steel based micromedical device as small kerf width and narrow heat affected 
zone (HAZ) can be achieved. The kerf width of the laser cut line was defined as the width 
of the groove measured from one edge of the cut to the other edge. It is fortuitous that 
laser cutting technology is also preferred in the laboratory context, where the safety of 
equipment and the flexibility of system to design changes are required. This allows for the 
direct translation of research activities into scale-up operations without the need for 
laborious system optimisation steps in between. 
The main components for laser cutting are the laser itself, focusing optics, and a moving 
beam or workpiece on the XY positioning table (Figure 3.1a). The beam is directed into 
the centre of the cutting head by the alignment mirrors. A focusing optic within the cutting 
head focuses the laser beam to produce an intense microscopic laser spot. The focusing 
optics can be transmissive or reflective optics depending on the type of laser (i.e. gas, 
solid-state, dye, or free-electron). The concentrated beam subsequently passes through a 
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nozzle within the cutting head at which an intersecting gas jet flows. The gas jet is used to 
assist the cutting process by removing molten material (Figure 3.1b) and also to protect 
the optics from spatter. Fibre laser cutting occurs as a result of either reactive-fusion or 
fusion depending on whether the gas jet is reactive (e.g. oxygen) or inert (e.g. nitrogen or 
argon). 
Laser cutting involves using large amount of energy to induce state and phase 
transformation of the material. Laser cutting can be achieved by vaporisation cutting, 
fusion cutting (melt and/or blow), reactive fusion cutting, controlled fracture (thermal stress 
cracking), scribing, cold cutting, and laser-assisted oxygen cutting (LASOX) (Steen and 
Mazumder, 2010). The choice of laser cutting method depends on the type of lasers to be 
used, thermo-physical properties as well as the thickness of the material.  
Figure 3.1: Laser cut set-up schematics. 
Illustrations of a laser cutting system (a) and an enlarged image of the dotted box showing the 
process of laser cutting with a coaxial gas jet removing the molten material. Molten materials 
that adhere to the edge of the cut are known as dross, slag or burr. Figure modified with 
permission from (Powell, 1998) Copyright © 1998, Springer London. 
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Table 4: Comparison of the benefits and limitations of different cutting techniques (Steen and Mazumder, 2010, Vilumsone-Nemes, 2012). 
Cutting techniques Benefits Limitations 
Laser Ability to cut all metals, all plastics, glass, and wood 
can be cut (depending on the source of energy). 
Ability to automate process. 
Fast cutting speed enabling high production volume. 
Produces small kerf width (0.15 mm). 
Produces narrowest HAZ. 
Low machine clean up.  
Relatively high equipment cost. 
Causes thermal stress to materials. 
Different parameters required for cutting different 
materials. 
Efficient for thickness between 0.1 to 10 mm. 
Difficulties for reflective metals. 
Punch Ability to automate process. 
Fast cutting speed enabling high production volume. 
Produces small kerf width. 
Produces narrow HAZ. 
Do not have the ability to cut both metal and non-
metal material. 
 
Plasma Ability to cut all metals including reflective metals. 
Ability to automate process. 
Fast cutting speed enabling high production volume. 
 
Do not have the ability to cut non-metal material. 
Causes thermal stress to materials. 
Produces relatively large kerf width. 
Produces relatively large HAZ. 
46 
 
Medium machine clean up required. 
Different parameters required for cutting different 
materials. 
Abrasive Water Jet Ability to cut both metal and non-metal material. 
Ability to automate process. 
Settings to cut are the same for all materials. 
Produces relatively small kerf width (0.05 mm). 
No thermal stress on materials. 
Relatively slow cutting speed. 
Relatively high equipment cost. 
High machine clean up. 
Efficient for thickness between 10 to 50 mm. 
Personal safety equipment required. 
Wire electric discharge 
machining 
Produces small kerf width. 
Produces narrow HAZ. 
Restricted to conductive materials. 
Process cannot be automated. 
Relatively slow cutting speed. 
Different parameters required for cutting different 
materials. 
Sawing Low equipment and operation costs. Produces large kerf width. 
Ultrasonic Ability to cut both metal and non-metal material. 
Excellent accuracy and clean edges finishes. 
Low production volume due to relatively slow 
cutting speed. 
Requires special surface fixation on vacuum table. 
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Vaporisation or evaporation laser cutting occurs through direct vaporisation of material 
after it has reached its evaporation point by laser energy. It is suitable for processing 
materials with low conductivity and low heat of vaporisation. In fusion cutting, the high 
intensity laser melts the material and molten material is then expelled by inert gas jet. This 
method is suited for materials that are high in conductivity. Examples of such material are 
nonferrous materials like aluminium and titanium. Reactive fusion cutting and LASOX are 
variations to fusion cutting method. The method requires the introduction of reactive gas or 
oxidising gas mixture to trigger an exothermic reaction that acts as an additional energy 
source to cut the material. This approach is suitable for high conductivity and reactive 
materials including mild steel and stainless steel. Controlled fracture is suited for brittle 
materials as it uses mechanical stresses created along the path of the laser beam to 
separate the material (Dahotre and Harimkar, 2008, Steen and Mazumder, 2010).  
The key advantages of laser cutting over alternative machining techniques include non-
contact process, rapid processing speed, flexible process, ease of automation, precise and 
better quality of cut (Dahotre and Harimkar, 2008, Steen and Mazumder, 2010) . Unlike 
conventional machining, there is no need to clamp or centre the workpiece on fixtures and 
precise position can be achieved with a XY table. Laser cutting is highly flexible as 
changes to the process can be easily programmed. Narrow kerf width with minimum heat 
affected zone (HAZ) and thermal stresses can be achieved with optimised laser cutting.   
Laser cutting is a dynamic process and the quality of laser cuts can be affected by multiple 
cutting parameters. Some of the most important parameters include laser power, cutting 
speed, beam properties (size, diameter, focal position) and material thickness. There are 
limited studies investigating parameter optimisation using fibre lasers. However, the 
relationship between cutting parameters using CO2 lasers and cut quality has been well-
established (Yilbaş, 1996, Keles and Oner, 2012, Russo Spena et al., 2014, Wang, 2000) 
and these parameters are directly relevant for other laser systems.  
Cutting parameters including thickness of workpiece, assisting gas pressure, cutting speed 
and laser power were described by Yilbas in 1996 (Yilbaş, 1996). One of the key 
observations noted in the study was the presence of irregular cut width and holes of 
variable diameters when mild steel was processed at very low cutting speeds (2 cm/s). 
This effect, known as self-burning, was reduced when the cutting speed was increased to 
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4 cm/s. Yilbas and others all agreed (Yilbaş, 1996, Steen and Mazumder, 2010, Wang, 
2000) that increasing laser power allows laser cutting at faster speeds. This relationship of 
the laser power and cutting speed is illustrated in Figure 3.2.  
Spena et al. (2014) assessed the quality of cut on twinning-induced plasticity steel sheet 
using CO2 laser. They examined laser power, cutting speed, pressure of oxygen, and laser 
frequency in the assessment. The kerf width, kerf deviation, surface roughness and dross 
attachment was analysed to determine the quality of the cut (Russo Spena et al., 2014). 
They found that the laser power and cutting speed primarily influenced dross attachment. 
Based on the analysis of variance (ANOVA) analysis, all the cutting parameters included in 
the study had significant impact on the kerf width of the cut. The primary contributor was 
the laser power followed by its interaction with frequency. The possible downside of 
increasing laser power was that the kerf width increases (impacting precision), and the 
associated burning damage to the material that affects quality of the finishing (e.g. sharp 
corners appear rounded). 
In the context of the microbiopsy, the goal was to rapidly and accurately prototype a 
multitude of designs. However, a general feature is that the microbiopsy needed to consist 
of sharp defined edges capable of piercing and cutting the skin (Figure 3.3).  Therefore, 
the following parameters were identified as critical for this purpose: power, speed and 
Figure 3.2: Correlation of laser power and cutting speed. 
Overall effects of increasing power (Q) on cutting speed and thickness of cut (t) on 304 stainless steel 
Reproduced with permission from (Steen and Mazumder, 2010). 
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frequency. These parameters were assessed and optimised based on kerf width, heat 
affected zone (HAZ), dross attachment and cut completeness, which were sufficient for 
rapid prototyping. A further round of optimisation will be necessary for mass manufacture 
utilizing an expanded range of assessment parameters, but this is outside the scope of this 
thesis. The optimised laser parameters were employed to cut single needle microbiopsies 
to determine the reproducibility of the fabrication process. The possibility of using different 
material thickness for the microbiopsy device was also explored in this Chapter. Lastly, 
integrity assessment was performed during microbiopsy prototype application. The focus 
of the next Chapter was to characterise the content of microbiopsy samples and optimise 
the physical and mechanical properties of the device to achieve maximum tissue 
collection.  
Figure 3.3: Extended cutting element of microbiopsy cutting die. 
A perspective view of the extended cutting elements with a hollow chamber of an assembled 
microbiopsy cutting die (PROW, 2013) 
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 Materials and Methods 3.2
 Laser cutting system optimisation 3.2.1
Laser power, speed and frequency were adjusted for the LaserPro S290-20 laser etching 
system (GCC, Taiwan)  to determine the optimal settings for cutting 0.05 mm thick 304L 
medical grade stainless steel sheet (Mastercut Technologies, Australia). The system has 
an integrated 20W fibre laser to cut at a resolution ranging from 125 to 1000 dots per inch 
(DPI). The system consisted of an air compressor to prevent moisture from damaging the 
laser optics and remove particles generated during the laser cutting process. Assisted gas 
at ultimate pressure of 8 KPa was used during the laser cutting process. This system is 
compatible with a variety of graphic design software including AutoCAD, Illustrator, 
CorelDRAW and Photoshop. CorelDRAW Graphics Suite X5 (Corel, Canada) was the 
main software used for microbiopsy prototyping.  
Optimisation of the laser system was carried out in a two-step process. The first step 
consisted of cutting a minimum of 10 single lines 3.2 mm in length and 1.6 mm apart. The 
laser power was varied between 0% and 100%, the speed 0.002 m/s and 0.060 m/s and 
the frequency 0 kHz and 1000 kHz. After initial optimisation, the second step consisted of 
cutting at least three microbiopsies per sheet with either a single needle or array design. 
For both steps, the cuts were characterised via stereo microscopy (Stemi 2000C with 
Axiocam ERc 5s camera, Carl Zeiss Microscopy GmbH, Germany) using the integrated 
image analysis software (AxioVision LE64, Carl Zeiss Microscopy GmbH, Germany). The 
main variables assessed were kerf width, amount of dross and line straightness/uniformity. 
The microbiopsy designs were further assessed for quality of corners and curved lines. 
The kerf width of the laser cut line was defined as the width of the groove measured from 
one edge of the cut to the other edge. The completeness of the cut ranged from complete 
to partial to no cut. 
Post laser cut polishing of the microbiopsy (Figure 3.3) was also investigated to improve 
the overall finish. The cutting die were polished using a Dremel® rotary tool (Model 225, 
Mount Prospect, USA) attached with a 428 carbon steel polishing brush while they were 
still affixed within the stainless steel sheet. The finished microbiopsies were analysed as 
above. 
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 Surface area calculation 3.2.2
Low and high resolution images (6.5x and 20x magnification, respectively) were imported 
into ImageJ (NIH, USA) for high throughput image analysis of the kerf properties and 
surface area of removed metal. The image of each line was cropped to remove excess 
stainless steel area to minimise background noise related to reflectance. The image was 
converted to 8-bit and automatic greyscale threshold was set by clicking the [Auto] button. 
Dark background was chosen and the area of materials removed from the line was 
represented by black signal in the binary image. The image scale was set to 0.304 
pixels/µm using a scale bar exported from Axiovision LE64 software. The total surface 
area of the materials was calculated using the “Analyze Particles” function in the software. 
The size of particles was set at zero to infinity. Circularity of particles was defined as 0.00 
– 1.00. The results of the analysis were presented as “Outlines” and artefacts that were 
created due to background were not included in the calculation. 
 First generation microbiopsy cutting die functionality test  3.2.3
Optimised settings defined in the laser optimisation experiments were used to laser cut 
0.05 mm thick sheet to fabricate the first generation microbiopsy cutting die. The 
microbiopsy cutting die were assembled by stacking three plates of cutting elements 
together. Assembled microbiopsy cutting die was fitted and held together on a brass 
applicator with plastic spacers. The microbiopsy alignment was verified using stereo 
microscopy to ensure that all three plates were flush. It was then applied to excised human 
skin obtained from abdominoplasty patients. Informed consent approved by The University 
of Queensland Human Research Ethics Committee (Approval no. 2008001342) was 
signed by all patients. For preparation procedure of excised human skin, refer to Section 
2.2.1. The site of application was assessed by reflectance confocal microscopy (RCM) 
(Vivascope 1500 Multilaser, Lucid Inc., USA). Confocal image stacks with a field of view of 
0.5 x 0.5 mm were taken at 5 µm increments from the surface of the skin. Automatic 
intensity control was selected during the imaging process.  
In the second experiment, the outer plates of the microbiopsy cutting die were filed with 
sandpaper to create a thin tapered end. The microbiopsy cutting die was examined before 
and after application. The site of application was assessed by RCM and stacks taken with 
previous settings.   
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In the third experiment, the outer cutting plates were replaced with the tapered end cutting 
element fabricated from 0.01 mm stainless steel. Optimised laser speed and frequency at 
0.016 m/s and 300 kHz were set to laser cut 0.01 mm thick 304L stainless steel sheet. The 
power was reduced to 50% given that the thickness is only one-fifth of the usual stainless 
steel sheet. Application assessment described in the previous experiment was followed. 
 Statistical analysis  3.2.4
One-way ANOVA analysis was performed to analyse if there was any significant impact of 
the cutting parameters on the kerf width. Tukey’s multiple comparisons test were used in 
conjunction with ANOVA to determine whether there was any significant difference 
between the means of the kerf width. All statistical analysis was done using GraphPad 
Prism 6.0 (GraphPad Software Inc., USA). 
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 Results and Discussion 3.3
 Laser setting optimisation with lines 3.3.1
It was hypothesised that reproducible fabrication of microbiopsies from stainless steel 
sheet was achievable when the laser cutting system was optimised. The important laser 
parameters that were optimised include power, speed and frequency. In this series of 
experiment, the optimal settings resulting in a complete cut with the smallest kerf size was 
defined. Based on previous studies the main performance parameters for quality of cut 
include kerf width, HAZ and dross attachment (Keles and Oner, 2012, Russo Spena et al., 
2014, Uslan, 2005, Wang, 2000, Yilbas et al., 2012).  
A recent study conducted by Spena et al. (2014) on 1.5 mm twinning-induced plasticity 
steel sheets concluded that laser power was the main contributor to kerf width. Laser 
power itself is a major contributing effect of 36.5% on top kerf width (Russo Spena et al., 
2014).  Therefore, the optimisation experiments started off with evaluation of the effect of 
laser power on 0.05 mm stainless steel sheet. Lines (n=3) were cut on the 0.05 mm 
stainless steel sheet at varying power from 0% to 100%. There was no cut in the first two 
sets of line across all power settings. Partial cuts with laser power starting from 80% to 
100% for the third set of lines were observed. The outcome of the cuts was not similar 
even though the settings were identical for all three lines (Figure 3.4a). Measuring kerf 
width at similar locations across all three lines was limited given the amount of dross 
produced. Therefore, the measurements of the kerf width at five random locations that 
were clear of dross were taken. There was an increase in the width of the cut produced 
when power increased from 80% to 100% (54.8 ± 7.66 µm to 70.4 ± 7.65 µm) (Figure 
3.4b). Tukey’s multiple comparisons revealed that the kerf width differences between 80% 
to 90% and 100% were significant (p < 0.05). These results agreed with the data reported 
in Uslan’s study (Uslan, 2005).  
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Figure 3.4: Laser power optimisation.  
The impact of increasing laser power from 0% to 100% was determined with lines (n=3), when set 
at a speed of 0.02 m/s and at a frequency of 0 kHz (a). The average kerf width (n=5) of the lines 
was wider with higher speeds (b). Standard deviation (SD) is represented by the red bar for each 
data group. 
55 
 
The next parameter that was evaluated was laser frequency. A frequency test with the 
same speed and at a laser power of 100% was performed to standardise and be able to 
compare results between experiments. Partial cuts were observed at 0 kHz and 
frequencies between 700 kHz to 1000 kHz when maximum power was used. However, no 
cut was seen for frequencies between 100 – 600 kHz (Figure 3.5). Further testing 
revealed that there was a software/hardware issue leading to inaccurate communications 
between the laser cutting system and CorelDRAW software. The issue was outsourced to 
the supplier and corrected by the technical team. 
A speed and power test was carried out to make sure that the problem of inconsistency 
caused by the software and laser system was resolved. The lines were laser cut in 
triplicates using mid (50%) and high (100%) power, at varying speeds from 0.002 to 0.02 
m/s and a frequency of 300 kHz (Figure 3.6a). The cuts were similar when compared 
across each setting. None of the lines were cut when power was set at 50% (Figure 3.6a, 
Figure 3.5: Laser frequency optimisation.  
Three sets of lines (n=3) were laser cut at varying frequency from 0 to 1000 kHZ to determine the 
optimal laser frequency when laser was set at 100% power and 0.02 m/s speed. 
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Figure 3.6 Laser power and speed optimisation.  
Two sets of lines (n=3) were laser cut at varying speed from 0.002 to 0.020 m/s at 50% and 
100% power. The frequency was set at 300 kHz and kept constant for both sets of lines. 
left panel). On the other hand, all 30 lines were cut when power was set to the maximum 
(Figure 3.6a, right panel). This indicated that the minimum threshold to produce a cut 
was more than 50% power for this laser cutting system.  
A reduction of heat affected zone (HAZ) was observed speed was increased for both sets 
(Figure 3.6a, left and right panels). Low cutting speeds resulted in thermal damage to 
the material. This finding was also reported by Wang when cutting speed was increased 
from 0.045 m/s to 4 m/s (Wang, 2000). The decreasing trend of HAZ was true regardless 
of the power. He also reported an increase in HAZ with increased power. Observations in 
this study also revealed similar a finding with more pronounced heat affected HAZ at 100% 
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power (Figure 3.6b). Presence of dross was observed when laser cutting at higher speeds 
and at 100% power (Figure 3.6b, bottom row).  
Based on the previous power and speed test, a complete cut with minimum dross was 
achieved at 100% power and speeds between 0.002 m/s and 0.020 m/s. In the next study 
the maximum power and speed of 0.006 m/s was kept constant, while varying the 
frequency to investigate its influence on the kerf quality. Complete to partial cuts were 
achieved when the frequency was equal to or less than 700 kHz (Figure 3.7a, left panel). 
The enlarged images on the right panel of Figure 3.7a showed that the cuts were wider at 
higher frequencies (300 kHz to 700 kHz) than lower frequencies (100 kHz to 200 kHz). 
Only lines cut at 300, 400 and 600 kHz had a complete cut. Minimum dross within the cut 
was observed at 300 kHz (Figure 3.7a, right panel). Five measurements were taken 
randomly across the entire line and data presented as individual measurements with SD  
(Figure 3.7b). There was an observational trend in decreased kerf widths when frequency 
shifted from high to low (1000 kHz to 100 kHz). The results agreed with what Keles and 
Oner reported in their study. They described smaller kerf widths were achieved at higher 
frequencies between 1000 kHz to 1500 kHz. However, they did not see a clear trend of 
decreased kerf width with increasing frequency in different workpiece thickness (Keles and 
Oner, 2012). The cut at 300 kHz had a smaller kerf width (44.10 ± 3.25 µm) than 400 kHz 
(56.52 ± 3.59 µm).  A decreasing trend of HAZ when frequency was reduced was also 
observed (Figure 3.7a). In summary, the optimal frequency was determined to be 300 kHz 
given that the cut was complete with the smallest kerf width.  
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Figure 3.7: Repeat of laser frequency optimisation. 
Single set of lines were laser cut at varying frequency from 0 kHz to 1000 kHZ to determine the 
optimal laser frequency when laser was set at 100% power and 0.006 m/s speed (a). Five kerf 
width measurements were taken randomly within each line. Standard deviations of the 
measurements were indicated as the red bar in the graph (b). 
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The relationship between laser parameters is complex. Therefore, a wider speed range 
with 300 kHz and 100% power was performed to re-assess the optimal speed. Complete 
and partial cuts were observed when speed ranging from 0.002 m/s to 0.060 m/s was 
tested (Figure 3.8a). The cuts were observed to be complete with minimum dross at low 
speeds (0.002 to 0.018 m/s, left panel). More dross within the cut was observed with 
increasing speed (0.020 to 0.060 m/s, middle and right panels).    
To enable more accurate identification of the optimal speed, lines that had complete cut 
and the least amount of dross were first selected.  Kerf width of the laser cut lines 
processed at 0.002 m/s to 0.040 m/s were measured. The average kerf width was found to 
be wider when speed was more than 0.004 m/s (Figure 3.8b). The measurements did not 
indicate any trend of wider kerf width with increasing cutting speed. The lines were re-
imaged at higher magnification (20x) for kerf width measurement as the image resolution 
of Figure 3.8a was not sufficient. There were limitations to obtaining kerf width 
measurements as the edge of the kerfs was not defined. This was caused by varying 
amount of light passing through the lines due to the positioning of the flexible light guide.  
The angle at which the light guide was positioned changed the amount of light passing 
through the lines even though the light intensity was kept the same. The size of the kerf 
widths was variable within the line when processed at cutting speeds greater than 0.026 
m/s.  Therefore, the average kerf width of the cut might not be the most accurate 
representation on how the cutting speed affected the end quality. 
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Figure 3.8: Laser speed optimisation.  
Single set of lines were laser cut at 100% power, 300 kHz frequency and at varying speeds from 
0.002 to 0.060 m/s (a). Kerf width measured at five random locations within the cut (b). 
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To improve the method of defining which laser speed results in better quality of cut, binary 
images of the optical images were generated using ImageJ. The binary image depicted in 
Figure 3.9a shows the total surface area of material that was removed from the line. The 
indicated red arrows in Figure 3.9a were positions of cuts that had smaller kerf width. 
Therefore, as assumed earlier, the average kerf width may not be the best parameter for 
identifying optimal cutting settings.  Instead of quantifying the kerf width, the total surface 
area was quantified using the particle counting function in ImageJ. Overall, lines cut with 
lower speeds (0.002 – 0.008 m/s) were observed to be relatively straight and wide. Cuts 
above 0.026 m/s were irregular in width and wavy even though the kerf width was mostly 
narrower. The calculated total surface area of material that was removed within the line is 
shown in Figure 3.9b. The cutting speed that achieved complete cut with minimum dross 
was determined to be 0.010 m/s (Figure 3.9b). In summary, the line optimisation 
experiments defined optimal laser parameter settings of 100% power, 300 kHz frequency, 
and speed of 0.010 m/s.   
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Figure 3.9: Laser speed optimisation.  
Binary image of laser cut lines derived from previous speed test (Figure 3.8). Red arrows 
indicate areas with smaller kerf width within the line (a). Total surface area of material being 
removed for each line was calculated with ImageJ software (b). The black circle represents line 
with a complete cut while the cross symbol represents incomplete cut. 
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 Laser setting optimisation with single needle microbiopsy 3.3.2
The previous optimisation studies utilised a single straight line. However, the microbiopsy 
design consists of both straight and curved trajectories that may not result in optimal 
cutting quality based on the previously defined parameters. The differences in quality of 
cut were more evident in the power and frequency tests, and less defined in the speed 
test. Therefore, the first parameter that was investigated in this test was cutting speed. 
Single needle microbiopsy cutting die was laser cut at 100% power, 300 kHz frequency 
and at varying speeds between 0.002 to 0.040 m/s (Figure 3.10a-t). Complete cut was 
achieved with 0.008, and 0.012 – 0.016 m/s laser speeds as highlighted by red boxes in 
Figure 3.10d and 10f-h. Unfortunately, complete cut at 0.010 m/s, which was identified as 
the optimal speed in the straight line optimisation test was not observed. One explanation 
for the incomplete cut at 0.010 m/s could be due to the unevenness of the stainless steel 
sheet that was used. The stainless steel shim was trimmed down into smaller sheets using 
a pair of scissor before the microbiopsies were laser cut. The process of trimming might 
have warped the sheet. 
Another set of microbiopsy cutting die at varying speeds but with power reduced to 90% 
was laser cut. The power was scaled down to compare the microbiopsies cut at different 
powers and at varying speeds. The only cutting die that had complete cut were done at 
0.006 m/s and 0.008 m/s (data not shown). This finding correlated with what Steen and 
Mazumder previously  described (Figure 3.2) (Steen and Mazumder, 2010). Total surface 
area calculation was not possible as strong reflection was captured in the optical images, 
negatively influencing the image threshold adjustments. Kerf width measurements were 
obtained for microbiopsies with complete cuts. Kerf width measurements ranged between 
38.15 ± 6.2 µm to 44.51 ± 8.01 µm (Figure 3.10u). One-way ANOVA analysis indicated 
that the width differences between different speeds were not significant. Based on the 
results, cutting speed at 0.016 m/s was defined as the optimal speed given that the cut 
was more even across the entire laser path (43.04 ± 5.7 µm). The uniformity of the cut was 
partially attributed to a reduction in the amount of dross. 
64 
 
Figure 3.10: Laser speed optimisation using single needle microbiopsy.  
Greyscale images of single needle microbiopsy that were laser cut at 100% power, 300 kHz 
frequency and at varying speeds (a-t). Kerf width measurements of selected microbiopsies that 
had complete cuts were taken at 17 different sites (u). Red bars represent SD of kerf width 
taken at 17 different area of the microbiopsy. Microbiopsies laser cut at a power of 90% and 
100% were represented by the closed circles and open circles, respectively. 
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The frequency optimisation test was repeated with cutting die at varying frequencies from 
0 kHz to 1000 kHz to reconfirm that 300 kHz was the optimal frequency.  Laser was set at 
optimal power and speed of 100% and 0.016 m/s, respectively. Positive cuts for 
frequencies between 100 - 300 kHz, and minimal or no cut for other frequencies (Figure 
3.11a-k) were observed. Even though the cut had the highest average kerf width when 
processed at a frequency of 300 kHz, the cut width was more even compared to others 
Figure 3.11: Laser frequency optimisation using single needle microbiopsy.  
Greyscale images of single needle microbiopsy that were laser cut at 100% power, 0.016 m/s 
speed and at varying frequencies (a-k). Measurements of kerf width were collected at 17 
different locations from microbiopsies that had positive cuts (l). Standard deviation is 
represented by the red bars. 
66 
 
(26.24 ± 8.19 vs. 32.33 ± 6.89 vs. 36.12 ± 4.63 µm) (Figure 3.11i). Another observation 
noted in this test was that the cut width along the curved trajectory was narrower and had 
higher amount of dross at lower frequency (100 kHz) (data not shown).  
The arrayed microbiopsy was considered to be the ideal configuration, given that multiple 
tissue biopsies can be collected from a single application. It was important to ensure that 
the current laser settings are optimised for efficient cutting to prevent thermal damage to 
the surrounding area. This may in turn cause burning and warping of the microbiopsy 
cutting die. Array microbiopsy cutting die was laser cut using the optimised parameter 
settings defined above. Warping on the right needle for all three microbiopsies when cut 
individually (data not shown) was observed. Similar observations were noted when 
microbiopsy cutting die was laser cut on individual sheets (data not shown). Subsequently, 
the power to 95% was reduced and maintained the other settings. The resulting 
microneedles were all straight and flat for all microbiopsies (n=5) (Figure 3.12a). This 
indicated that the power was slightly above optimal level for laser cutting curved or angled 
trajectories.  Width and length measurements showed that the width and length for all 
microbiopsies were comparable and within ± 10% of the defined measurements (Figure 
3.12b). The widths and lengths of the right needle were observed to be more variable than 
Figure 3.12: Width and length measurements of array microbiopsies.  
Greyscale image of array microbiopsy that was laser cut at 95% power, 0.016 m/s speed and 300 
kHz frequency (a). Graph shows the average width and length of each needle (n=5) of array 
microbiopsies (b). The microbiopsy had needle length of either 700 µm or 1000 µm with a width of 
250 µm. 
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the other 2 for both 700 µm (SD: 5.47 vs 9.43 vs 10.22) and 1000 µm (SD: 5.95 vs 6.89 vs 
7.65) width microbiopsies. This might indicate slight distortion of the microbiopsy during 
the laser cutting process even though it was not visible to the eye.  
One focus of this project was to validate the microbiopsy technology as a platform for 
molecular analysis of small tissue samples. The amount of tissue sample collected was 
dependent on various factors. For example, if an arrayed microbiopsy was applied at an 
angle, there is a possibility that one microneedle may collect more tissue than others. To 
reduce possible risk of complications arising from arrayed microbiopsy, future 
assessments and validations were performed using a single needle configuration 
microbiopsy. In the final optimisation test, the goal was to verify the reproducibility of the 
channel width. In this test, microbiopsies with 5 different channel widths (Figure 3.13a-d) 
were included and five microbiopsies of each width were fabricated. A single measurement 
of the channel width was taken from each microbiopsy and compared within each group to 
determine if reproducible channel width could be achieved. The channel widths of all 
microbiopsies were within ± 10% of the defined measurements (Figure 3.13e).  
 
Figure 3.13: Channel width measurements of single microbiopsies.  
Single microbiopsies of varying channel widths that were laser cut at 100% power, 0.016 m/s 
speed and 300 kHz frequency (a-d). Graph shows the average width measurements for 
microbiopsies with different channel widths (n=5) (e). Red bar is the standard deviation of the 
width measurements. 
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 Device integrity assessment  3.3.3
It was important to establish the functionality of the microbiopsy cutting die configurations 
described in Figure 3.3. The geometry of the inner and outer plates of the microbiopsy 
cutting elements were shown in Figure 3.14a and 14b, respectively. The dimension of the 
hollow channel was approximately 0.42 mm in width and 0.87 mm in length. The 
microbiopsy cutting die was tested on a piece of excised human skin. No tissue was found 
in the channel but very small pieces of tissue were hanging on the edge of the cutting die 
(data not shown).  The site of microbiopsy revealed a circular hole that was approximately 
0.12 mm x 0.11 mm in size (Figure 3.14c). Reflectance confocal microscopy (RCM) 
identified a microbiopsy puncture site that was approximately 0.11 mm x 0.32 mm in 
dimension and penetrated up to 0.028 mm in depth (Figure 3.14d).  RCM mosaics were 
used to detect puncture site and observe impact of microbiopsy application to the skin. 
The microbiopsy site was identified with presence of cellular damage (indicated by red 
arrow) around the puncture site. The confocal stacks indicated that microbiopsy 
penetration was superficial (data not shown). This might imply that the cutting elements of 
the microbiospy were inefficient in piercing the skin. This could be due to a blunt cutting 
Figure 3.14: Functionality test of microbiopsy cutting die.  
Inner plate (a) and outer plate of cutting elements that forms the microbiopsy cutting die. Optical 
image shows site of microbiopsy application (c). RCM image shows a puncture site at 0.028 mm 
below skin surface (d). 
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edge or that the cutting elements were too thick to penetrate the skin. This also explained 
the lack of tissue present in the channel of the cutting die. The average thickness of 
human stratum corneum can range between 0.017 mm (cheek) to 0.179 mm (palm) 
depending on the body site (Egawa et al., 2007).   It was very likely that the cutting die just 
passed the rigid stratum corneum layer and penetrated superficially into viable epidermis. 
Therefore, only small pieces of cornified tissue was torn and removed from the skin during 
application. 
Accordingly, a sharp tapered end of the outer cutting elements was created by filing the 
edges and one side of the tip with sandpaper (Figure 3.15a and 15b). The microbiopsy 
cutting die was assembled with the tapered side of the outer cutting plate facing outwards, 
effectively creating a wedge (Figure 3.15c). This allowed the blade to cut into the skin 
without being pushed apart during penetration. Similar to the previous test, no tissue within 
the channel of the cutting die but only small pieces of tissue hanging on the edge of the 
cutting die (data not shown) was found. RCM mosaics identified the puncture site next to a 
hair folicle that was approximately 0.25mm x 0.75 mm in dimension (Figure 3.15d). Stacks 
of mosaics at 0.05 mm increments were taken to assess the penetration depth and scope 
of cellular damage around the application site (Figure 3.15e and 15f). The RCM image 
taken at 0.033 mm (Figure 3.15e) and 0.066 mm (Figure 3.15f) below skin surface 
revealed a distinct puncture region and intact tissue within the puncture site. This indicated 
that the the outer cutting plates penetrated efficiently into the skin but the cutting die did 
not remove the tissue from the skin.  This experiment showed that a sharp and thin outer 
cutting element may be necessary for effective penetration to get pass the rigid cornified 
layer. Confirmation of penetration depth was not possible using RCM due to the lack of 
contrast in the excised skin. 
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The outer plate was replaced with 0.01 mm thick 304L stainless steel to create a cutting 
die of similar width to the manually filed plate (Figure 3.16a). The hypothesis was that a 
thinner outer cutting blade would result in improved penetration due to less resistance 
during application. The microbiopsy cutting die was applied to the skin using the same 
applicator and speed. However, both the 0.01 mm outer cutting plates were bent post 
application (Figure 3.16b). There was no visible penetration into skin when examined 
under the stereo microscope. This suggested that a sharp tapered edge was the key to 
achieve effective skin piercing. The thickness of the outer cutting element was not the 
cause for superficial penetration into skin as seen in the previous experiment.  
Figure 3.15: Functionality test of tapered tip cutting die.  
Outer cutting plates were filed on one side of the tip (a) - (b) to create sharp tapered end for the 
cutting die (c). RCM image shows a puncture site located next to a hair follicle at a various depths 
below skin surface (d) – (f). 
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 Conclusions 3.4
Fabrication of the microbiopsy device was not possible without first optimising the laser 
cutting parameters. However, the optimisation process was not straight forward and 
instead consists of a complex matrix of parameters such as frequency, speed and power. 
Additionally, the laser parameters were unique for different type of materials and their 
thickness with optimised settings for one material of a certain thickness not applicable for 
the same material of different thickness. Furthermore, parameters were machine 
dependant.  
Even though assisting gas pressure and beam divergence were also important factors to 
consider when optimising laser parameters, adjustments to these laser parameters were 
not possible due to the set-up of the laser system The trends observed correlated with 
previous publications even though the lasers were of vastly different powers and the 
materials were also thicker in the industrial applications than what was used in these 
experiments. For example, the kerf width was reduced from 65.67 ± 2.44 to 44.10 ± 3.25 
by decreasing the laser frequency to the optimal level of 300 kHz from 800 kHz. This 
improvement enabled relatively accurate microneedles to be fabricated in just a few 
seconds for the studies described in the following Chapters 4, 5, 6, and 7. This showed 
that the previous observations could be adapted for micromedical device prototyping. 
Figure 3.16: Functionality test of cutting die with 0.01 mm thick outer plates.  
The optical images show the before (a) and after (b) microbiopsy application.  
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These experiments were sufficient to optimise the laser parameters for the purpose 
microbiopsy prototype fabrication. Further optimisation of laser cutting parameters is 
required for mass manufacturing but this is outside the scope of this thesis.  
Compared to industrial optimisation of laser cutting systems, these optimisations were 
limited to thin shim material and therefore not as detailed as what has been described in 
more sophisticated systems/applications. Others have reported the use of high resolution 
scanning electron microscopic images for accurate measurements of the heat affected 
zone (HAZ) and kerf width. Making these measurements in the context of the microbiopsy 
was not as relevant as the industrial applications, so the analysis was limited to optical 
assessment of kerf width and dross characterisation.  
The findings from this Chapter have highlighted the importance of laser parameter 
optimisation. The conceptual path outlined in the literature was followed and applied to the 
principals of microbiopsy fabrication protocol using a laser etching system. This opened up 
the possibility for microbiopsy fabrication. The preliminary experiments have shown the 
potential of the first generation microbiopsy cutting die for microsampling of skin tissue. 
However, more optimisation was needed once functional testing began and these 
experiments were discussed in Chapter 4.  
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  Chapter 4
Microbiopsy optimisation and characterisation 
 Introduction 4.1
Skin biopsy is one of the most essential techniques in dermatology for accurate diagnosis 
of neoplastic or inflammatory skin diseases through histopathological assessment. This 
technique is performed under local anaesthetic by trained medical personnel, normally a 
dermatologist, to remove a skin sample 2–4 mm in diameter using a punch biopsy tool or a 
scalpel (Figure 4.1). The wound is then either sutured or left to heal. The sample is then 
preferably sent to a dermatopathologist for histopathological diagnosis. Pathological 
examination using skin biopsies often complements and/or confirms diagnosis of common 
neoplastic or inflammatory skin diseases (Sina et al., 2009). 
An excisional biopsy, a common alternative in neoplastic skin conditions, is performed 
when the entire tumour is needed for histopathological examination, or when melanoma is 
suspected. This depends on the size and location of the lesion and can be performed 
using a larger 4 – 6 mm diameter punch biopsy, a deep shave biopsy, or with a fusiform 
excision (Pickett, 2011a). These biopsy techniques coupled with histopathology diagnosis 
enable accurate analysis of the disease occurrence and progression. However, the 
downsides of these techniques are that they require local anaesthesia and sutures in 
addition to the time required to carry out the procedure. Furthermore, use of a sample that 
is generally fixed with formalin hinders molecular analysis.  
Molecular pathology is rapidly advancing as a field and will become increasingly important 
in dermatology. The first step to molecular analysis is DNA and RNA preparation and 
isolation. They are basic but important steps for many molecular analysis protocols. 
Individual or parallel isolation and purification of DNA, RNA and protein from mammalian 
cells can be done using commercially available kits and reagents. These kits utilise either 
anion-exchange columns (Budelier and Schorr, 2001), silica membrane columns (Moore 
and Dowhan, 2001a), magnetic beads (Berensmeier, 2006) or organic extraction (Moore 
and Dowhan, 2001a). General benefits include time-saving, straight forward process and 
effectiveness in isolation and purification.  
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The downsides of using kits are higher cost per sample and inflexibility for isolation of 
samples that involve special conditions (Moore and Dowhan, 2001b, Kingston, 2001). Kit 
selection depends on the amount of starting material, the compatibility of sample types 
and the nature of downstream applications. The small size of microbiopsy samples creates 
challenges for downstream processing. Pre-analytical variability can cause bias and 
variability to downstream molecular analysis (Espina et al., 2009, Spruessel et al., 2004). 
Cells within the tissue biopsy can react to the sampling procedure (Spruessel et al., 2004). 
Figure 4.1: Size comparison of needle biopsy devices and biopsy comparisons.   
A conventional biopsy punch is shown on the left, an 18 gauge syringe needle in the centre and 
the inner chamber of the microbiopsy device on the right, Panel (a) the microbiopsy device 
chamber is 0.15 mm in width with an outer width of 0.25 mm. The top row of Panel (b) contains a 
conventional 3 mm biopsy site and tissue, whereas the bottom panels show microbiopsied skin 
and tissue. Reproduced from (Lin et al., 2013). 
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Therefore, commercially available reagents used for stabilising tissue (PAXgene), and 
DNA and/or RNA (RNALater®) are used to preserve the integrity of the macromolecule 
(Gundisch et al., 2013, Staff et al., 2013, Lee et al., 2013, Pérez-Portela and Riesgo, 
2013).  
Molecular fingerprinting of skin disease has the potential to dramatically improve 
diagnostic sensitivity and open the door for personalised medicine (Greinert, 2009, Shivers 
et al., 2007, Ugurel et al., 2009). To date, there have been no reports on biomarker 
profiling of lesional samples in a prospective study. This is due to the lack of suitable 
technologies to perform multiple, non-destructive sampling over time. Furthermore, the 
iatrogenic issue of cutting out the lesion through biopsy precludes further study of that 
lesion. This problem exists in many medical disciplines and has led to the evolution of 
experimental diagnostic devices that tend to be miniature versions of their predecessors. 
This miniaturisation trend is enabled by several factors including improved micro-
manufacturing tolerances, decreased costs and increased availability. One of the earliest 
micro-devices developed to obtain biopsy samples was patented by Krulevitch et al 
(Krulevitch P.A., 1999). They patented vascular microbiopsy/precision cutting devices 
fabricated by conventional machining, silicon micromachining, precision machining and 
injection moulding. Over the years, there have been many similar patents that report a 
variety of similar microbiopsy devices.  
The unifying theme is that the vast majority of these patents describe micro-biopsy devices 
for breast or intestinal tissue sampling (Byun S., 2005, Cho D., 2011, Cosnier et al., 2009, 
Pflueger D.R., 2004) and importantly none were engineered for skin or skin lesions. Our 
group has developed a new microbiopsy platform technology that enables the collection of 
tiny pieces of skin using a micro-medical device that is minimally invasive and does not 
require local anaesthesia (IP Australia Appl. Num. 2012901490, filed on 16/04/2012). 
There are situations when conventional biopsies are not appropriate. Skin disease may 
present with multiple lesions and/or in a cosmetically sensitive area. The microbiopsy 
device has the potential to fill a void in dermatology where conventional biopsies are not 
feasible or could do more harm than good. The aims of this Chapter were to: 
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AIM 1 Determine the content of microbiopsy samples 
AIM 2 Observe the wound healing kinetics of microbiopsy site 
AIM 3 Evaluate commercial extraction approaches 
AIM 4 Optimise microbiopsy application and configuration parameters 
This Chapter compared conventional biopsy and microbiopsy. Characteristics of the 
microbiopsy tissue and microbiopsy site were evaluated. Different molecular processing 
methods using commercially available kits and protocols were explored to determine the 
optimal handling procedure for microbiopsy samples. This Chapter also discussed 
important application and configuration parameters of the cutting tip, which were critical for 
optimisation of tissue collection. To summarise briefly, the experiments included in this 
Chapter show that the microbiopsy sample can contain 1000 to 3000 cells corresponding 
to approximately 5 – 10 ng of DNA. The use of the microbiopsy did not cause any adverse 
reactions in volunteers. Small sample size was overcome by amplification via polymerase 
chain reaction (PCR) and the samples were comparable, in terms of quality and quantity, 
to the much larger matched conventional biopsies.  
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 Materials and Methods 4.2
 Fabrication of cutting tips with varying widths, geometries and micro-4.2.1
texturing 
The cutting tips were fabricated from 304L stainless steel with varying widths using 
the S290-20 laser system at 100% laser power (Chapter 3, Figure 10), speed of 
0.016 m/s (Chapter 3, Figure 10) and frequency of 300 kHz (conditions optimised in 
Chapter 3, Figure 11).The cutting tips used in the volunteer studies were polished 
and assembled according to the protocol described in section 2.1.1. However, the 
microbiopsy devices were sterilised in 70 % isopropanol prior to use instead of 
gamma irradiation. To accommodate the large amount of microbiopsies required for 
the studies, their fabrication was outsourced to Mastercut Technologies (Burleigh 
Heads, Australia). The microbiopsies supplied were cut according to my 
specifications. The microbiopsies that were subjected to micro-texturing were 
fabricated using photochemical etching and the designs with different geometries 
were fabricated using Mastercut’s laser cutting systems. Different levels of micro-
texturing were achieved in-house by adjusting the laser’s cutting speed and 
resolution as shown in Table 5.  
Table 5: Laser parameters used for micro-texturing of cutting tip. 
Microbiopsy O1 O3 O4 O5 O6 O8 M4 M6 
Resolution (DPI) 125 250 380 380 500 500 380 500 
Speed (m/s) 0.026 0.026 0.011 0.026 0.011 0.026 0.011 0.011 
 
A clean microscope slide was put on top of M4 and M6 cutting tips during micro-
texturing to prevent the cutting element from warping. Increasing the resolution (DPI) 
of the laser decreases the spacing between each laser pulse. Higher DPI produces 
more etching in a fixed surface area, creating a rougher surface. On the other hand, 
lower cutting speed can achieve a deeper etch.  
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 Punch biopsy and microbiopsy characterisation 4.2.2
Conventional punch biopsies (Proscitech, Australia) and microbiopsies were taken 
from excised human skin. The punch biopsy diameters were 3 mm, 1 mm, 0.50 mm 
and 0.35 mm. The dimensions of the microbiopsy tested in this experiment were 
0.25 mm (width) x 1 mm (length) x 0.15 mm (thickness). The excised skin was 
mounted on a cork board, stretched and held down by blunt syringe needles. 
Microbiopsies were applied to the excised skin using the standard spring from the 
Unistik® 2 blood lancet (Owen Mumford, UK, # 08470-0702-01).  
Optical images were collected using a Stemi 2000C stereo microscope (Carl Zeiss, 
Microscopy GmbH, Germany) after biopsies were applied. Tissue samples extracted 
by either the microbiopsy or the standard punch biopsy were treated with DRAQ5™ 
DNA dye (5 mM, BioStatus Limited, UK, #6313) diluted in phosphate buffered saline 
(PBS). Nuclear labelling of microbiopsy samples were done with the tissue remaining 
within the chamber of the cutting tip. Microbiopsy samples were incubated in the 
DNA dye solution for 5 minutes; 0.35 mm and 0.50 mm punch biopsy samples for 15 
minutes, and; 1 mm and 3 mm punch biopsy samples for 30 minutes. Incubation was 
done in the dark at room temperature. The samples were removed, rinsed and 
stored in PBS. The tubes were wrapped in aluminium foil to prevent photo-bleaching 
by light exposure. Reflectance and fluorescence confocal images were acquired 
using Vivascope® 2500 (Caliber Imaging & Diagnostics, Inc., USA). Single-field (0.5 
mm x 0.5 mm) or mosaic (single-field images that were stitched together) vertical 
stacks were taken using automatic intensity control (AIC) settings. Images were 
acquired using L2 (fluorescence) and L3 (reflectance) filter bars at an excitation 
wavelength of 488 nm. Zero depth was marked at surface on fluorescence channel 
to ensure both reflectance and fluorescence images were taken from the same initial 
depth. In the repeated experiment, the tissue samples were subjected to 5-10% citric 
acid (Sigma-Aldrich, USA, #251275) treatment before incubating with DNA dye to 
enhance nuclear visibility in the reflectance channel.  
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 Total cell count 4.2.3
Microbiopsy tissue samples were imaged using confocal microscopy (Zeiss 510 
META, Carl Zeiss Microscopy GmbH, Germany) at 2-µm incremental optical 
sections. A three-dimensional projection of the microbiopsy with tissue sample was 
created using Imaris (Bitplane Scientific Software, Switzerland) from the z-stacks. 
ImageJ software (NIH, USA) was used to count the number of nuclei in the 
microbiopsy tissue samples. The grey threshold was adjusted for each image. The 
size of ten individual nuclei was measured to determine the average diameter and 
area of the cells, which was used to guide the software’s automated particle 
analysis. The cell count per stack or block (mosaic) was estimated by dividing the 
sum of area over the average size per nucleus. 
 Histology of microbiopsy skin defect 4.2.4
Excised human tissue that was subjected to microbiopsy application was embedded 
in Tissue-Tek® optimal cutting temperature (OCT) compound (VWR International Pty 
Ltd., USA, #25608-930) and cryosectioned (CM1850, Leica Microsystems Pty Ltd, 
Australia). Histology sections of 10 µm thickness were fixed with 100% cold 
methanol (VWR International Pty Ltd., Australia, #US006360) for 10 minutes, air 
dried and stained with haematoxylin and eosin (Varistain Gemini ES, Thermo Fisher 
Scientific Inc., USA) to visualize the microbiopsy sites. 
 DNA isolation comparison 4.2.5
Commercially available DNA isolation kits, NucleoSpin® Tissue kit (MACHEREY-
NAGEL, Germany, #740952) and QIAamp DNA Micro kit (QIAGEN, GmbH, 
Germany, #56304) were used to compare the DNA yield from 2 mm punch biopsies 
and 0.20 mm microbiopsies. The punch biopsies were collected from excised human 
skin and stored in -80oC freezer until they were ready for processing. The samples 
were finely chopped using a disposable surgical scalpel blade on a microscope slide. 
Each tissue sample (punch biopsy or microbiopsy) was put into a Lysing Matrix D 
tube (MP Biomedicals, USA, #116913050) containing either 180 µl Buffer T1 and 25 
µl Proteinase K (NucleoSpin® Tissue kit) or  180 µl Buffer ATL and 20 µl Proteinase 
K (QIAamp DNA Micro kit). Only punch biopsies were subjected to additional 
homogenisation using a FastPrep® FP120 (Thermo Savant, USA) at 6.5 m/s speed 
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for 45 seconds per cycle. Tissue disruption was completed with 3 cycles. 
Subsequent DNA isolation steps were carried out according to manufacturers’ 
protocol for both kits.  
This experiment was repeated with NucleoSpin® Tissue XS kit (MACHEREY-
NAGEL, Germany, #740901) and QIAamp DNA Micro kit (QIAGEN, GmbH, 
Germany, #56304).  
 Channel width pilot study 4.2.6
Microbiopsy cutting tips of four different channel widths ranging from 0.05 mm to 
0.20 mm were evaluated. These cutting tips were fabricated by our S290-20 laser 
cutting system. Microbiopsies were applied on excised human skin and repeated 
until three successful microbiopsies for each width were collected. The microbiopsy 
tissue samples were treated with 1 mM Acridine Orange (Sigma-Aldrich, USA, 
#A6014-25G) for 20-30 seconds to stain for both DNA and RNA. This assay allowed 
quantification of the total amount of nucleic acid. Each tissue sample was removed 
from the microbiopsy device with a clean 30-gauge syringe needle prior to imaging to 
avoid background noise in the reflectance channel from the metal cutting tip. Single-
field fluorescence and reflectance images at 2 µm incremental step-wise vertical 
stacks were acquired with Vivascope® 1500 Multilaser at an excitation wavelength of 
488 nm. L1 filter bar was used. The number of nuclei from each image was counted 
using ImageJ software. 
The experiment was repeated with the addition of 0.40 mm, 0.60 mm, 0.80 mm and 
1 mm channel widths. Three microbiopsy cutting tips from each width were applied 
to excised human skin. DNA was extracted from each successful collection using the 
QIAamp DNA Micro Kit (QIAGEN, GmbH, Germany, #56304) as described in section 
2.3.1. The total amount of DNA per sample was determined by the Qubit® dsDNA 
HS assay (refer to section 2.3.3). 
 Surface roughness (RA) pilot study  4.2.7
Four microbiopsy cutting tips of decreasing surface roughness (RA) on the channel 
edge were evaluated. The microbiopsy with the highest roughness amplitude 
consisted of a jagged inner channel wall. The other three RA were fabricated with 
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cutting tips of 0.15 mm channel width. The cutting tip was polished with either 428 
carbon steel brush (cut and polish) or fine sandpaper (smooth). It was assumed that 
the microbiopsy that was not subjected to polishing after laser cutting had higher 
roughness amplitude than the cutting tips that were polished.  Three cutting tips from 
each test group were collected. DNA from each sample was extracted using the 
QIAamp DNA Micro Kit as described in section 2.3.1. DNA quantification was done 
using the Qubit® dsDNA HS assay (refer to section 2.3.3).  
 High resolution device imaging 4.2.8
A bench top scanning electron microscope (SEM) (JCM-6000 Neoscope, JEOL, 
USA) was used to acquire high-resolution images of the microbiopsy device. The 
roughness amplitude of the microbiopsy chamber was obtained by measuring the 
average distances of the edge to a regression-fitted straight line using MatLab 
(Mathworks, Australia). The Matlab equation was developed by Hames S. (PhD 
student within the Group). 
 Quasi-static and velocity-aided biopsy application 4.2.9
The conventional cylindrical punch biopsy and the microbiopsy were applied using 
either quasi-static or dynamic (velocity-driven) application. Static administration was 
achieved by manually pushing and twisting the biopsy tool into excised skin. For 
dynamic application, the cylindrical cutting blade of the punch biopsy was removed 
and attached to a modified plunger (refer to details on section 2.1.4).The number of 
successful and unsuccessful punch biopsies was recorded. The sites of application 
for the second method were imaged with the Vivascope® 1500 Multilaser. Prior to 
imaging, the sites of biopsy were treated with 5% citric acid as per protocol 
described in section 4.2.2. 
 Pre-load and application velocity pilot study  4.2.10
Microbiopsy cutting tip with a channel width of 0.15 mm was used in the pre-load and 
application velocity preliminary study. Pre-load is the force or pressure applied to the 
skin prior to applying the microbiopsy resulting in pre-tensioning of the skin.  Three 
different preloads were defined for the study being none, medium and high, which 
corresponded to approximately 0, 10 and 20 N, respectively. Zero preload was 
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achieved by resting the applicator lightly on the excised skin before application. The 
two higher preloads were achieved by firmly pressing the applicator onto the skin 
prior to and during microbiopsy application. The force was controlled by placing the 
skin on a scale. The applicator was pressed firmly on the skin before application to 
achieve medium preload. The preloading application forces determined by Alex 
Ansaldo (research engineer) were 0 N, 10N and 20 N respectively. Increasing 
application velocities were achieved with the use of different compression springs 
and making modification to the standard plunger from the UniStik® 2 blood sampling 
device. The test groups included in this study were (1) standard plunger with spring 
from punch biopsy device, (2) plunger with a long scallop (cut) and spring from 
punch biopsy device, (3) standard plunger with standard spring from blood sampling 
device, and (4) application without spring (quasi static). The corresponding velocities 
of these groups were 15 m/s, 13.4 m/s, 9.4 m/s and 0 m/s. Three microbiopsy 
samples were collected from each test group.  
The application velocity experiment was repeated to determine the upper velocity 
limits. This experiment was performed on the volar forearm of a single volunteer. The 
microbiopsy applicator (Figure 4.2) was designed by Alex Ansaldo and fabricated 
using a V-Flash® Personal 3D Printer (3D System, USA). A range of compression 
springs were used to achieve different application velocities. Velocity of the springs 
was calculated using a spring velocity calculation software developed by Alex 
Ansaldo. Microbiopsy cutting tip of 0.15 mm channel width was used in the 
experiment. The application velocities tested were 0.5 m/s, 2.3 m/s, 6.0 m/s, 8.3 m/s, 
12.0 m/s and 14.2 m/s. Microbiopsy applications were carried out according to 
protocol described in section 2.2.2. Clinical photographs were used to documented 
skin after microbiopsy application. The sites of microbiopsy application were 
examined under reflectance confocal microscopy (RCM).  
DNA from each sample obtained from these preliminary experiments was extracted 
using the QIAamp DNA Micro Kit as described in section 2.3.1. The total amount of 
DNA per sample was quantified by the Qubit® dsDNA HS assay as described in 
section 2.3.3.  
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  Wound healing kinetics 4.2.11
A single microbiopsy was applied onto the forearm of each volunteer (n=2). The 
microbiopsy site was imaged using handheld dermoscopy and reflectance confocal 
microscopy. Images were taken before and at various time-points (immediate, 24-
hours, Day 8, Day 14, and Day 21) after microbiopsy application. Single mosaic and 
single-field of 2 µm-step increment images were collected at each time point. This 
experiment was conducted under the approval from Metro South Human Research 
Ethics Committee, Princess Alexandra Hospital (HREC/11/QPAH/442).  
 Measurement of pain score 4.2.12
A blinded pain score evaluation was conducted among 20 volunteers who were 
recruited in the width and application velocity study. Each volunteer was presented 
with an assessment form to grade his/her expected pain score based on a numerical 
rating 10-point Likert scale, 0 as having no pain and 10 as pain as bad as they can 
imagine before the start of the experiment. The order of microbiopsy application was 
randomised in the study. Each microbiopsy application was performed one minute 
apart and the pain score recorded immediately after application. Five minutes after 
the final microbiopsy application, the volunteers were asked to rate the level of pain 
for each microbiopsy site to understand if the pain they experienced would last more 
than five minutes. The volunteers also provided descriptive words related to the pain 
they felt during and after the microbiopsy application. Zero channel width 
Figure 4.2: In-house microbiopsy applicator.   
Microbiopsy applicator fabricated by 3D printing system. It consists of a housing case with 
three loading positioner, compression spring and a plunger with a slit at the tip to fit the 
microbiopsy cutting tip.  
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microbiopsy and application without spring were included in the study as negative 
controls. Based on the findings of Gill et al. (2008), it was considered unnecessary to 
include the commercially available 0.35 mm conventional punch biopsy was not 
necessary to be included in the study based on previous study (Gill et al., 2008).  
 Human volunteer study 4.2.13
Two volunteer studies were conducted under Metro South Human Research Ethics 
Committee, Princess Alexandra Hospital approval (HREC/12/QPAH/082).  
The first study investigated the influence of channel width, application velocity and 
surface roughness on the amount of tissue collected. The second examined the 
impact of micro-texturing and different geometries on the amount of tissue extracted. 
 Channel width, application velocity and surface roughness study  4.2.14
A total of 20 volunteers were recruited for this study. Ten microbiopsies were 
collected from each volunteer’s forearm. Six channel widths and four application 
velocities were evaluated in the study. The bore size of the channel ranged between 
0 mm to 0.30 mm. The tested velocities were between 1.1 m/s to 20.2 m/s. The bore 
size of microbiopsy used to test application velocities was 0.15 mm. Clinical images 
of the forearm were documented before and after microbiopsy application. 
Dermoscopic photographs of each microbiopsy site before and after application were 
collected. The photographs were collected with a Canon Power Shot G10 digital 
camera (Canon, Japan) and a dermatoscope attachment (Dermlite©, 3Gen, USA). 
Each microbiopsy was applied according to the protocol described in section 2.2.2. 
Presence of tissue and/or blood were confirmed under stereo microscopy and noted 
in the collection form. DNA was extracted from all of the microbiopsy samples using 
the QIAamp DNA Micro Kit (refer to section 2.3.1). Each DNA sample was eluted 
with 23 µl of AE buffer. The maximum amount of sample volume (20 µl) was used in 
the Qubit® dsDNA HS Assay (refer to section 2.3.3) to quantify the amount of DNA 
in each sample. 
A separate study was conducted to evaluate cutting tips that had lower surface 
roughness than the microbiopsies fabricated with the S290-20 laser cutting system. 
In this study, the cutting tips fabricated with two different laser cutting systems (in-
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house S290-20 and a customised industrial laser cutting system), in addition to 
chemical milling were compared. Four cutting tips from each test group were 
collected. 
All samples were processed for DNA extraction. The total amount of DNA per 
sample was quantified using the Qubit® dsDNA HS assay (refer to section 2.3.3). 
Statistical analysis was performed using PRISM 6 for Windows (GraphPad Software, 
Inc., USA). Channel width, velocity and roughness amplitude data were presented as 
mean ± SD. Pain score for channel width and velocity were presented as minimum 
to maximum box-and-whiskers plot. One-way ANOVA combined with a Tukey’s 
multiple comparison post-test was performed to determine the statistical significance. 
 Micro-texturing and geometry study 4.2.15
Ten volunteers were recruited to test 15 different cutting tips that were either micro-
textured using the in-house laser engraving system or had a different geometry from 
the standard cutting tip. Examinations of the microbiopsy devices post application to 
check for presence of tissue or blood were not done. DNA was extracted from all of 
the microbiopsy samples using the QIAamp DNA Micro Kit (refer to section 2.3.1). 
Each DNA sample was eluted with 23 µl of AE buffer. Maximum amount of sample 
volume (20 µl) were used in the Qubit® dsDNA HS Assay (refer to section 2.3.3) to 
quantify the amount of DNA in each sample. 
 RNA isolation, quantification and quality control  4.2.16
Three pieces of excised human skin samples were cut up into finer pieces and 
subjected to different isolation methods. For RNA isolation with TRIzol® (Life 
Technologies, USA, #15596-018), 500 µl of TRIzol® reagent was added to the tissue 
sample. The sample was frozen at -20oC and thawed on ice repeatedly for 4 to 8 
times to disrupt the tissue. Post disruption, 100 µl of chloroform was added to the 
sample. The tube was then shaken vigorously. The sample was incubated at room 
temperature for 2-15 minutes or until a phase separation was seen.  The sample was 
centrifuge at 12,000 x g for 15 minutes at 4oC. The mixture separated into a lower 
red phenol-chloroform phase, an interphase and a colourless upper aqueous phase. 
The aqueous phase was collected and transferred to a new microcentrifuge tube. An 
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equal volume of isopropanol was added and mixed well with the sample. The sample 
was then incubated at room temperature for 10 minutes. Centrifugation of the 
sample was performed at 12,000 x g for 8 minutes at 4oC. Most of the isopropanol 
(supernatant) was removed without disrupting the pellet. The pellet was washed 
using 500 µl of 75% ethanol prepared with nuclease-free water. The sample and 
ethanol solution was then vortexed followed by centrifugation at 7,500 x g for 5 
minutes at 4oC. The majority of the ethanol solution was removed and a 10-µl pipette 
tip was used to remove the remaining solution without disrupting the pellet. The 
pellet was air dried on a Kimwipes towel (Kimberly-Clark Professional, USA, #34120) 
for approximately 10 minutes. Nuclease-free water (30 µl) was added to the pellet 
and mixed well by pipetting. The sample was then incubated at 55-60oC in a water 
bath for 10 minutes to solubilise the pellet. 
The other isolation method evaluated was with RNeasy Mini kit (QIAGEN, GmbH, 
Germany, #74106). The chopped up tissue sample was further disrupted either by 
liquid nitrogen in a pestle and mortar or in a Lysing Matrix D tube. A small volume of 
liquid nitrogen was poured onto the mortar containing the tissue sample. The snap-
frozen sample was then ground using the pestle. Post processing, the sample was 
placed in a clean microcentrifuge tube containing 350 µl of Buffer RLT using a 
spatula. Disruption of the tissue in a Lysing Matrix D tube was carried out as 
described in section 4.2.4 of this Chapter except that 350 µl or 600 µl of Buffer RLT 
was used. Prior to use, 10 µl of beta-mercaptoethanol (Sigma-Aldrich, USA, 
#M6250) was added to every 1 ml of Buffer RLT. Isolation and purification of RNA 
samples were carried out according to the manufacturer’s protocol. 
The total amount of RNA was quantified using the Qubit® RNA BR Assay (Life 
Technologies, USA, #Q10211) as per the manufacturer’s protocol. Quality control of 
the samples post quantification was done using the Bioanalyzer RNA 6000 Pico Kit 
(Agilent Technologies, USA, #5067-1513) as per the manufacturer’s protocol. 
After determination that good quality total RNA could not be extracted via the 
protocols described earlier, a commercial kit (Arcturus® PicoPure® RNA Isolation 
Kit, Life Technologies, USA, #KIT0204) designed for single cell was tested. 
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Microbiopsies collected from excised actinic keratoses were selected to compare 
total RNA quality of microbiopsy to lesional samples.  The total RNA was isolated 
from microbiopsy and lesional samples according to the protocol described in 
sections 2.4.1 and 2.4.2. The total RNA was quantified using the Qubit® RNA HS 
Assay (Life Technologies, USA, #Q32855) and RNA BR Assay following protocol 
described in section 2.4.3. The quality and integrity of the total RNA were determined 
using the Bioanalyzer RNA 6000 Pico kit.  
  Molecular characterisation of lesional and microbiopsy samples 4.2.17
Comparison of DNA and RNA from microbiopsy and its matched lesional samples 
were assessed. Identical amounts of total DNA (1.85 ng) for both lesional and 
microbiopsy samples were subjected to whole genomic amplification. The 
amplification procedure was carried according to manufacturer’s instructions (REPLI-
g Single Cell Kit, QIAGEN, Australia, #150345). The integrity and quality of amplified 
DNA were assessed using the Bioanalyzer DNA 120000 Kit (Agilent Technologies, 
USA, #5067-1508). 
Identical amounts of total RNA (14 ng) for both lesional and microbiopsy samples 
were subjected to whole transcriptome amplification. The procedure was carried out 
using the supplied instructions (QuantiTect Whole Transcriptome Kit, QIAGEN, 
Australia, #207043). The cDNA obtained from the amplification process was used as 
a template in a polymerase chain reaction (PCR) reaction using human beta actin 
primers (forward: ATC TGG CAC ACC TTC TAC AAT GA; reverse: CGT CAT ACT 
CCT GCT TGC TGA TCC AC) (Integrated DNA Technologies, NSW, Australia). 
There was an initial denaturation for 2 minutes at 98°C, followed by 30 cycles of 
98°C for 30s (denaturation), 67°C for 30s (annealing), and 72°C for 1 minute 
(extension). The cDNA and PCR products were run on a 1% agarose gel (Bio-rad 
Laboratories, Inc., Australia) and visualized with RedSafe (ChemBio Ltd., UK, 
#21141). HyperLadder™ 1 kb (Hyper- Ladder I) (Bioline, UK, #BIO-33053) was used 
to determine the mass of cDNA and human beta actin amplicons. 
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 Results and Discussion 4.3
 Characterisation of microbiopsy content and site of application 4.3.1
Figure 4.3 provides a visual presentation to the reader on the varying sizes of 
conventional punch biopsy compared to the microbiopsy. RCM was used to visualise the 
microbiopsy application site. RCM images revealed a microbiopsy site similar to the size of 
a small hair follicle in the dermal papillary post microbiopsy application (Figure 4.4a and 
4.4b). The inset shows that microbiopsy application resulted in a puncture site that was 
approximately 0.10 × 0.50 mm in dimension (Figure 4.4b). Microbiopsy samples were 
Figure 4.3: Conventional punch biopsy and microbiopsy sites and biopsy materials.  
Site of four punch biopsies and microbiopsy application on excised human skin (a), and 
respective biopsy materials of varying sizes (n=2) (b). Clockwise from top left: microbiopsy, 1 
mm, 0.50 mm, 0.35 mm; centre is 3 mm (a-b). Middle row shows the enlarged optical images of 
biopsy sites (c-g). Bottom row are the enlarged optical images of the biopsy materials (h-l).  
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stained with DRAQ5™ (BioStatus Limited, UK) to highlight the nuclei. Confocal images 
were used to generate a 3D model of the microbiopsy sample. The usual skin strata were 
apparent in this model. I estimated that there were 1634 nuclei in Figure 4.4c. Puncture 
sites that were approximately 0.22 ± 0.12 mm wide and 0.26 ± 0.09 mm deep in excised 
abdominal skin from 10 histological sections were observed (Figure 4.4d). 
 
Figure 4.4: Site of microbiopsy and microbiopsy content.  
Panels (a) and (b) are reflectance confocal microscopy mosaics of a microbiopsy site, hair 
follicles are featured in the centre and on the right hand side of the images for size comparison 
(bar indicates 0.50 mm in a and b). Panel (c) shows a 63x magnification, 3D rendering of the 
microbiopsy tissue with a nuclear counter stain (orange) derived from a confocal microscopy z-
stack of the sample within the microbiopsy device. The stratum corneum (SC), viable epidermis 
(VE), dermal-epidermal junction (DEJ) and superficial dermis (DER) are labelled. This 
microbiopsy contained an estimated 1634 nuclei. Haematoxylin and eosin stained section of 
human skin after microbiopsy application shows a 0.10 mm wide and 0.25 mm deep puncture 
(n=10) (d). * indicates the site of microbiopsy application. Reproduced from (Lin et al., 2013). 
90 
 
Figure 4.5: Visualisation and quantification of tissue biopsy from microbiopsy device.  
Tissue samples were extracted using varying channel widths from 0.05 mm to 0.20 mm (left to 
right). Three microbiopsies from each width were applied on excised human skin. Merged 
fluorescence (red) and reflectance (grey) confocal images were taken either as single-field or 
mosaics. 
  Quantification of cellular material 4.3.2
The previous experiment illustrated that increasing the size of the punch biopsy results in 
greater tissue yield. Therefore, it was hypothesised that increasing the chamber volume of 
the microbiopsy by widening the channel of the cutting element will increase the amount of 
tissue collected. To test this, four microbiopsy cutting tips with channel widths ranging from 
0.05 mm to 0.20 mm (Figure 4.5) were applied to excised human skin. The tissue sample 
was treated with 5% citric acid with the biopsy in situ to improve the nuclear visibility of the 
samples. Tissue was observed on the edges, surface of the cutting element and within the 
channel of the cutting tip.  Single-field images were successfully acquired for 
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mostsamples. Four out of 12 samples were too big and the images of the samples were 
acquired in cubes (z-stacks of mosaic images). 
This method can provide a gross estimate of the total cell count for each tissue biopsy. 
However, the signal-to-noise ratio and z resolution of the confocal system were not 
sufficient to separate individual cells. Hence, this analysis method was not pursued to 
quantify amount of cellular material. An accurate quantification method to compare the 
amount of tissue was to quantity the DNA within each microbiopsy sample.  
4.3.4 DNA isolation comparison 
Two commercially available DNA kits were selected to compare the total DNA yields from 
2 mm punch tissue biopsy and microbiopsy sample. The total DNA yield from the QIAamp 
DNA Micro kit was higher in both samples compared to the NucleoSpin® Tissue kit 
(Figure 4.6a). The punch tissue biopsy was included in the study as a positive control to 
ensure that the kits functioned as expected. The difference could be due to the latter kit 
not being suitable for small tissue samples. The experiment was repeated to compare the 
QIAamp DNA Micro kit and another kit from NuceloSpin® that was advertised to effectively 
isolate DNA from small tissue samples. The number of microbiopsy tissue samples was 
Figure 4.6: DNA isolation kits comparison.  
Panel (a) and (b) show the comparison in total DNA yield isolated by two commercially available 
kits. One sample from punch biopsy and microbiopsy were compared for assessing Nucleospin 
kit to QIAamp kit (n=1) (a). Kits recommended for DNA isolation from small tissue samples were 
also compared (n=5) (b). Punch tissue biopsy of 2 mm in diameter is indicated as ●, Microbiopsy 
tissue biopsy with a channel width of 0.20 mm is indicated as ■, and the negative control (elution 
buffer) is indicated as ᵡ. Mean with standard deviation (SD) is represented by red error bar. 
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increased in this experiment to see the range of total DNA that could be obtained with the 
0.20 mm channel microbiopsies. There was no significant difference between the average 
total DNA yield from the NucleoSpin® Tissue XS kit (5.99 ± 2.22 ng) and the QIAamp DNA 
Micro kit (6.97 ± 2.46 ng) (Figure 4.6b). Overall, QIAamp isolated a higher yield of DNA 
from the microbiopsy samples. Therefore, unless specifically mentioned all future DNA 
isolations were carried out using the QIAamp DNA Micro kit.  
 Wound healing kinetics 4.3.3
Immediately after microbiopsy application, local erythema developed that resolved within 
24 hours. The tiny excision site from the microbiopsy healed quickly and was invisible to 
the naked eye after 24 hours (Figure 4.7). Dermoscopy and RCM were used to monitor 
the wound healing process at regular intervals (Figure 4.7, center and right columns).  It 
was hypothesised that the microbiopsy device enables acquisition of tissue samples with 
minimal to no risk of infection. The healing kinetics advocates potential for minimal 
infection and is a safe device for biopsy collection in humans. A study by Donnelly et al. 
supports this hypothesis by showing that the site of microneedle array application results 
in significantly less microbial infiltration than puncture by a 21G hypodermic needle. They 
also showed that the the infiltrated microorganism did not cross the viable epidermis in the 
microneedle-punctured site (Donnelly et al., 2009). Even though the dimensions of each 
microneedle was smaller  (0.25 x 0.28 mm) than the microbiopsy (0.50 x 0.80 mm), it was 
shown in Figure 4.4d that the puncture sites were only 0.22 ± 0.12 mm wide and 0.26 ± 
0.09 mm deep and were no deeper that what one could expect from a hypodermic needle.  
In addition, there was no adverse reaction reported by 20 volunteers when applied with the 
microbiopsy device. This suggested that the process is not prone or no more prone to 
infection than an injection. 
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Figure 4.7: Wound healing kinetics of microbiopsy site.  
The left column shows dermoscopic images of the microbiopsy site (n=2) over time. The middle 
and right column are mosaics and at 30x magnification reflectance confocal microscopy (RCM) 
images, respectively, of the microbiopsy site. Reproduced from (Lin et al., 2013). 
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 Influence of channel width on tissue extraction 4.3.4
It was hypothesised that optimal tissue extraction can be influenced by different 
geometries and configurations, application velocity, and surface roughness of the 
microbiopsy cutting tip. A series of preliminary experiments were conducted to determine 
the correlation between these factors and amount of tissue collection. Based on the 
previous experiment shown in Figure 4.5, more tissue biopsy was observed with 
microbiopsy cutting tips consisting of wider channel widths. A pilot study was performed by 
testing channel widths ranging from 0.05 mm to 1 mm (Figure 4.8a-h) to determine the 
width limit at which unsuccessful tissue collection occurred.  
Microbiopsy cutting tips with a channel width of 0.05 mm collected the least amount of 
tissue with an average of 4.28 ± 2.83 ng DNA. The cutting tips with 0.10 mm channel width 
had the highest amount of tissue collected (9.26 ± 2.06 ng). The cutting tips with 0.05 mm 
and 0.15 mm channel widths ranging had 100% collection rate (3 out of 3). Four out of six 
microbiopsies with a channel width of 0.10 mm resulted in successful tissue extraction. 
The microbiopsy extraction decreased to three out of six when the width was increased to 
0.20 mm. Tissue collection was unsuccessful when channel widths were greater than 0.20 
mm (Figure 4.8i). It was determined that there was a moderate correlation of increased 
total DNA with increasing channel width when there were successful tissue biopsy 
collections (correlation coefficient, r = - 0.7884). However, increased width results in lower 
successful microbiopsy extraction. 
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Figure 4.8: Pilot channel width study.  
Panel (a) to (h) shows cutting tip of different channel width ranging between 0.05 mm to 1 mm. 
Average total DNA (n=3) was compared between different channel widths (i). 
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A volunteer study with 20 healthy individuals was conducted to determine the optimal 
channel width and application velocity. Isolated DNA mass was chosen to be the primary 
indicator for sample-to-sample comparisons. Tissue collection (4.5 ± 1.5 ng DNA) was 
observed around the rough edges of a microbiopsy device without a chamber (Figure 
4.9a, channel width of 0 mm). Successful collection was achieved when tissue was evident 
within or around the device and unsuccessful if no tissue was present. Tissue was 
collected from all volunteers (n=20) when a 0.15 mm channel width microbiopsy device 
was used. Only 13 successful collections were achieved when a 0.20 mm channel width 
microbiopsy device was used. This indicated that the collection rate decreased from 100% 
to 65% when channel width was increased by 0.05 mm. This experiment showed that a 
channel width of 0.15 mm resulted in the highest average amount of DNA (5.9 ± 3.4 ng), 
which was significantly higher than 0.25 and 0.30 mm channel widths (p < 0.0001). There 
was no significant difference in the total DNA extracted between 0 to 0.20 mm channel 
widths (Figure 4.9a). High resolution images of the microbiopsy cutting tips were 
illustrated in Figure 4.9b.There was no change in the level of pain reported when 
microbiopsies with varying channel widths were applied (Figure 4.9c). The pain score 
study did not include the 0.35 mm conventional punch biopsy as previous studies have 
shown that it was the length and not the width of the microneedle that significantly 
influenced level of pain experienced by volunteers. 
 Influence of pre-loading on tissue extraction  4.3.5
It was hypothesised that a higher amount of pre-loading creates higher surface tension to 
the skin, which in return penetrates the cutting tip deeper into skin. By penetrating deeper 
into the skin, more tissue can be collected in the process. The outcome of the experiment 
shows that a minimum of 10 N is required for successful extraction of the microbiopsy 
sample. Preloading application forces higher than 10 N did not appear to increase tissue 
collection (n=1, 4.5 ng vs. 4.76 ng).  
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 Influence of application velocity on tissue extraction 4.3.6
One of the questions was whether velocity-aided application of the microbiopsy was 
required for successful tissue biopsy. Quasi-static and velocity-aided biopsy applications 
were compared using both the punch biopsies and the microbiopsy. Tissue biopsy 
collection was defined as successful if there was presence of tissue within the device after 
Figure 4.9: Microbiopsy channel width optimisation in a volunteer study.  
Channel width and velocity were varied to optimise the microbiopsy device configuration. Total 
DNA was used as a surrogate for sample size. Panel (a) shows the DNA extracted from device 
with varying channel width (n=20 per channel size) and that the maximum amount of DNA was 
collected with 0.15 mm channel width. Panel (b) displays high resolution scanning electron 
microscopy images showing different channel widths of the microbiopsy device. Panel (c) shows 
the level of pain volunteers reported when different channel width microbiopsies were used. 
Figure modified from (Lin et al., 2013) 
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application. In the quasi-static experiment, all the punch biopsies (n=3 for each group, 0.35 
mm, 0.50 mm, 1 mm and 3 mm) successfully collected tissue. However, no tissue was 
observed within the microbiopsy cutting tips in this experiment (data not shown). The 
results from dynamic application showed that one out of three 0.35 mm and 1 mm punch 
biopsies successfully extracted tissue while two out of three tissue biopsies were collected 
using the 0.5 mm punch biopsy. The success rate for tissue extraction with the 
microbiopsy device in this experiment was 100% (n=3). The potential to extract tissue from 
velocity-aided punch biopsy was found to be variable compared to the microbiopsy. This is 
expected as it was shown in Section 4.3.5 that the success rate decreased as the width of 
cutting tip increases. Reflectance confocal microscopy was used to examine the site of 
unsuccessful biopsy applications. Confocal images showed that the skin was penetrated 
by the punch biopsy at the application sites but tissue biopsies remained intact.  There 
was 0% success rate for the 3 mm velocity-aided punch biopsy. 
The comparison between quasi-static and dynamic microbiopsy application emphasised 
the importance of velocity on microbiopsy extraction. The velocity was further investigated 
by varying the speed using different compression springs and adjusting the height where 
the spring sits before the device was loaded. Microbiopsy cutting tips did not penetrate the 
skin when applied under quasi-static application. The highest amount of DNA was 
obtained at 15 m/s (6.75 ± 1.22 ng) followed by 13.4 m/s (4.94 ± 2.83 ng) and 9.4 m/s 
(2.47 ± 1.55 ng). All groups except the standard spring had 100% collection rate (three out 
of three). Only two microbiopsies from the standard spring group successfully obtained 
tissue sample. Although the study demonstrated an increase in velocity resulted in 
increased tissue extraction it was limited by the lack of identical plungers. Hence, in order 
to expand the range of application velocities in the study, an alternate applicator and 
plungers were fabricated. Also, the range of velocity tested was too small to identify the 
upper limit of application velocity. In order to expand the range of application velocity, 
proper device applicator and plunger had to be fabricated.   
Following fabrication of an alternate microbiopsy applicator suitable for varying 
administration velocity (described in Section 4.2.10), six different velocities were tested. 
Dermoscopy and reflectance confocal images showed that the microbiopsy did not 
penetrate the skin when applied at 0.5 m/s and 2.3 m/s. Superficial skin penetration was 
seen when the microbiopsy was applied at 6.0 m/s. There was no tissue found in those 
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Figure 4.10: Pilot application velocity study.  
Panel (a) shows dermoscopic (left panels) and reflectance confocal (middle panels) images of 
application sites and the tissue biopsies collected from each group (right panels). Total DNA 
extracted from each application velocity (b). The red error bar is the SD. 
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Figure 4.11: Application velocity optimisation.  
Panel (d) shows the varying velocity applied and that the maximum amount of DNA was 
collected when the device was applied at 16.6 m/s. Panel (e) shows the level of pain volunteers 
reported when application velocity was varied. The red error bars represent the SD. Figure 
modified from (Lin et al., 2013) 
 
microbiopsies when examined under stereo microscopy (Figure 4.10a). Successful tissue 
collection was obtained when microbiopsies were applied at minimum a speed of 8.3 m/s  
(4.49 ng). The amount of DNA plateaued between 3.62 ng to 4.25 ng when application 
velocity was higher than 8.3 m/s (Figure 4.10b).  
The study was repeated in a volunteer study (n=20). Microbiopsy application velocity was 
evaluated by using defined applicator springs to achieve velocities between 0 to 20.2 m/s 
(Figure 4.11a). Only negligible amounts of DNA were recovered when the device was 
applied at less than 9.2 m/s. However, there was a 7.5-fold increase (0.8 ± 0.8 to 6.0 ± 3.0 
ng) in DNA recovered when the application velocity was increased from 9.2 m/s to 16.6 
m/s (p < 0.0001). An additional increase to 20.2 m/s increase in application velocity did not 
result in significant increases in DNA collection. 
The level of pain and variation increased when microbiopsies were applied at increasing 
velocities but there was no significant relationship between increased velocity and the 
amount of pain experienced (Figure 4.11b). All of the volunteers had a pain score of 0 at 5 
minutes after the final microbiopsy application (data not shown). The volunteers scored 
pain between 0 to 10 with an average score of 1.5 ± 1.1, when the 0.15 mm channel width 
microbiopsy was applied at 20.2 m/s. 
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Figure 4.12: Pilot surface roughness study.  
Panel (a) to (d) shows cutting tip of different surface roughness. Average total DNA (n=4) was 
compared between different groups (e). SD is represented by the red error bar.  
 Influence of surface roughness on tissue extraction 4.3.7
Surface roughness was hypothesized to increase friction between the sample and 
microbiopsy. Rougher edges were produced by having jagged lines within the channel 
edge. Smoother edges were achieved by performing a polishing step to the cutting tips 
after laser cutting (Figure 4.12a-d). There was no significant difference in increased total 
DNA with increasing surface roughness in this test (Figure 4.12e). One reason to explain 
this outcome is that polishing was only applied on the surface of the cutting tips and not 
within the channel edge. The roughness amplitude of the main surface should have 
minimal to no impact on tissue collection given that surface contact with skin during 
application only happens on the edges of the cutting tip. In addition, the roughness of the 
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Figure 4.13: Roughness amplitude optimisation.  
Panel (a) shows that microbiopsy devices with higher roughness amplitude channels are 
capable of collecting more DNA. Panel (b) contains high resolution scanning electron 
microscopy images showing different channel widths and roughness of the microbiopsy device. 
Reproduced from (Lin et al., 2013). 
 
edges was only assessed visually and not quantified in this pilot. Therefore, this may not 
be an accurate representation on how roughness amplitude may affect tissue collection.  
The findings from the channel width study showed that successful collection was achieved 
using microbiopsy cutting tips without a centre chamber (Figure 4.9a, 4.5 ± 1.4 ng from 
channel width 0 mm). Therefore, it was hypothesized that the surface roughness of the 
cutting tip edge might play an important role in tissue collection. Microbiopsy devices with 
varying roughness amplitudes (RA) were compared and resulting in a trend of increasing 
total DNA extracted with increasing RA (Figure 4.13a) (n=20 for 5.36 RA and n=5 for 0.92 
and 1.32). The SEM images of the inner chamber edge were used to measure the RA. 
These measurements ranged from relatively smooth (RA 0.92) to rough (RA 5.36) (Figure 
4.13b, side view). 
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 Influence of geometry and surface texturing on tissue extraction 4.3.8
The previous static and velocity-aided punch biopsy application experiments demonstrated 
that geometry of the cutting tips might influence the success of extracting tissue. In this 
volunteer study, 18 microbiopsies were tested on each volunteer. Out of the 18 
microbiopsies, ten were of different geometry (Figure 4.14, G1B to G2A) and eight were 
surface textured on the outer cutting elements (Figure 4.14, 01 to M6).  Based on 
previous usage experience, the microbiopsy that was identified with the highest total 
amount of DNA in the earlier volunteer study could have unsuccessful tissue collection. 
Therefore, the optimal microbiopsy design in the current study was defined as the one that 
resulted in the most reproducible tissue extraction efficiency (highest total amount of DNA 
and smallest SD). Microbiopsy cutting tips with a short hook shape (G1B, G2B, G2E) and 
standard G2A had the least variability in amount of tissue collected (Figure 4.14, graph). 
Tissue collection using other geometries had inconsistent results. Of those four cutting tip, 
G2A had the least variability (3.06 ± 0.76 ng). Out of the surface textured microbiopsies, 
01 had the most reproducible outcome (2.91 ± 0.91 ng). G2A was identified as the optimal 
microbiopsy as it had higher total DNA than 01. 
A new laser was commissioned by Mastercut Technologies after the first volunteer study. 
Roughness amplitude of the laser cut edge was re-assessed to ensure that this was not a 
contributing factor to the total DNA variability in the geometry study. The roughness 
amplitude of cutting tips fabricated by the existing laser in Mastercut Technologies was 
0.92 µm.  
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Figure 4.14: Geometry and surface texturing optimisation.  
Scanning electron microscopy (SEM) showed high resolution images of the microbiopsy cutting 
tip with different geometries (G1B to G2A, row 1 and 2) and those that were surface-textured on 
the outer cutting elements (01 to M6, row 3 and 4). Mean with SD (red error bar) of total DNA 
isolated from each group were illustrated in the graph. 
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  Microbiopsy RNA isolation optimisation 4.3.9
Only 1-5% of total RNA consists of messenger RNAs (mRNA) while the rest are comprised 
of ribosomal RNAs (80-85%), low molecular weight RNAs and small nuclear RNAs (15-
20%). For small tissue samples like the microbiopsy, it is critical to determine the most 
efficient method for good quality RNA extraction. The ideal quality of RNA for most 
downstream applications is determined as RIN 8-10. The RNA yield from frozen human 
skin using different extraction methods was compared. RNA yield can vary depending on 
quantity of tissue sample. Excised human skin of similar weight was used to compare the 
efficiency of different extraction methods. RNA yield of 2.53 µg was obtained using the 
TRIzol® reagent and 0.44 µg using pestle and mortar disruption and the RNeasy Mini kit. 
The amount of RNA was too low for detection when the FastPrep® instrument and the 
RNeasy Mini kit were used together. This could be due to insufficient amount of RLT Plus 
lysis buffer during the disruption step. Sample was lost when disruption step was done 
with pestle and mortar. This explains the low RNA yield outcome using this method. I 
repeated the experiment comparing the TRIzol® reagent and the FastPrep® instrument 
with the RNeasy Mini kit. The RNA yields were 0.66 µg and 0.13 µg, respectively. RNA 
yields from both experiments using the TRIzol® reagent were relatively similar and higher 
than sample isolated with the RNeasy Mini kit. The RIN for both TRIzol®-extracted sample 
was 2.6, and <1 for RNA extracted using pestle mortar and FastPrep® instrument. The 
tube containing tissue sample and lysis buffer was observed to be warm during disruption 
step with FastPrep® instrument. The samples also had two freeze-thaw cycles before 
quality analysis. These may have contributed to RNA degradation. Both methods did not 
appear to isolate RNA of sufficient quality.  
In order to make relevant comparison of total RNA quality, microbiopsy and its matched 
lesional sample were included in this experiment. A commercial kit, Arcturus® PicoPure® 
RNA Isolation Kit, which was designed to isolate total RNA from single cell was used.  The 
quality of RNA for four out of five microbiopsy samples compared to their matched lesions 
was comparable but slightly lower.  This was expected as microbiopsy samples were 
collected 20 to 30 minutes after lesions were excised. Changes to the integrity of RNA 
within minutes post excision was expected as reported by Spruessel et al. (Spruessel et 
al., 2004). Similar variability in integrity of the lesions that were preserved using 
RNALater® reported by Pérez-Portela and Riesgo (Pérez-Portela and Riesgo, 2013) was 
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also observed. The RIN ranged from 2.6 to 7.2 for the lesions and 1.2 to 7.6 for the 
microbiopsy tissue samples. 
Representative Bioanalyzer results for the conventional biopsy (RIN 6.50) and microbiopsy 
(RIN 5.10) are shown in Figure 4.15, Total RNA. The results showed that there are 
similarities and differences in the RNA bands, which may be due to the large amount of 
tissue sampled with conventional biopsy and the relatively small number of cells sampled 
with the microbiopsy. The small sample size is an inherent limitation of the microbiopsy 
device. To mitigate this, a pilot experiment was conducted where the microbiopsy sample 
was subjected to whole transcriptome amplification for RNA analysis. A skin sample with 
the same amount of starting material (14 ng) was included as an amplification control in 
the experiment. A 2000-fold increase in cDNA from both samples based on total RNA and 
cDNA measurements was noted. The cDNAs were of comparable quality and quantity 
(Figure 4.15, Transcriptome Amplification to cDNA). Subsequently, PCR was used to 
amplify human beta-actin mRNA. Two identical bands at 800 bp with comparable PCR 
product quality both lanes were observed (Figure 4.15, Actin PCR). 
Berglund et al. (2007) reported that their optimised methodology yielded an average 1.4 ± 
0.4 μg of consistently high quality RNA (8.4–8.9 RIN) from 3 mm skin punch biopsies 
(Berglund et al., 2007). Another group reported that they had isolated an average of 1.5 μg 
of RNA with an average RIN value of 8.1 from half of a 4 mm punch biopsy skin sample 
(n=97) (Bruning et al., 2011). The average total RNA yielded from the microbiopsy device 
was 9.0 ± 10.1 ng (n=5). Even though far less RNA with the microbiopsy device was 
isolated, this proof-of-concept study supports the hypothesis that this limitation can be 
addressed using commercial amplification kits and PCR (Figure 4.15) for investigating the 
molecular basis of skin disease. Through the course of these experiments, RNA integrity 
values that ranged between 1.2 and 7.6 were observed with the microbiopsy. These 
values correlated with matched conventional shave biopsies. In some cases the values 
were quite low (e.g. RIN 5.1 in Figure 4.15) and would not be considered for whole 
transcriptome approaches. Sampling for RNA analysis can be difficult and optimizing this 
application for the microbiopsy is one of our priorities as we move forward with this 
technology.  
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 Conclusions 4.4
Characterisation experiments have shown that a typical microbiopsy sample contained 
approximately 1000 to 3000 cells. Image analysis was used to estimate the number of 
cells based on counting nuclei, as the viable epidermis has relatively few multinucleated 
cells. This approach was fast and non-destructive to the samples but was limited by only 
estimating the number of cells. Total DNA was eventually used as a marker to determine 
the amount of microbiopsy tissue that was collected. The microbiopsy was optimised 
through testing various application (velocity) and configuration (i.e. channel width, surface 
roughness, geometry designs and surface texturing) parameters in volunteers. The first 
volunteer study included testing a range of application velocities between 1.1 m/s to 20.2 
Figure 4.15: Molecular characterisation of conventional shave biopsies and 
microbiopsies.  
The left panel shows the Bioanalyzer readout from amplified DNA from a conventional actinic 
keratosis (AK) shave biopsy next to the microbiopsy DNA sample obtained from the same AK 
lesion. The right panel compares the RNA quality of a shave biopsy and normal skin 
microbiopsy that were subjected to total transcriptome amplification to generate cDNA. The 
cDNA was then used as a template for a PCR reaction containing actin specific primers with an 
expected product at 800 bp. Figure modified from (Lin et al., 2013). 
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m/s; microbiopsy with channel widths ranging from 0 mm to 0.30 mm and surface 
roughness from 0.92 µm to 5.36 µm. In the second volunteer study, ten different 
geometries and eight different surface textured microbiopsies were tested. Total DNA and 
RNA from microbiopsy samples can be isolated effectively using commercial kits designed 
for small samples. The quality and integrity of microbiopsy samples can be affected by the 
pre-analytical process (i.e. how tissue was collected and stored). The RIN of microbiopsy 
samples isolated using the same kit ranged from 1.2 to 7.6. To conclude, the outcome of 
this Chapter firstly identified G2A microbiopsy with a channel width of 0.15 mm as the 
optimal design for reproducible tissue collection. Optimal application velocity was 
determined as 16.6 m/s. Secondly, isolation of total DNA and RNA with commercial kits 
ranged from 2.12 ng to 9.90 ng and 1.09 ng to 25.52 ng, respectively. Finally, the problem 
of small sample size for extensive downstream molecular analyses was overcome through 
amplification where a 2000-fold increase in cDNA from 14 ng of starting material was 
observed.  
There are several benefits of microbiopsy over a ready-made 0.35 mm punch biopsy that 
is also in the submillimetre size range as the microbiopsy device. One apparent benefit is 
that microbiopsy samples can be safely collected in volunteers without the need to 
administer local anaesthetics unlike the approach with conventional punch biopsy. There 
was also no report of adverse reaction from the application of microbiopsies. Considering 
that the channel width of the microbiopsy is at least half the size of the 0.35 mm punch 
biopsy, the healing process for a microbiopsy application site would have been quicker 
than an area that had been biopsied by the punch biopsy. The current cost of making one 
microbiopsy in a small laboratory scale is approximately $10 and is 1.5 times the price of a 
single punch biopsy. However, it is anticipated that the cost will be reduced once the 
production is scaled-up. In terms of diagnostic utility, both devices are unsuitable for 
histopathological analysis given their sizes.  
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 Chapter 5
Genotyping and mutation profiling applications 
 Introduction  5.1
In Chapter 4, the characterisation of the microbiopsy content and the quality compared to 
conventional punch biopsy tissue was examined. It was hypothesised that microbiopsy 
technology is a minimally invasive approach to assess conventional biomarkers for skin 
diseases. The primary focus of this Chapter was to assess the Microbiopsy technology for 
molecular analysis of pigmented and non-pigmented skin lesions. These proof-of-concept 
experiments tied to clinical skin disease research described here were published as three 
articles in JAMA Dermatology journal. The following four aims were addressed: 
AIM 1 Assess the suitability of microbiopsy extracted samples for genotyping  
AIM 2 Determine the effects of microbiopsy application on histopathologic 
diagnosis in melanocytic skin lesions 
AIM 3 Evaluation of BRAF and NRAS mutation profiles in pigmented lesions 
AIM 4 Profile somatic mutation status of significant p53/Rb pathway genes in non-
pigmented lesions 
The diagnosis of skin lesions can be confounded by the quality of clinical information and 
morphological nature of the histopathologic interpretation (Ferrara et al., 2009). 
Considering that histopathological analysis is the current gold standard for diagnosing 
dermatological diseases, it is critical that microbiopsies will not jeopardise downstream 
histopathology assessment. Conventional chemical fixation of the lesions after being 
excised can hinder downstream molecular analysis. The microbiopsy device provides the 
opportunity to acquire a small tissue sample for molecular analysis without the need to 
remove the entire lesion.  
Validating the microbiopsy device in these skin lesions is critical for future translation of 
this technology into clinical practice. There is significant interest and need for a better 
understanding of the underlying genetic basis of disease development and progression in 
both melanoma and non-melanoma skin cancer. 
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The B-Raf proto-oncogene (BRAF) is expressed in many human cells including the 
melanocytes. The occurrences of BRAF mutations are approximately 70% - 82% in naevi 
and 50% - 60% in melanomas (Davies et al., 2002, Pollock et al., 2003). The most 
prevalent BRAF mutation is a valine to glutamine substitution that occurs at position 600 
(V600E, 74% - 90%), followed by V600K (16% - 29%) (Thomas, 2006). These mutation 
sites account for 95% of all BRAF mutations. It is speculated that the BRAF mutation plays 
an important role in the genetic basis of melanoma development and progression. This 
series of morphological changes begin as a benign naevus and then becomes a 
melanoma through the formation of a dysplastic naevus as described by the Clark model 
(Bennett, 2003).  
The discovery of BRAF as an important oncogene in disease progression has led to 
development of targeted molecular therapies such as BRAF inhibitors. These therapies 
have significantly, but importantly, only temporarily, improved the survival of patients with 
advanced melanoma and have shown promising outcomes in the treatment of other 
diseases (Girotti et al., 2014, Nguyen et al., 2014, Berghoff and Preusser, 2014). 
BRAFV600E inhibitors blocked tumor growth and induced partial or complete regression in 
metastatic melanoma (Flaherty et al., 2010). Considering that the BRAFV600E mutation is 
highly prevalent in benign naevi (Pollock et al., 2003), it is of no surprise to see changes to 
existing melanocytic naevi and the appearance of new naevi during kinase inhibitor 
therapy (Haenssle et al., 2012, Dalle et al., 2011, Perier-Muzet et al., 2014). New primary 
melanomas arising from naevi that are rapidly changing or proliferating during the early 
stages of vemurafenib therapy were found to be BRAF wild type (Dalle et al., 2011, Perier-
Muzet et al., 2014, Zimmer et al., 2012). Clearly, the outcome of the targeted therapy 
depends if the mutation is present within the naevus and there is a need to develop 
personalised treatment for individual patients. It is likely that there will be targeted 
inhibitors for local skin treatment in the future. The development of the microbiopsy as a 
companion diagnostic for such therapeutics would be beneficial. 
Similar to melanocytic skin lesions, actinic keratoses (AK) are thought to progress into 
squamous cell carcinoma (SCC). However, the majority of the actinic keratoses do not go 
on to become SCC (Feldman and Fleischer, 2011, Fuchs and Marmur, 2007). Molecular 
profiling of AK, SCC and normal skin suggested that the dysplastic lesions and carcinomas 
share certain differentially expressed genes (Hameetman et al., 2013, Padilla et al., 2010). 
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To date, there has been no report on biomarker profiling of lesional samples in a 
prospective study given the lack of suitable technologies to perform multiple sampling over 
time. The microbiopsy technology platform is capable of collecting multiple micro-size 
samples that can be potentially used for biomarker profiling of these lesions. Given the 
sample size differences, it is crucial to validate the molecular profiles from both 
microbiopsies and shave biopsies.  
The Chapter begins with discussion on preliminary experiments to optimise and validate 
the potential of the microbiopsy device for DNA genotyping. Disease formation and 
progression is a complex process. In order to shed light on the role of relevant mutations in 
disease progression, microbiopsy samples were acquired from suspicious dysplastic 
lesions for molecular analysis. Three independent case studies were conducted to 
evaluate the mutation status of BRAF and Neuroblastoma RAS viral oncogene homolog 
(NRAS) genes in dysplastic melanocytic lesions. The data from these three case studies 
were published in JAMA Dermatology, a leading Dermatology journal (McClenahan et al., 
2014, Banan et al., 2013, Tan et al., 2015). The last experiment of this Chapter described 
the somatic mutation profiling of significant genes related to p53/Rb pathway in dysplastic 
non-pigmented skin lesions.  
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 Materials and Methods 5.2
 Melanocortin 1 receptor (MC1R) and Oculocutaneous albinism II (OCA2) 5.2.1
genotyping  
These experiments were conducted with approval from Metro South Human Research 
Ethics Committee in Princess Alexandra Hospital (HREC/12/QPAH/082) and The 
University of Queensland Human Ethics Review Committee (Approval number: 
2012000648). 
The subjects were recruited from an ongoing clinical study at the Dermatology Department 
of Princess Alexandra Hospital (HREC/09/QPAH/162). One microbiopsy was collected 
from the forearm of each subject. A total of five subjects, four Caucasians and one Asian, 
were included in these preliminary genotyping experiments. DNA was extracted according 
to protocol described in Section 2.3.1. Nested PCR and Sanger sequencing were 
performed by Kasturee Jagirdar to determine the genetic variant of MC1R gene (Box et al., 
2001, Box et al., 1997).  
Given that four out of five samples had insufficient amounts of DNA for MC1R genotyping, 
Two to three microbiopsy samples was re-collected from each of these four subjects and 
pooled for analysis. The usual amount of DNA they used in these reactions was 100 ng, 
thus the need to pool samples. In addition, a single microbiopsy sample was collected 
from each subject for OCA2 genotyping. DNA from the saliva samples that were collected 
for the clinical study were used as controls. TaqMan-based genotyping was again 
performed by Kasturee Jagirdar for OCA2 genotyping (rs12913832) (Sturm et al., 2008). 
MC1R genotyping was repeated with amplified DNA samples obtained from a small clinical 
study described in Section 5.2.2. DNA from matched peri-lesional samples was also 
included in this experiment. 
Samples post sequencing reaction were sent to the Australian Equine Genetics Research 
Centre (Queensland, Australia) for sequencing analysis. Chromatographs were analysed 
using Sequencer version 5.2 (Gene Codes Corporation, USA). 
 Small clinical study on pigmented skin lesions 5.2.2
Five patients that presented with dysplastic naevus were recruited and consented from the 
Dermatology Department by a clinical researcher (Dr. Paras Banan). The study was 
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conducted under the approval of the Metro South Human Research Ethics Committee in 
Princess Alexandra Hospital (HREC/11/QPAH/363) and The University of Queensland 
Human Ethics Review Committee (Approval number: 2011001201). A total of five 
dysplastic naevi were included in this case study. Clinical and dermoscopic photographs 
were obtained using a Canon Power Shot G10 digital camera (Canon, USA) with a 
dermatoscope attachment (Dermlite©, 3Gen, USA). Photographs were collected before 
excision and after the lesions were excised. The excised lesion was bisected by Dr. Paras 
Banan. Half of the lesion was sent for routine histopathologic analysis. Microbiopsy 
samples were collected from the other halved lesion as per the protocol described in 
Section 2.2.3. The halved lesion that was applied with microbiopsies was sent to a 
dermatopathologist (Dr. Duncan Lambie) for histopathological assessment including 
microbiopsy damage assessment. The sites of microbiopsy application were numbered 
and samples labelled accordingly (Figure 5.1). The lesion that was applied with 
microbiopsies was sectioned by the Department of Anatomical Pathology in Princess 
Alexandra Hospital according to routine protocols.  
 
At least five microbiopsies were collected from each excised lesion and kept in 
RNAse/DNase-free microfuge tubes containing RNAlater® RNA Stabilization Solution (Life 
Technologies, USA, #AM7024). Microbiopsy samples were stored at -80oC until the 
Figure 5.1: Microbiopsy sample collection and site documentation. 
This is an illustration showing a piece of excised pigmented lesion that was applied with six 
microbiopsies. The sites of application were documented and microbiopsy samples were stored in 
their respective tubes.  
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samples were processed. Microbiopsy samples from two out of five lesions were excluded 
in the study as the locations of microbiopsy application were not evident. Three 
microbiopsy samples were selected for downstream molecular analysis. DNA was 
extracted from the microbiopsy samples and quantified according to the protocol described 
in Sections 2.3.1 and 2.3.3. DNA samples were subjected to whole genomic amplification 
according to protocol described in Section 2.3.4. A 15-fold dilution was prepared using 2 µl 
of each amplified DNA sample prior to quantification. DNA quantification was performed 
using Qubit® dsDNA BR assay (Life Technologies, USA, #Q32853) according to the 
manufacturer’s instructions. The quality and integrity of amplified DNA products was 
confirmed as per protocol described in Section 2.3.5. Amplified DNA samples were stored 
in 1.5 ml microcentrifuge tubes at -80oC. A small piece of the peri-lesional tissue was 
collected from each naevi as a control. DNA was extracted according to protocol described 
in Section 2.3.2.  
Bi-directional Sanger sequencing of BRAF Exon 15 and NRAS Exon 2 were performed 
based on the protocol described by Richter et al. and Tschandl et al. (Richter et al., 2013, 
Tschandl et al., 2013). PCR amplification was performed in a 25 µl reaction mixture 
containing 5X Taq reaction buffer (200 mM Tris pH 8.4, 500 mM potassium chloride), 5% 
dimethyl sulfoxide (DMSO), 10 mM deoxynucleotide triphosphates (dTNPs), 50 mM 
magnesium chloride (MgCl2), 25 pmol/µl forward (F) and reverse (R) primers, 1.25 U of 
Taq DNA Polymerase, Native (Life Technologies, USA, #18038018) and 50 ng/sample of 
genomic DNA template. Forward and reverse primers used in the PCR amplification of 
BRAF Exon 15 were: F-5’-TCATAATGCTTGCTCTGATAGGA-3’ and R-5’- 
GGCCAAAAATTTAATCAGTGGA-3’. Forward and reverse primers used in the PCR 
amplification of NRAS Exon 2 were: F-5’-GATTCTTACAGAAAACAAGTG-3’ and R-5’-
ATGACTTGCTATTATTGATGG-3’. PCR amplification was carried out with an initial 
denaturation at 94oC for 5 minutes, followed by a 40-cycled template denaturation for 40 
seconds at 94oC; primer annealing at 60oC for 40 seconds and primer extension for 1 
minute at 72oC, and completed with a final elongation at 72oC for 7 minutes. The settings 
for NRAS Exon 2 PCR amplification were similar to BRAF PCR amplification settings, 
except that the primer annealing temperature was reduced to 58oC. Positive (saliva-
derived DNA) and negative (nuclease-free water) controls were also examined under the 
same PCR conditions.  
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The presence of amplified PCR products were confirmed by gel electrophoresis using 2% 
agarose gel stained with 1x SYBR® Safe DNA Gel Stain (Life Technologies, USA, 
#S33102). Amplified products were extracted from bands resolved on the gel and purified 
using QIAquick Gel Extraction Kit (QIAGEN GmbH, Germany, #28704). Amplified products 
were subjected to sequencing reaction using BigDye® Terminator v3.1 Cycle Sequencing 
Kit (Life Technologies, USA, #4337455), 3.2 pmol/µl forward BRAF or NRAS primers and 
10 ng/sample DNA template (GeneWorks Pty Ltd, Australia). Samples, post sequencing 
reaction, were sent to the Australian Equine Genetics Research Centre (Queensland, 
Australia) for sequencing analysis. Chromatographs were analysed using Sequencer 
version 5.2 (Gene Codes Corporation, USA). 
 Case Study 1 – BRAF mutation status in regressing and stable naevi 5.2.3
This was a case study on a 30-year-old male patient who participated in a naevus 
surveillance study within the Dermatology Department of Princess Alexandra Hospital. The 
study was conducted with approval from Metro South Human Research Ethics Committee 
in Princess Alexandra Hospital (2009/126 and HREC/11/QPAH/363) and The University of 
Queensland Human Ethics Review Committee (Approval number: 2009001307 and 
2011001201). The patient developed metastatic melanoma and was enrolled in a clinical 
trial where participants were given either a BRAF inhibitor (dabrafenib) drug only or a 
combination therapy with a MEK inhibitor (trametinib). Full-body and dermoscopic 
photographs were taken with a FotoFinder system (FotoFinder Systems, Inc., Germany). 
Naevi that were more than 2 mm on the back and 5 mm on the rest of the body were 
documented by the imaging system. Imaging was repeated another five times over a 
period of 27 months at approximately 7-month intervals.  
Two naevi were selected for excision and BRAF and NRAS mutation status screening. 
One of the naevi regressed over time and the other remained similar throughout the 
monitoring period. Six microbiopsies were collected from each naevus as per the protocol 
described in Section 2.2.3. Five out of six microbiopsies were collected fromthe naevus 
and one from the peri-lesional region. The microbiopsy application sites were documented. 
All 12 microbiopsies from both naevi were processed and analysed according to the 
procedures described earlier. 
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 Case Study 2 – Targeted microbiopsy sampling 5.2.4
This was a case study on a 58-year-old male patient who presented with an unevenly 
pigmented lesion on the left lower back that had recently changed in appearance. The 
study was conducted under the approval of the Metro South Human Research Ethics 
Committee in Princess Alexandra Hospital (HREC/11/QPAH/363) and The University of 
Queensland Human Ethics Review Committee (Approval number: 2011001201).  
Clinical and dermoscopic photographs were obtained before and after excision using a 
Canon Power Shot G10 digital camera with a dermatoscope. Three different regions of 
interest were identified within the lesion from the dermoscopic photograph.  
A targeting cassette made from a modified Tissue-Tek® Cyromold® mold (VWR 
International Pty Ltd., USA, #25608-916) was used as an aiming guide for microbiopsy 
collection. The accuracy of the targeting cassette was defined by a research engineer 
(Ross Flewell-Smith). A minimum of three microbiopsies were applied to each region. 
Microbiopsy devices were opened up and examined to check for the presence of tissue. 
Successful collections were kept in RNAse/DNase-free microfuge tubes containing 180 µl 
of Buffer ATL from QIAamp DNA Micro Kit (QIAGEN GmbH, Germany, #56304). A total of 
nine microbiopsy samples collected from this case study were processed and analysed 
according to the procedures described earlier. Twenty micrometer stepwise stacks of 
reflectance confocal mosaics made up of 500 x 500 µm field of view images were collected 
before and after microbiopsy application. 
Aliquots of DNA sample sets from the microbiopsies were sent to an independent 
sequencing facility (IMVS, SA Pathology, Australia) to perform quantitative BRAFV600E 
single nucleotide polymorphism (SNP) genotype analysis using matrix-assisted laser 
desorption ionization time-of-flight (MALDI-TOF) mass spectrometry assay. Genomic DNA 
from human saliva and MM96L melanoma cell line were used as negative and positive 
controls, respectively. The positive controls consisted of samples with different ratio of 
mutant to wild type DNA. 
 Somatic mutation profiling 5.2.5
Four sets of matched microbiopsies and lesional samples were included in this 
experiment. Clinical and dermoscopic photographs were collected before and after lesions 
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were excised. Five microbiopsies were collected from the bisected lesions after they were 
excised. Ex vivo microbiopsy collections were performed according to protocol described 
in Section 2.2.3. This study was conducted under the approval of the Metro South Human 
Research Ethics Committee in Princess Alexandra Hospital (HREC/11/QPAH/236) and 
The University of Queensland Human Ethics Review Committee (Approval number: 
2011001386). Human neonatal foreskin was included in the experiment as wild type 
control samples. The foreskin tissue was provided by A/Prof. Nick Saunders.  
Three out of five microbiopsies were selected for somatic mutation profiling using p53/Rb 
Pathway Mutation PCR Array (Sabiosciences, QIAGEN GmbH, Germany, #SMH-011ARE-
12). The kit is a real-time PCR-based array that profiles over 70 mutation hotspots in 
Serine/threonine protein kinase (ATM), Cyclin-dependent kinase inhibitor 2A (CDKN2A) 
and Tumor protein p53 (TP53) genes. DNA from microbiopsies was extracted, amplified 
and tested for integrity and quality following protocols described in Sections 2.3.1, 2.3.4 
and 2.3.5. DNA manipulations of halved lesions were also performed according to 
protocols described in Sections 2.3.2 to 2.3.5. Unamplified lesional and foreskin DNA 
samples were included as controls in the real-time assay to determine false positives and 
negative results from the amplification process. Real-time PCR was performed according 
to the manufacturer’s instructions (qBiomarker Somatic Mutation PCR Array version 
August 2012, Page 22 – 28). Data analysis was performed on an integrated web-based 
software package (Qiagen GmbH, Germany) 
(http://pcrdataanalysis.sabiosciences.com/mutation/somaticpcrarraydataanalysis.php) 
using the delta-delta Ct (ΔΔCt) method.  
Real-time PCR data was compared to RNA sequencing (RNA-Seq) data for two out of four 
samples (VH006 and VH009). The sequencing and bioinformatics analysis were 
conducted in the laboratory of A/Prof. Marcel Dinger at the Garvan Institute of Medical 
Research Sydney, Australia.  
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 Results and Discussion 5.3
 MC1R and OCA2 genotyping of single and pooled microbiopsy samples 5.3.1
Only one out of five samples (#305AR) was successful for MC1R genotyping when a 
single microbiopsy was used. Subject 305AR was wild type for MC1R gene (Table 6). 
Unsuccessful genotyping was likely due to insufficient genomic DNA to seed the reaction. 
The average total DNA from each single microbiopsy sample was between 7 – 9 ng, and 
approximately 25 - 50 ng of DNA was required for MC1R genotyping.  
The experiment was repeated with pooled samples from four out of five subjects. MC1R 
genotyping was successful for one out of four pooled samples (#303TP). This subject was 
heterozygous for V92M variant. The genotypes from saliva samples compared to matched 
microbiopsy samples were identical for both subjects (Table 6). This shows that samples 
can pooled to improve rate of success but was still insufficient for MC1R genotyping. Two 
out of four samples (303TP and 305AR) were successfully genotyped for OCA2 gene 
when a single microbiopsy was used. The genotypes were also identical when comparing 
microbiopsy sample to saliva sample (Table 6). 
Table 6: Genotype outcome comparing microbiopsy and saliva samples.   
Volunteer ID 
MC1R genotype OCA2 genotype 
Microbiopsy Saliva Microbiopsy Saliva 
302PS Unsuccessful Wild type Unsuccessful C / C 
303TP V92M+/- V92M+/- C / C C / C 
304LL Unsuccessful R163Q-/- Not done T / T 
305AR Wild type Wild type C / C C / C 
306CP Unsuccessful R151C+/- Unsuccessful C / C 
 
MC1R genotyping was also performed using three amplified DNA samples collected from 
a small clinical study described in the next few sections. It was hypothesized that limited 
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molecular material can be overcome with amplification and will not affect outcome of 
genotyping. All three samples were successfully genotyped. One of the patients was wild 
type for MC1R gene and the other two patients had two variant alleles within the gene. 
The genotypes from the amplified DNA matched their respective peri-lesional skin 
samples. Allelic drop-out may occur during amplification process. Hence, non-amplified 
DNA from peri-lesional skin was included in the study to validate that there was no allelic 
drop-out as a result of whole genomic amplification by REPLI-g Single Cell Kit.  
 Effects of microbiopsy application on histopathological diagnosis 5.3.2
The average dimension of four microbiopsy defects identified from the sections was 113 ± 
50 µm wide and 146 ± 37 µm deep. The microbiopsy defects were similar but not identical 
to the artefacts arising from processing of the tissue sections from the halved lesions that 
were not applied with microbiopsies. The dimensions of the processing artefacts ranged 
from 20 – 2100 µm wide and 70 – 600 µm deep. Histopathological diagnoses of each pair 
of halved lesions were examined separately. The outcomes of the diagnosis were identical 
in all lesions. The diagnoses of the five naevi included compound naevus, junctional 
lentiginous naevus, compound dysplastic naevus, junctional dysplastic naevus and solar 
lentigo. 
A total of 29 microbiopsies were applied to the five naevi. However, not all microbiopsy 
defects were found. In this section, two out of five naevi were presented. An example of a 
compound dysplastic naevus is shown in Figure 5.2a. The naevus was identified on the 
left flank of an 88-year-old male patient who had a history of metastatic melanoma. A deep 
shave excision was performed and the lesion was bisected by the registrar on duty. Five 
microbiopsies were applied to the bisected lesion (Figure 5.2b) and microbiopsy samples 
were stored in 1.5 ml nuclease-free microcentrifuge tubes containing RNALater® solution 
to preserve the integrity of the samples. A microbiopsy defect was identified within the 
melanocytic region. The dimension of this defect was approximately 132 x 74 µm (Figure 
5.2c and 5.2d).  
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Another 56-year-old female patient who was presented with a changing naevus on the left 
scapula was recruited in the study. The diagnosis was a junctional lentiginous naevus 
(Figure 5.3a). The lesion was excised and bisected prior to microbiopsy application 
(Figure 5.3b). The microbiopsy defect was observed outside the lesional region and had 
penetrated the superficial dermis. The size of the defect was approximately 145 x 201 µm 
(Figure 5.3c and 5.3d). 
The severity of the defects due to microbiopsy application was comparable to artifacts 
commonly seen in routine sectioned specimens. Given that the diagnosis outcomes for all 
five naevi were identical, the defects contributed by microbiopsy application did not appear 
to hinder the diagnosis process. In addition, ordering multiple levels of tissue sectioning 
Figure 5.2: Clinical and histomicrograph of a compound dysplastic naevus. 
Clinical photograph of a compound dysplastic naevus (a) that was bisected and applied with 
microbiopsy device (b) White arrow represents the sites of microbiopsy application. Panel (c) and 
(d) shows a microbiopsy defect at low and high magnifications, respectively. Figure modified with 
permission from (Banan et al., 2013) Copyright 2013, American Medical Association. 
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can overcome the potential diagnostic complications with histopathological assessment in 
microbiopsied lesions. Given the small defect size observed in the histomicrographs, it 
was foreseen that the use of microbiopsy should not affect the diagnostic process even in 
equivocal cases. The data have shown that the application of microbiopsies did not 
interfere with the downstream histopathology diagnosis of those lesions. 
Figure 5.3: Clinical and histomicrograph of a junctional lentiginous naevus. 
Clinical photograph of a junctional lentiginous naevus (a) that was bisected and applied with 
microbiopsy device (b) White arrow represents the sites of microbiopsy application. Panel (c) and 
(d) shows a microbiopsy defect at low and high magnifications, respectively. Figure modified with 
permission from (Banan et al., 2013) Copyright 2013, American Medical Association. 
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 Detection of BRAF Exon 15 and NRAS Exon 2 mutations  5.3.3
The microbiopsy samples collected in the same study were processed for mutational 
status analysis of BRAF Exon 15 and NRAS Exon 2. A dysplastic naevus located on the 
chest of a 76-year-old woman (Figure 5.4a) was removed surgically and bisected before 
microbiopsy samples and peri-lesional tissue was collected (Figure 5.4b). One of the 
microbiopsy sites identified from the histopathological sections was outside the lesional 
region (Figure 5.4c). No BRAF or NRAS mutations were detected from the matched peri-
lesional skin and all three of the microbiopsy samples taken within the lesion (Figure 
5.4d).  
The second case study was a dysplastic naevus that was surgically removed from the left 
flank of an 88-year-old man. The lesion was bisected before microbiopsies were applied 
on one half. All three microbiopsy tissue samples collected from the compound dysplastic 
naevus had BRAFV600E mutation and wild type for NRAS Exon 2 (Figure 5.5). The 
matched peri-lesional skin was also identified as wild type for both BRAF Exon 15 and 
NRAS Exon 2 (Figure 5.5). Histopathological assessment confirmed both lesions as 
compound dysplastic naevi. 
The third lesion that was histopathologically diagnosed as a junctional lentiginous naevus 
was wild type for both BRAF Exon 15 and NRAS Exon 2 from all samples (data not 
shown). In conclusion, six out of nine microbiopsy tissue samples from two different 
dysplastic naevi were determined as wild type for BRAF Exon 15 and the remaining three 
microbiopsies from another lesion had BRAFV600E mutation. All three matched peri-lesional 
skin samples that were included as control from all three naevi were wild type. This 
confirmed that BRAFV600E mutation that was detected in microbiopsy samples were indeed 
mutations found in melanocytes within the lesional tissue. Similar to the previous lesion, 
wild type NRAS Exon 2 were detected from all samples. This result is expected given that 
the percentage of reported NRAS mutations in melanocytic lesions or melanoma is 10-
20% (Lee et al., 2011, Zebary et al., 2014). 
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Figure 5.4: BRAF
V600E
 negative case study.  
Clinically dysplastic naevus identified on chest of 76-year-old female patient was excised 
surgically (a). Five unguided microbiopsy applications (indicated by white arrowheads) were 
applied on naevus post excision and matched peri-lesional skin (indicated by asterisk) was 
included as BRAF
V600E
-negative control (b). One of the microbiopsy sites was identified in the 
non-lesional region (c). All samples including peri-lesional skin were negative for BRAF and 
NRAS mutations (n=3) (d). 
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 BRAFV600E Mutation status in regressed and stable naevi 5.3.4
A case study from an ongoing study was selected to demonstrate the feasibility and 
benefit of the microbiopsy for determining the mutation status of changing naevi in 
individuals. A total of 31 naevi on the body of a 30-year-old male melanoma patient 
(129BR) were monitored over 27 months. Of these, 25 naevi were larger than 2 mm and 
ten were greater than 5 mm. Based on the dermoscopic photographs, there were no 
significant changes to the naevi 14 months after the study had started. Significant 
dermoscopic changes to 16 naevi (51%) were observed six months after he commenced 
participation in the inhibitor drug trial. Examples of naevi that had significant dermoscopic 
changes and those that were stable were illustrated in Figure 5.6. The changes observed 
in those naevi were regression, and decrease in size and level of pigmentation. Flattening 
of raised naevi was observed in this study, which has also been reported by others 
(Haenssle et al., 2012). 
Figure 5.5: BRAFV600E positive case study. 
All microbiopsy samples were positive for BRAFV600E but negative for NRAS mutations (n=3), while 
peri-lesional skin were negative for both BRAF and NRAS mutations (n=1). 
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During the final imaging at the 27-month visit, only five naevi were observed to have 
regressed since the previous visit. Increased pigmentation was not observed in any naevi 
and no new naevus was identified.  The patient was reported to have excellent systemic 
response to the therapy with the exception of a node near the pancreas that remained 
unchanged. 
  
Figure 5.6: Surveillance of naevi in male patient on clinical trial with BRAF inhibitor and/or 
MEK inhibitor drugs. 
Clinical photograph of the patient’s back showing regressed (white circles and arrow) (n=3) and 
stable (black circle and arrow) (n=2) naevi. Excised naevi that were included in the case study are 
indicated by the arrows (a). Panel (b) to (d) represent naevi that has significant dermoscopic 
changes observed at 21-month visit. Panel (e) and (f) show naevi that they were stable throughout 
the monitoring period. The red line indicates the commencement of the clinical trial. Figure 
modified with permission from (McClenahan et al., 2014) Copyright 2014, American Medical 
Association. 
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The changes and appearance of new naevi over time can be influenced by UV radiation 
(Hofmann-Wellenhof et al., 1997), hormone changes associated with pregnancy and 
targeted therapy (Haenssle et al., 2012). The influence of UV exposure was not 
considered as the major factor as regressing and stable naevi in the patient was observed 
at the same body site. Pregnancy-related factor was also ruled out. Therefore, it was 
hypothesized that changing naevi had a positive BRAFV600E mutation, which had 
responded to the targeted therapy. 
Microbiopsy sampling was performed for detection of BRAFV600E mutation in a changing 
and an unchanging naevus (Figure 5.7a and 5.7b). Sanger sequencing showed that the 
regressing lesion was heterozygous for BRAFV600E mutation (Figure 5.7c). Two out of five 
microbiopsies collected within the naevus was positive for BRAFV600E mutation. On the 
other hand, no BRAF mutation was detected in the stable naevus (Figure 5.7d). Peri-
lesional samples were also collected from both naevi as negative controls. Similar to the 
previous study, the samples were also screened for NRAS mutation within Exon 2 but no 
mutation was detected for both naevi (data not shown).  
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Figure 5.7: BRAFV600E mutation status in regressed and stable naevi.  
Dermoscopic photograph of regressing (a) and stable (b) naevi. Sites of microbiopsy application 
within the lesional region were chronologically labelled from 1 – 5. Microbiopsy 6 was taken on the 
peri-lesional area. Positive BRAFV600E mutations were identified in Microbiopsy 1 and 5 of the 
regressing naevus (c). No BRAF mutation was detected in the peri-lesional area and in the 
unchanging naevus (d). Figure modified with permission from (McClenahan et al., 2014) Copyright 
2014, American Medical Association. 
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 Unguided and guided tissue sampling 5.3.5
The initial microbiopsy design introduced within the Thesis consisted of a micro-sized 
biopsy cutting tip that is attached to a modified spring-loaded blood lancet applicator 
(Unistik, Owen Mumford, UK). The microbiopsy device is loaded (Figure 5.8a) and fired at 
high speed into the skin with sampling accuracy to certain extent (Figure 5.8a and 8b). 
The current unguided microbiopsy device has limited targeting accuracy and was unable 
to achieve consistent sampling within regions of interest approximately 1 mm in diameter 
(Figure 5.8b). Ross Flewell-Smith determined from the application spread test that the 
unguided microbiopsy sampling has a targeting accuracy of 0.29 ± 0.32 mm (horizontally) 
by 1.05 ± 0.56 mm (vertically) (Figure 5.8c). 
The use of a dermoscope and a targeting cassette (indicated by a black arrowhead) were 
incorporated to improve on the targeting accuracy of the microbiopsy device (Figure 5.8d). 
The hand-held dermoscope can help to align the targeting cassette within a 1 mm 
diameter hole to enable improved sampling accuracy. After the targeting cassette is 
aligned on the region of interest, the microbiopsy is placed on top of the cassette and 
standard microbiopsy sampling procedures are followed (Figure 5.8d). Targeted tissue 
sampling within the region of interest ≤ 1 mm in size (Figure 5.8e) was achieved when the 
microbiopsy was used in conjunction with the targeting cassette. The application spread 
test confirmed that the targeting accuracy with the use of a dermoscope and targeting 
cassette was 0.19 ± 0.11 mm (horizontally) by 0.66 ± 0.24 mm (vertically) (Figure 5.8f). 
The addition of a targeting cassette and dermoscope improved horizontal and vertical 
targeting accuracy by 4.8- and 1.6-fold, respectively. This device is designed to enable 
precise tissue sampling that can be performed repeatedly without damaging the lesion. In 
the next experiment, I validated the use of this device as a targeted tool for more precise 
sampling in melanocytic lesions. 
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 Targeted sampling from regions of interest within lesion 5.3.6
To establish the feasibility of precise sampling (≤ 1 mm) in a small region of interest within 
a lesion, a clinically interesting case study of an atypical melanocytic naevus that will allow 
us to study three individual regions within the lesion will be discussed.  
Figure 5.8: The targeted skin microbiopsy.  
Non-guided microbiopsy device (a) when applied to the skin, collects tissue samples on or around 
region of interest (b) that has an average targeting accuracy of 0.29 mm horizontally and 1.05 mm 
vertically (n=10) (c). Microbiopsy guided with a targeting cassette (indicated by black arrowhead) 
(d) can collect tissue samples more accurately within region of interest (e) and has an average 
targeting accuracy of 0.06 mm horizontally and 0.66 mm vertically (n=10) (f). 
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A 5 x 3 mm clinically diagnosed atypical lentiginous melanocytic lesion identified on the left 
lower back of a 58-year old male was excised through shave biopsy (Figure 5.9a). This 
clinical case had allowed assessment for the precision of tissue sampling from three 
different regions of interest identified within the lesion (Figure 5.9b). Three microbiopsies 
were applied within the 1 mm dotted outline of each area as highlighted in Figure 5.9a.  
DNA was isolated from each microbiopsy sample independently and processed for whole 
genomic amplification. The amplification was even and unbiased (data not shown) across 
Figure 5.9: Case study demonstrating precision microbiopsy sampling.  
A 5 x 3 mm dysplastic naevus that has clinically different regions (A-C) within the lesion was 
diagnosed as lentiginous naevus on the lower left back of a 56-year-old male patient. Three 
microbiopsies were applied within each white dotted circle indicated as region A, B and C (a). Two 
microbiopsy sites were identified from one of the histopathological sections within region C (b). The 
reflectance confocal microscopy mosaics show the sites of application before (c) and after (d) 
microbiopsy. The red outline and white dotted outlines on the images represent the outline of the 
naevus and the site of microbiopsy applications on the three regions that are identified to be 
clinically different. 
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all samples and amplified DNA output ranges between 40-66 µg. Histopathological 
sections revealed two microbiopsy sites within region C (Figure 5.9b). The reflectance 
confocal mosaics of the lesion taken at the dermal-epidermal junction dermis 
(approximately 60 µm in depth) before (Figure 5.9c) and after microbiopsy application 
(Figure 5.9d) was compared, and microbiopsy sites were observed within the region of 
interest.   
Results from Sanger sequencing showed that two out of three regions have 
heterogeneous BRAFV600E mutation, while no mutation was detected in the microbiopsy 
samples from region C (Figure 5.10). Also detected were BRAFV600E and a rare BRAFS605R 
mutation in one of the microbiopsies and a BRAFS605R mutation in another area within 
region A. Two BRAF mutations were detected in one microbiopsy and only BRAFV600E was 
detected in another area within region B. Both regions had a single microbiopsy that 
detected wild type BRAF.  
On the other hand, microbiopsy samples obtained from region C that was diagnosed as 
melanoma in-situ were all BRAF wild type. One may speculate that this could be due to 
insufficient sampling of melanocytes that carry BRAF mutations or that only a small 
percentage of the melanocytes that carry BRAF mutations were present in the melanoma 
in-situ. Therefore, the microbiopsy may not be able to detect positive BRAFV600E mutation if 
less than 25% of the melanocytes carry BRAF mutations (Richter et al., 2013). Similar to 
other lesions, NRAS Exon 2 mutations were not able to be detected in any of the 
microbiopsy samples (data not shown). 
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Figure 5.10: BRAF mutations from microbiopsy samples.  
Two BRAF mutations within Exon 15 were identified from the microbiopsy samples taken from 
three regions of interest, a common BRAFV600E and a rarer BRAFS605R mutation. Both mutations 
were found in at least one out of three microbiopsy samples in region A and B. No BRAF mutation 
was detected in any of the microbiopsy samples from region C (n=3 per region). 
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The sensitivity of Sanger sequencing was previously tested by Kasturee Jagirdar using 
genomic DNA from human saliva (negative control) and samples from a melanoma cell 
line with different concentrations of BRAFV600E mutation (positive controls) (Figure 5.11a).  
An identical set of samples (n=9), in addition to samples of known BRAFV600E mutation 
ratios were sent to a sequencing facility for independent quantitation of BRAFV600E 
mutation analysis. The assay detected 6% of BRAFV600E mutation in one out of three 
microbiopsies from both region A and B. BRAFV600E mutation was not detected in 
microbiopsies from region C (Figure 5.11b). The results from Sanger sequencing and 
MALDI-TOF assay were relatively similar except for region B. It was observed that positive 
BRAFV600E mutations in two out of three microbiopsies with Sanger sequencing but only 
Figure 5.11: Quantitating BRAF
V600E
 mutations from microbiopsy samples.  
Genomic DNA from human saliva and DNA containing different mutant to wild type ratios extracted 
from MM96L melanoma cell line were used as controls to test the sensitivity of Sanger sequencing 
to detect BRAF
V600E
. BRAF
V600E
 is detected as A/T in the chromatographs. The green arrows 
highlight the peak of BRAF
V600E
 signal (a). The amount of BRAF
V600E
 mutation in microbiopsies 
taken from the three distinct regions and the controls were independently quantified using MALDI-
TOF assay by a sequencing facility (b). Reproduced with permission from (Tan et al., 2015) 
Copyright 2015, American Medical Association. 
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one out of three was detected with MALDI-TOF assay. Results based on the positive 
controls suggested that MALDI-TOF assay was not as sensitive. This explained the 
difference in detection outcome. 
Tschandl et al. (2013) investigated the number of positive BRAF mutations in melanoma 
that arise from a pre-existing naevi. They performed one or more laser capture 
microdissections on 5 µm thick formalin fixed paraffin embedded histology sections to 
selectively obtain cells from the naevus or the melanoma. Sanger sequencing was 
performed to detect BRAF mutations within Exon 15 and immunohistochemistry was 
included to confirm the mutations. They observed five out of 46 cases (10.9%) of 
melanoma with wild type BRAF adjacent to a pre-existing naevus with BRAFV600E mutation 
(Tschandl et al., 2013). They concluded that the findings based on phenotypic and 
genotypic analysis did not concur with the existing concept of stepwise tumor progression. 
On contrary, the phenotypic features of our lesion matched Clark’s progressive clinic-
pathologic model even though this is challenged by the conflicting genetic profile of the 
lesion. Otherwise, the case study well-demonstrated the benefits of microbiopsy device for 
in vivo sampling to provide insights in heterogeneity of melanocytic lesions. One may 
reason that either the microbiopsy did not sample at the right location or melanocytes were 
not sampled from the melanoma in-situ, thus leading to a wild type sequence. However, 
this proof-of-concept study did illustrate the potential of the device for future melanoma 
diagnosis. Ongoing work in the laboratory is focused on detecting the presence of 
melanocyte markers in conjunction to mutation analysis. 
 Somatic mutation status in non-pigmented skin lesions 5.3.7
Microbiopsy and its matched non-pigmented lesions (n=4) were compared for genetic 
signatures using a real-time p53/Rb PCR Array kit. This PCR assay is capable of detecting 
down to 1% of somatic mutations from the background of wild type genomic DNA using 
amplification refractory mutation system (ARMS®) technology. DNA from non-sun 
exposed foreskin was used in this experiment as the wild type control. The diagnosis of all 
four samples was intraepithelial carcinoma (IEC). Table 7 shows the summary of positive 
mutation calls identified by the analysis software. A total of 17 positive mutations (18.8%) 
were detected in 20 samples. The most prevalent p53 mutation occurred at codon 535 
consisting of a C – T substitution, where 20% of the samples had this point mutation. No 
RB1 mutation was detected in any of the samples.  
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Only one out of four sample sets (AKSFS15) detected a G>A at codon 330 of CDKN2A 
gene in both lesions and microbiopsies (100% match). Most mutations were detected 
within the TP53 gene in this experiment. None of the sample sets (amplified DNA from 
lesion and microbiopsies) had a 100% match when compared to the non-amplified lesional 
sample. Comparing only microbiopsy to its non-amplified lesional sample, only one out of 
four (AKSFS30) had a 100% match. In the sample set from AKSFS15, there were one 
100% and two 50% matches in the microbiopsy samples. It was observed that only one 
out of four lesional samples that was subjected to whole genomic amplification matched its 
non-amplified lesional samples. This suggested that amplifying DNA can create false 
positive mutation signals possibly by creating mutations during the amplification process. 
Borderline mutation call, which represents mutation that is present at low percentage, was 
also identified by the analysis software. It is represented by the +/- symbol in Appendix 1.  
There were 15 different borderline mutations identified among the 20 samples 
(microbiopsies and lesions). The most common mutations among the samples were all 
within TP53 gene (c. 422G>A, c.535C>T and c.844C>T). At least seven out of 20 samples 
(35 – 45%) have one or more of these mutations detected from the assay. Only one 
microbiopsy had a 100% match to the non-amplified lesional sample. Overall, using 
amplified DNA samples resulted in the increased detection of borderline mutations 
regardless of the sample source (microbiopsy or lesion). Up to eight borderline mutation 
calls were identified in an amplified DNA sample while none was detected in the non-
amplified lesional sample. Unfortunately, there is no sample remaining to confirm the 
mutations detected in this experiment. In the future, I would like to do a prospective study 
in photodamaged and non-photodamaged skin but it is beyond the scope of this Thesis. 
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Table 7: Summary of positive mutation calls in p53/Rb pathway PCR array. 
Sample 
Mutation 
found 
Gene Cosmic ID 
Nucleotide 
change 
Amino 
acid 
residue 
No. of 
mutation 
% match to 
non-
amplified 
lesion 
AKSFS15-L1 NA Yes CDKN2A 12547 c.330G>A p.W110 1 
 
AKSFS15-L1 Amp Yes CDKN2A 12547 c.330G>A p.W110 1 100% 
AKSFS15-MB2 Yes 
CDKN2A, 
TP53 
12547, 43635 
c.330G>A, 
c.536A>T 
p.W110, 
p.H179L 
2 50% 
AKSFS15-MB3 Yes CDKN2A 12547 c.330G>A p.W110 1 100% 
AKSFS15-MB4 Yes 
CDKN2A, 
TP53 
12547, 10768 
c.330G>A, 
c.535C>T 
p.W110, 
p.H179Y 
2 50% 
        
AKSFS30-L2 NA No - - - - 0  
AKSFS30-L2 Amp Yes TP53 10768, 10939 
c.535C>T, 
c832C>T 
pH179Y, 
p.P278S 
2 0% 
AKSFS30-MB1 No - - - - 0 100% 
AKSFS30-MB2 No - - - - 0 100% 
AKSFS30-MB3 No - - - - 0 100% 
        
VH006-L1 NA No - - - - 0 
 
VH006-L1 Amp Yes TP53 10768 c.535C>T pH179Y 1 0% 
VH006-MB1 Yes ATM 21624 c.9139C>T p.R3047* 1 0% 
VH006-MB2 No - - - - 0 100% 
VH006-MB4 Yes TP53 10727 c.438G>A P.W146* 1 0% 
        
VH009-L1 NA No - - - - - 
 
VH009-L1 Amp Yes TP53 43635, 10863 
c.536A>T, 
c.833C>T 
pH179L, 
p.P278L 
2 0% 
VH009-MB1 Yes TP53 
1081, 43708, 
43609, 10727, 
10690, 10687, 
10768, 43635, 
11089, 10704, 
10726 
c.404G>T, 
c.422G>A, 
c.856G>A, 
c.451C>T, 
c.461G>T, 
c.469G>T, 
c.476C>T 
p.C135Y, 
p.C141Y, 
p.W146*, 
p.W146*, 
p.R158H, 
p.C176Y, 
p.H179Y, 
p.H179L, 
p.I195T, 
p.R282W, 
p.E286K 
11 0% 
VH009-MB2 No - - - - - 100% 
VH009-MB3 Yes TP53 43947, 10659 
c.614A>G, 
c.817C>T 
p.Y205C, 
p.R273C 
2 0.0% 
NA: non-amplified DNA from lesion, Amp: amplified DNA from lesion, MB: microbiopsy 
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 There is currently no published data on the use of this kit for mutational profiling. 
Transcriptome wide SNP analysis results from the RNA-Seq data using methods that were 
described previously by Quinn et al. (Quinn et al., 2013) were performed. Comparison of 
data from both RNA-Seq and p53/Rb real-time PCR were made to look for mutations that 
were detected by both assays. A total of seven and five distinct loci were reported for 
sample VH006 and VH009, respectively, at CDKN2A, ATM, TP53 and RB1 gene regions. 
The read depth and coverage of these gene regions were summarized in Table 8.  
Unfortunately, none of these mutations corresponded to the 90 cosmic mutations found on 
74 distinct sites assayed by the p53/Rb PCR Array kit.  
Table 8: Average gene coverage and read depth of ATM, CDKN2A, RB1 and TP53 
genes. 
Sample 
ATM CDKN2A RB1 TP53 
Gene 
coverage 
Read 
depth 
Gene 
coverage 
Read 
depth 
Gene 
coverage 
Read 
depth 
Gene 
coverage 
Read 
depth 
VH006 97% 24.05 100% 27.29 9% 3.10 100% 22.88 
VH009 95% 9.00 100% 15.86 12% 2.00 100% 13.63 
 
The lack of concordance between results from the RNA-Seq assay and the p53/Rb PCR 
Array kit can be largely attributed to intrinsic differences between the technologies of the 
two assays. The p53/Rb PCR Array kit is a DNA-based assay designed to pick up specific 
mutations from these gene regions. Unlike the p53/Rb PCR Array, RNA-Seq technology 
measures the abundance of different mRNA species, which may varies between gene and 
samples (Wang et al., 2009). Hence, any mutations of poor transcription activity that lie 
within regions will not be detected using RNA-Seq (Mercer et al., 2012). 
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 Conclusions 5.4
The genotyping experiments established the framework for downstream processing of 
microbiopsy samples to carry out a range of molecular analytical techniques. The success 
of MC1R and OCA2 genotyping using microbiopsies was confounded by quantity of 
sample used for techniques suited for much larger samples. This limitation was overcome 
when DNA sample was amplified, although with some limitations.  
The sub-millimetre microbiopsy demonstrated its potential for repeated micro-tissue 
sampling in excised melanocytic lesions without interfering downstream histopathological 
analysis. The defects from microbiopsy application found in the histology sections were 
similar to artefacts caused by routine sample processing. However, it is important to 
recognise that a more clinically relevant question is whether previous microbiopsy 
application sites might contain residual inflammation as this may impact histopathological 
interpretation of difficult dysplastic lesions or early melanomas. Exploring this question is 
an exciting area of research that needs to be done prior to widespread use of the device. 
Such a clinical trial would need to include a substantial number of cases to address the 
question. In the future I see molecular diagnosis replacing histopathological assessment, 
but until that vision is realized, this is an important question. 
Positive BRAFV600E mutation in microbiopsy samples were successfully detected through 
Sanger sequencing. Rarer BRAF mutations (S605R) were detected in the microbiopsy 
samples collected from the dysplastic naevus adjacent to a melanoma in-situ. No NRAS 
mutation was identified in all samples including the lesions. Multiplex mutation profiling has 
become a common technique in research settings to characterise a disease. PCR 
amplification is usually required for multiplex assays. Microbiopsy samples were 
successfully profiled for significant mutations in the p53/Rb pathway. A total of 17 positive 
and 15 borderline mutations were identified in the samples. The overall results have, 
however, highlighted the consequence of introducing mutations when samples were 
subjected to genomic amplification. In conclusion, these proof-of-concept studies have 
demonstrated that the guided skin microbiopsy device has the potential to study in vivo 
molecular changes within a targeted area over time, which were impossible in the past.  
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 Chapter 6
Microbiopsy – a new approach for live cell assay 
6.1 Introduction 
The skin is a major target for a wide range of therapeutics and cosmeceuticals. However, 
analysis of active pharmaceutical ingredients or excipients with the skin often requires 
tissue extraction followed by downstream analysis. Current approaches, in particular those 
related to the cosmeceutical arena are limited to restrictive regulations on animal testing 
and the fact it is often not deemed ethical or practical to use conventional biopsy 
techniques to assess the effect of cosmetics. It has been demonstrated in Chapter 4 that 
cell imaging can be performed on tissue acquired by the microbiopsy device. Furthermore, 
considering that small skin tissue samples can be acquired using the microbiopsy without 
the need of local anaesthetic or scarring, this technology platform can have significant 
benefits in the area of animal-free cosmeceutical testing. 
One of the most common topical formulation ingredients are UV-filters zinc oxide and 
titanium dioxide nanoparticles. However, there is evidence that zinc-oxide and titanium 
dioxide nanoparticles could induce free radicals in the presence of sunlight, which may 
cause damage to skin cells (Anreddy et al., 2013). Yet, the relevance of this data and of 
others within a clinical context remains debatable.  The question is to know whether these 
nanoparticles would penetrate into viable skin cells in people. The focus of this Chapter 
was to explore microbiopsy potential for assessing the effects of zinc-oxide nanoparticles 
(ZnO-NP) on viable tissue within volunteers. The aims were to: 
AIM 1 Establish microbiopsy tissue sample staining and imaging with live tissue 
AIM 2 Live cell assay development for assessing oxidative stress in viable tissue 
AIM 3 Determine the potential of ZnO-NP to induce oxidative stress in intact and 
barrier compromised skin 
Nanotoxicology investigation in volunteers is generally carried out using minimally invasive 
imaging technology such as fluorescence lifetime imaging microscopy (FLIM). This 
technique has been previously established in the lab, and was used to monitor metabolic 
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changes in ZnO-NP treated volunteer’s skin (Lin et al., 2011). Nanoparticles are discrete 
objects ranging from a size of 1 nm to 100 nm. ZnO-NP commonly used in sunscreens 
range from 5 to 50 nm but often aggregate forming larger sizes. The commercial success 
of such formulations is reflected by these products remaining in the market for more than 
30 years (Wang and Tooley, 2011).  Today, ZnO-NP continues to be incorporated not just 
into sunscreens but also in a diverse range of cosmeceutical products. Preference for 
these nanoparticles is, however, not universal. There have been suggestions that these 
nanoparticles are small enough to penetrate damaged skin resulting in immune 
perturbation (Nel et al., 2006).   
Nanoparticles have greater relative surface area compared to micro-sized particles. This 
allows more atoms to be exposed to the environment resulting in unique properties (Nel et 
al., 2006). Nanoparticles often form larger clusters through interaction with one another 
leading to decreased relative surface area. Therefore, elucidating the probability of 
nanoparticles as individual entities to cause cytotoxic effects remains an academic area of 
study. The clinical relevance of this topic is limited because of the rapid adsorption of 
biological material that occurs through corona formation on the nanoparticle surface when 
it is introduced to a biological environment. The current data suggests that the nanoparticle 
aggregate corona plays a major role in cellular uptake (Xia et al., 2011, Monteiro-Riviere et 
al., 2013). This may be a crucial difference between in vitro and clinical experimental 
outcomes.  
Multiple ZnO-NP sunscreen studies have been carried out to elucidate the fate of ZnO-NP 
within the skin after being applied. The results from these studies were confounded by 
varying experimental models with authors using a range of in vitro, ex vivo and in vivo 
animal models (Sharma et al., 2009, Xia et al., 2011, Anreddy et al., 2013, Nel et al., 2006, 
Jeng and Swanson, 2006, Rasmussen et al., 2010). Few were done in human volunteers. 
However, a majority of those that were, came from our Group, where I have been involved 
with both the research design and implementation investigating the effects of ZnO-NP 
exposure on changes to cell metabolic activities. (Gulson et al., 2010, Leite-Silva et al., 
2013, Lin et al., 2011, Raphael et al., 2013). Clinical experiments remain the most relevant 
but the most challenging to do. In vitro studies have illustrated the cytotoxicity effects of 
ZnO-NP on cells. Sharma et al. (2009) showed that ZnO-NP even at a low concentration 
of 0.008 µg/ml had damaging effects on DNA (Sharma et al., 2009). Others concurred that 
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oxidative stress appeared to be the key inducer for cytotoxic effects (Jeng and Swanson, 
2006, Rasmussen et al., 2010).  In contrast, the clinical safety concerns for ZnO-NP are 
minimal based on current reports from clinical and ex vivo studies (Raphael et al., 2013, 
Leite-Silva et al., 2013, Gulson et al., 2010, Lin et al., 2011) demonstration poor 
nanoparticle tissue infiltration. 
In this Chapter, the changes in oxidative stress induced by ZnO-NP exposure to intact and 
barrier compromised human skin (Figure 6.1) were investigated. Intact or barrier disrupted 
skin was treated with ZnO-NP suspended in a caprylic capric triglycerides (CCT) solution. 
Skin barrier disruption was achieved using tape-stripping resulting in obvious clinical 
differences (increased erythema / moisture content) compared to intact regions (Figure 
6.1b). ZnO-NP were applied to the contralateral forearm to reduce the possibility of cross-
contamination. After treatment incubation, the microbiopsy was applied to the treated 
areas resulting in a micro-scale extraction site (Figure 6.1c, arrow head). The tissue was 
collected within the microbiopsy (Figure 6.1d) and used for downstream analysis of 
reactive oxygen and nitrogen species, and mitochondrial superoxide production.
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Figure 6.1: Schematic and clinical photographs showing ZnO-NP administration to 
volunteers followed by microbiopsy enabled oxidative stress analysis. 
Top left panel show the three layered structure of the skin (SC – stratum corneum, VE – 
viable epidermis and dermis) (Panel (a), left). The SC was removed using tape-stripping to 
expose the viable epidermis (Panel (a), middle). ZnO-NPs were applied topically to intact and 
tape-stripped skin (Panel (b), right). The tissue was then stained for oxidative stress followed 
by fluorescence confocal microscopy analysis (a, right). Clinical photographs of a volunteer 
arm that has been tape-stripped (Panel (b), left and center). The asterisks show the areas 
that have been tape-stripped. ZnO-NP treatment was done on the separate forearm to 
prevent any risk of cross-contamination (Panel (b), right). Clinical photographs showing the 
microbiopsy procedure (Panel (c), left). The middle panel shows minimally invasive nature of 
the microbiopsy (Panel (c), middle). The microbiopsy site is indicated by the arrowhead. The 
tissue is collected in the microscopy chamber ready to oxidative stress analysis (Panel (c), 
right).  
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6.2 Materials and Methods 
6.2.1 Study volunteers 
Six volunteers were recruited in this study approved by the Metro South Health Human 
Research Ethics Committee (HREC/12/QPAH/251) and the University of Queensland 
Human Research Ethics Committee (Approval number: 2012000992). All volunteers gave 
informed consent and signed a Participant Information and Consent Form before the study 
commenced. Equal numbers of male and female volunteers were recruited.  
6.2.2 Tape-stripping and Trans-epidermal water loss (TEWL) 
Tape-stripping was used to disrupt the skin barrier. Commercially available 3M Scotch® 
810 Magic™ adhesive tape (3M Australia, Australia) with a width of 12.7 mm was used to 
remove the skin layers. The tape was applied to the ventral forearm and even pressure 
was applied across the tape using a metal roller to ensure that uniform adhesion of the 
tape on the skin was achieved. The adhesive tape was stripped off quickly from the skin 
after the metal roller was pressed over twice.  
Each volunteer was requested to sit in the laboratory for 10 minutes before the start of the 
study while the process of the experiment was discussed. This approach is to prevent the 
influence of sweating on the increased TEWL measurements. Single TEWL measurement 
was taken periodically on tape-stripped skin during the tape-stripping process with a 
closed chamber VapoMeter (Delfin Technologies, Finland). The tape-stripping procedure 
was repeated with a new piece of tape until trans-epidermal water loss (TEWL) increased 
greater than 20 g/m2h.  
6.2.3 Zinc-oxide nanoparticle (ZnO-NP) preparation and application 
Micronised zinc-oxide nanoparticle (ZnO-NP) with a hydrophobic coating (Z-Cote® HP 1, 
BASF, Germany) was applied to intact and tape-stripped skin in volunteers. The average 
size of ZnO-NP determined by transmission electron microscopy was approximately 60 nm 
(data not shown). The manufacturer reported a guaranteed size of less than 200 nm as the 
aggregation of such small particles is very common during synthesis. The concentration of 
ZnO-NP in commercially available sunscreens can vary depending on the sun protection 
factor of the product. A commercially available SPF 30+ sunscreen from Cancer Council 
contains 200 mg/g ZnO-NP while the SPF 50+ sunscreen contains 50 mg/g. The 
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concentrations of ZnO-NP tested in previous studies varied from 2% to 60%. The total 
amount of ZnO-NP applied can vary but the dose was consistent across most studies at 2 
mg/cm2.  
In this experiment, 100 mg of ZnO-NP powder was suspended into 1 ml caprylic capric 
triglycerides (CCT) solution. The solution was mixed thoroughly using a vortex mixer at a 
speed of 8 a.u. for 1 minute. Further mixing was performed using a FXP10MH Sonicator 
(Unisonics Australia, Australia) at 30oC for 20 minutes. Vortex mixing was repeated for 
another minute after sonication. The ZnO-NP solution was applied at a final concentration 
of 100 mg/ml. There were three 2 x 2 cm treatment areas mapped out on each forearm, 
with a total of six treatment areas for each volunteer (Figure 6.1). Tape-stripped and intact 
skin were treated with either ZnO-NP at a dosage of 2 mg/cm2 (for a total of 8 mg on the 
site) or CCT solution over a total area of 4 cm2 per treatment site. Treatment duration was 
two hours. Untreated sites were included as a negative treatment control. ZnO-NP was 
applied on the contralateral forearm to prevent cross contamination of treatment sites. No 
adverse reactions or effects were observed after all treatments.  
6.2.4 Microbiopsy sample collection 
Type G2A microbiopsy cutting die fabricated by our S290 laser system was used in this 
study. The microbiopsy device fabrication was carried out as per protocol described in 
Section 2.1. Two microbiopsies were collected from each treatment group after being 
treated for two hours. Microbiopsy tissue collection was performed as per protocol 
described in Section 2.2.2 except that samples were immersed in Hank’s Balanced Salt 
Solution (HBSS). Preparation of in-house HBSS was carried out as per protocol adopted 
from theLabRat.com website (http://www.thelabrat.com/protocols/Hanks.shtml). 
Microbiopsy sample was stored at 37oC water bath prior to fluorogenic probe labelling. No 
adverse effects were observed following microbiopsy application.  
6.2.5 Reactive Oxygen and Nitrogen species and Mitochondrial Superoxide 
assessment 
Samples were incubated in a water bath at 37oC throughout the entire staining process 
except during washing steps. Negative control samples were obtained from tape-stripped 
and intact, untreated sites. Negative control samples were incubated in 8-well chamber 
slides (Nunc™ Lab-Tek™ II Chambered Coverglass, Thermo Fisher Scientific Inc, 
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Australia, #155409) containing 300 µl HBSS and maintained at 37oC throughout the 
staining process. Positive control samples were obtained from the same areas but were 
subjected to 60 minutes of incubation with 200 µM Luperox® TBH70X (Sigma-Aldrich, 
USA, #458139) prior to fluorogenic probe labelling. tert-Butyl hydroperoxide (tBHP) 
solution was used to induce oxidative stress and reactive oxygen species (ROS). tBHP  
solution was washed off twice with HBSS prior to labelling.  
CellROX® Green reagent (Life Technologies, USA, #C10444) and MitoSOX™ Red 
mitochondrial superoxide indicator (Life Technologies, USA, #M36008) were used to 
assess the level of oxidative stress and superoxide in microbiopsy tissue samples.  
CellROX® is a live cell dye that measures ROS in the nucleus and mitochondria. 
MitoSOX™ is another live cell dye that measures superoxide only in the mitochondria. 
Staining was carried out in 8-well chamber slides according to manufacturer’s instructions. 
The cell nuclei were counterstained with 10 mg/ml Hoechst 33342 trihydrochloride, 
trihydrate (Life Technologies, USA, #H3570) at 1:1000 dilution for 10 minutes.  
6.2.6 Confocal Microscopy 
The microbiopsy cutting die was opened up using clean sharp tip forceps (ProSciTech Pty 
Ltd, Australia) prior to imaging. A separate pair of forceps was used to handle cutting die 
containing ZnO treated tissue sample to prevent cross contamination. Confocal images of 
the tissue sample were obtained with a Zeiss 510 Meta confocal microscope (Carl Zeiss 
Microscopy GmbH, Germany). Excitation wavelength of 488 nm was used for both 
CellROX® and MitoSOX™ indicators. The confocal images were taken using an optical 
power of 25x, and a constant gain of 529 and 488 for CellROX® and MitoSOX™, 
respectively. The field of view for each confocal image was 359.3 µm x 359.3 µm. Stacks 
of confocal images at 5 µm-incremental steps were obtained for each sample. The number 
of steps acquired for each sample varied, depending on the thickness of the sample. 
6.2.7 Image analysis and statistical analysis 
Fluorescence raw integrated density was acquired from each confocal image using 
ImageJ analysis software (National Institutes of Health, USA). The number of cell nuclei 
were counted based on Hoechst 33342 signal. The method of cell counting was performed 
as per procedure described in Section 4.2.3. Normalised fluorescence signal of CellROX® 
and MitoSOX™ was determined by calculating the raw integrated density per nuclei.  
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Statistical analysis was performed using one-way ANOVA with Tukey’s multiple 
comparison test (GraphPad Prism 6, Graphpad Software Inc., USA). Paired two-tailed t-
test was used to determine the significant difference between tape-stripped and intact skin. 
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6.3 Results and Discussion 
Stratum corneum removal resulted in increased water loss through the skin. Therefore, 
TEWL was used to assess barrier integrity post tape-stripping. The average TEWL reading 
of intact skin based on single measurement from six volunteers was 5.4 ± 1.3 g/m2h. 
Tape-stripped sites had significantly higher average TEWL reading of 22.5 ± 4.7 g/m2h 
compared to the intact skin (p ≤ 0.0001). Following TEWL acquisition, the skin (in both 
intact and disrupted states) was either treated with CCT, ZnO-NP in CCT or left untreated 
for two hours. The treatment area was then untouched until microbiopsy sampling (Figure 
6.1). 
The microbiopsied samples were stained and the level of fluorescence produced by the 
oxidation of the cell permeable dyes was measured. The overall level of reactive oxygen 
and nitrogen species resulted in no obvious visual difference between intact and tape-
stripped skin (Figure 6.2a & 6.2b, respectively). Both groups of untreated skin resulted in 
negligible oxidative stress signals. In contrast, the tBHP positive controls generated 
relatively high oxidative stress signal. ZnO-NP and CCT treatment resulted in comparable 
signals to the untreated skin. The same trends were observed following mitochondrial 
superoxide analysis (intact – Figure 6.3a, tape-stripped – Figure 6.3b). 
The normalised fluorescence signal was then measured by dividing the level of integrated 
density per nuclei in each microbiopsy sample. Higher oxidative stress was correlated with 
higher levels of normalised fluorescence signal in the sample. The fluorescence signals 
from positive and untreated controls were compared in both assays.  
Microbiopsy sample from tBHP treated intact skin had fluorescence signal with a 
significant 2.1-fold (p ≤ 0.01) increase compared to the untreated intact skin. Likewise, 
tape-stripped skin treated with tBHP also had a significant increase (2.5-fold) in 
fluorescence signal compared to untreated tape-stripped skin (Figure 6.4a). Overall, the 
positive control (tBHP) resulted in significantly higher signal than all other groups of intact 
skin (p = 0.0026, p = 0.0014 and p = 0.0007, respectively). Tape-stripped skin treated with 
tBHP followed the same trend (p = 0.0010, p = 0.0027 and p = 0.0023, respectively).  
Similar observations were seen in the mitochondrial superoxide assay where both the 
tBHP  treated samples were significantly higher than untreated samples taken from intact 
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and tape-stripped skin (2.0- and 2.3-fold increase) (Figure 6.4b). The positive control 
resulted in significantly higher signal than untreated, ZnO-NP and buffer (CCT) in intact 
skin (p = 0.0051, p = 0.0063 and p = 0.0006, respectively). Tape-stripped skin, once again, 
followed the same trend (p < 0.0001, p = 0.0001 and p < 0.0001, respectively). 
There was no difference in fluorescence signal from untreated and ZnO-NP treated 
samples taken from both intact and tape-stripped skin. The relative difference in reactive 
oxygen and nitrogen species analysis in ZnO-NP treated samples compared to untreated 
samples from intact skin was 0.9-fold and for tape-stripped skin 1.1-fold. A similar outcome 
Figure 6.2: Confocal microscopy images of microbiopsies. 
Reactive oxygen and nitrogen species assay on intact skin (n=6) (a). Reactive oxygen and 
nitrogen species assay on tape-stripped skin (n=6) (b). Degree of oxidative stress corresponds to 
intensity of fluorescent signal (green). Cell nucleus counterstained with Hoechst 33342 (red). 
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was observed in the mitochondrial superoxide assay, where a 1.0- and 1.2-fold change for 
intact and tape-stripped skin, respectively, was noted (Figure 6.4b). 
When compared to the positive control, the intact skin treated with ZnO-NP produced 
reactive oxygen and nitrogen species and mitochondrial superoxide signal that was 
significantly lower (p ≤ 0.01) (2.3- and 2.0-fold decrease) (Figure 6.4).  Similarly, ZnO-NP 
treated tape-stripped skin resulted in signal significantly lower (p ≤ 0.001) than tBHP 
treated tape-stripped skin for both assays (2.2- and 2.0-fold decrease, respectively). 
Figure 6.3: Confocal microscopy images of microbiopsies. 
Mitochondrial superoxide assay on intact skin (n=6) (a). Mitochondrial superoxide assay on tape-
stripped skin (n=6) (b). Degree of oxidative stress corresponds to intensity of fluorescent signal 
(green). Cell nucleus counterstained with Hoechst 33342 (red). 
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Finally, ZnO-NP and CCT treatment were compared in terms of induced oxidative stress in 
both intact and tape-stripped skin. No significant differences were seen in either the 
reactive oxygen and nitrogen species or the mitochondrial superoxide signals (Figure 6.4). 
CCT treated intact and tape-stripped skin produced fluorescence signals that were also 
significantly lower than tBHP treated skin (p ≤ 0.001 and p ≤ 0.0001, respectively). 
There were a few major trends observed from the results of this study. Firstly, 
comparisons between the controls for the intact and the tape-stripped groups showed no 
significant difference in the oxidative stress. The results suggested that neither tape-
stripping nor nanoparticle treatment on barrier disrupted skin induced detectable levels of 
oxidative stress. Secondly, the oxidative stress induced fluorescence signals were not 
significantly different to each other when treated with either ZnO-NP or CCT in both intact 
and tape-stripped skin. Thirdly, tBHP treatment resulted in signal that was significantly 
greater than ZnO-NP and CCT treated groups. Finally, increase in oxidative stress was not 
observed with ZnO-NP treatment.  
The potential of ZnO-NP to induce cytotoxicity have been shown repeatedly in many in 
vitro studies. The most well-known mechanism is caused by the imbalance between the 
formation of ROS and the antioxidant radical quenching, leading to oxidative stress in 
cells. Quantifying this dynamic status is extremely challenging and dependent on a 
complex environment with multiple confounding factors. However, it is an important area 
with ROS affecting a range of biological processes including cellular viability, cellular 
growth and proliferation, tissue repair and regeneration, inflammatory and immune 
processes, and the regulation of various haemodynamic and haemostatic forces.  
Sharma et al. (2009) demonstrated that human epidermal cells went through significant 
oxidative stress after the cells were treated with 0.8 µg/ml of ZnO-NP for 6 hours (Sharma 
et al., 2009). They reported indications of oxidative stress from the cells by monitoring 
levels of oxidative stress related markers. The concentration of ZnO-NP passing through 
the skin barrier and into the viable epidermis can vary. Tape-stripping did not induce an 
increase in oxidative stress in this study despite any potential increase in the number of 
nanoparticles interacting with keratinocytes. Therefore, it might not be completely relevant 
to compare the outcome from an in vivo study to an in vitro study.  
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There were a few groups who studied the impact of ZnO-NP exposure on metabolic 
changes in the skin. One of the studies also investigated changes in nicotinamide adenine 
dinucleotide phosphate (NAD(P)H) levels using fluorescence lifetime imaging microscopy 
(FLIM) (Leite-Silva et al., 2013) established in our lab. FLIM is a non-invasive technique 
facilitating real-time investigation of metabolic and oxidative state of the cell (Labouta et 
al., 2011, Lin et al., 2011). Leite-Silva et al. (2013) were studying the effects of coated and 
uncoated ZnO-NP of different formulations on penetration into the viable epidermis in 
human volunteers. The study also employed a similar treatment dosage at 2 mg/cm2 but 
for a longer treatment time of 6 hours.  They found limited penetration of both coated and 
uncoated ZnO-NP into stratum granulosum through the skin furrows. Yet, no signs of 
metabolic or morphological changes to the keratinocytes were detected (Leite-Silva et al., 
2013). The method that Leite-Silva et al. (2013) employed was slightly different from what 
was done in this volunteer study. However, the outcome and interpretations from both 
studies were consistent and support the hypothesis that ZnO-NP do not induce cell toxicity 
Figure 6.4: Analysis of oxidative stress in volunteers of cells exposed to topical 
application of ZnO-NPs. 
Raw integrated density of fluorescence per nuclei in intact skin (n=6) and tape-stripped skin (n=6) 
(a). No significant differences were observed between the treatment groups, excluding the tBHP 
treatment group. Raw integrated density of fluorescence from the microchondrial superoxide 
probe per nuclei in intact and tape-stripped skin (b). No significant differences were observed 
between the treatment groups examined, with the exception of tBHP treatment. Intact and tape-
stripped skin are represented by black closed circle and grey closed square, respectively.  
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in an in vivo environment. The outcome from both studies suggests extrapolation of in vitro 
cell line based outcomes should not be the sole basis for cytotoxicity regulatory decisions. 
Overall, there is little doubt that the gold standard for assessment of topical formulations 
should be investigated in in vivo using human volunteers. 
Considering that it is the skin barrier properties that protect the viable cells from any toxic 
nanoparticle effects, one can postulate that the cells will be susceptible to these effects 
once the barrier is compromised. In the volunteer study, stripping was performed to 
remove the stratum corneum and expose cells within the viable epidermis to ZnO-NP. The 
thickness of stratum corneum varies among individuals and body-site. Therefore, TEWL 
was used to assure all subjects had similar levels of skin barrier disruption.  
It was also assessed if tape-stripping and ZnO-NP can together increases oxidative stress. 
The average fluorescence signals for both groups did not differ significantly in both assays. 
This suggested that either the cells within the viable epidermis tolerate well to the oxidative 
insult or there was no insult to begin with. One may also postulate that despite removal of 
stratum corneum through tape-stripping, the viable epidermis remains an effective barrier. 
The outcome of this study correlated with the findings that was published previously (Lin et 
al., 2011). The study in 2011 was investigating the effect of ZnO-NP on changes in level of 
NAD(P)H in intact and barrier disrupted skin in volunteers. The detectable concentrations 
of ZnO-NP in the stratum corneum of intact and tape-stripped skin after 4 hours were 5.16 
± 3.85 mg/ml and 34.03 ± 15.13 mg/ml, respectively. A significant increase of 
NAD(P)H/keratin signal in the ZnO-NP treated viable epidermis of tape-stripped skin when 
compared to vehicle-only treated skin was reported in the study. However, there was no 
enhanced penetration or significant ZnO-NP signal within detectable limits in the viable 
epidermis of tape-stripped skin treated with ZnO-NP.  
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6.4 Conclusions 
In summary, viable skin tissue were extracted using the microbiopsy device to perform live 
cell assays for detection of oxidative stress in volunteers. There was no observable 
increase in fluorescence level when tape-stripping was applied to the skin. There was no 
evidence from the study that oxidative stress was induced in skin treated with ZnO-NP 
when compared to untreated tissue in both intact and barrier disrupted skin. The findings 
showed that barrier disruption followed by ZnO-NP exposure did not result in an 
observable increase in oxidative stress. The outcome of these experiments supported 
previously published results that ZnO-NP did not cause any metabolic changes to viable 
cells. This Chapter illustrated the potential of using the microbiopsy device as a novel 
approach to assess viable tissue for live cells assay. In the following Chapter, empirical 
applications of the microbiopsy as a future molecular diagnostic tool are described. 
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 Chapter 7
The feasibility of advanced analytical platforms for molecular 
analysis 
 Introduction 7.1
Since a decade ago, there has been increasing interest in personalised human genome 
sequencing to acquire information that can predict disease and provide tailored treatment 
for individuals. The advancement of computational and sequencing technologies has 
resulted in the falling price per genome sequencing from billions to thousands. The cost of 
personal genomic sequencing is anticipated to drop even further in the near future (Mattick 
et al., 2014). In parallel, the emerging field of proteomics and commercially available high 
throughput technologies has provided powerful tools to study diseases. These new 
technologies are becoming common place in research and sampling plays a crucial role. In 
this Chapter, the focus was to explore the possibility of using the microbiopsy samples in 
different omics technologies with the aims being: 
AIM 1 Tandem mass spectrometry (MS/MS) identification of selected cytokines of 
microbiopsy samples 
AIM 2 Gene expression profiling of single microbiopsy using direct digital 
detection technology platform 
AIM 3 Generation of indexed cDNA library from microbiopsy samples using 
SMARTer® Stranded RNA-Seq Kit 
One of the exploratory omics technologies was proteomic characterisation of microbiopsy 
skin samples using mass spectrometry. Conventional liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) offers better analytical specificity for low molecular weight 
analytes than immunoassays (Grebe and Singh, 2011). Despite that, conventional LC-
MS/MS approaches are limited by detection sensitivity and sample throughput (Grebe and 
Singh, 2011). This limitation has led to many peptides remaining unidentified with this 
technology.  
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The targeted MS approach was developed to overcome these sampling limitations and 
facilitate the identification of peptides, proteins and/or post-translational modifications 
(Gillette and Carr, 2013). The development of triple quadropole has permitted targeted MS 
analysis. The mass spectrometers commonly used in current clinical practice are mostly 
single- or triple-quadrupole mass filter spectrometers coupled with liquid chromatography 
(LC). A quadrupole is a set of four electrodes that are electrically connected in opposite 
pairs and applied with a constant (DC) voltage and an alternating (AC) voltage to create 
alternating electric field. The alternating electric field filters ions of specified size as they 
maintain constant drift and transit across the field without colliding with the electrode 
(Burns et al., 2005).  
Triple quadrupole mass spectrometer (QqQ) is a form of MS/MS method. Small molecules, 
peptides or metabolites known as analytes are commonly analysed in clinical proteomics 
research using the MS/MS approach. Clinical proteomics research uses targeted MS 
approaches to facilitate diagnosis for early detection of disease, determine prognosis, 
direct therapy, or monitor disease activities.  
In both conventional and targeted MS approaches, analytes are converted to gas-phase 
ions by an ionization source. Ionized peptides are then filtered by their mass and 
fragmented (Q2) by inducing collisional excitation of the ions with a neutral gas. 
Fragmented ions are passed through another mass analyser and scanned. The identity of 
the peptide is established by parent and fragment masses. The amino acid sequences are 
derived from tandem mass spectra, and peptide identification is performed through 
database search engines (Gillette and Carr, 2013). Figure 7.1 compares conventional and 
targeted MS. The targeted MS method provides absolute structural specificity of selected 
analytes. Relative or absolute quantification of the analytes can also be established with 
isotopically-labelled internal standards of known quantities.  
Proteomic profiling for identification of peptides may be limited with small samples as 
amplification could not be performed to increase detection signals. Direct digital detection 
is a cutting edge technology to detect molecules without the need to convert or amplify the 
targets. The molecular targets developed for their analysis platform were identified in 
discovery experiments using new-generation sequencing (NGS) approach. Figure 7.2 
illustrates the overview of the technology process.  
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This technology was first introduced in 2008 (Geiss et al., 2008). The authors reported that 
direct gene expression profiling could be achieved without enzymatic reactions or bias, 
which are common in existing gene expression technologies. A seven position and a four 
color barcode system was established that could create a max of 16,384 different 
barcodes unique to individual mRNA targets. Each unique seven dye-coupled RNA 
segment corresponded to a single code. The reporter probe consisted of a gene-specific 
sequence and a unique RNA segment that was ligated to the backbone. The capture 
probe was a ligated product containing a unique sequence-specific oligonucleotide for 
each gene and a biotinylated universal sequence. Purification of the hybridised probe-
target complex was performed using magnetic beads and excess probes were removed to 
prevent binding and imaging interference. Sample processing steps post hybridisation 
were handled by a liquid-handling robot (nCounter® Prep Station). Automated imaging and 
data collection was done by the Digital Analyzer. Approximately 10 mm2 of the binding 
surface for each sample, which corresponded to 600 fields-of-view was imaged at a 
resolution of 1376 x 1024 pixels. 
Type of MS 
Conventional 
Targeted 
Mass analyser 1 
Mass selection of all 
peptide ions 
Mass selection of 
precusor ions 
Collison cell Mass analyser 2 
Full scan 
Sequence-specific 
fragment ions 
(transitions) analysed 
Figure 7.1: Comparison of conventional and targeted MS. 
Flow chart illustrates the differences between conventional data-dependent and targeted MS. 
The process differences between the two approaches happen in the second mass analyser. In 
targeted MS, only ions of interest which is also known as precursor ions are filtered and 
analysed in Q1. Post fragmentation, sequence-specific fragment ions (transitions) are filtered 
and analysed in Q3. 
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Figure 7.2: Schematic of digital mRNA profiling technology. 
Total mRNA is mixed with capture and reporter probes that carry color-coded barcode 
unique to a single target molecule (a). The probes hybridised directly to a molecular 
target in solution (b). Excess probes are removed (c) and the probe-target complex is 
added to the cartridge using the automated sample processing station (d). The 
hybridised complexes are bound (e) and immobilised (f) on the cartridge. The 
immobilised complexes are aligned on the cartridge as illustrated by the false-color 
image (g). The cartridge is transferred to the digital analyser for barcode counting and 
data organisation (h). Figure modified with permission from (NanoString Technologies, 
2014) Copyright 2014, Nanostring Technologies, Inc. All rights reserved. 
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They compared the nCounter® results to microarrays (Affymetrix U133Plus2 array) and 
quantitative reverse-transcriptase PCR (qRT-PCR) of the MAQC gene set results. They 
detected 17 to 35 more genes with their technology compared to the microarrays when 
identical non-amplified sample input was used. The nCounter® analysis system was 
reported as a sensitive and reproducible technology, which had a 0.1 - 0.5 fM detection 
limit and achieved an average correlation coefficient (R2) of 0.999.  The nCounter® system 
showed good correlation with both microarray (R2 = 0.79) and qRT-PCR (R2 = 0.95), and 
was more sensitive than the microarrays but had similar accuracy and sensitivity to qRT-
PCR (Geiss et al., 2008). 
Giess et al (2008) highlighted four advantages of their nCounter® technology over 
microarrays and qRT-PCR. The four advantages being: 1) direct quantification without 
gene-specific or 3’ biases given that no amplification of sample was required; 2) higher 
sensitivity with lower amounts of sample input when compared to the microarrays; 3) 
digital readout of mRNA transcript counts showed less background noise and provided 
more definite downstream analysis, and finally 4) less time, effort and sample requirement 
was needed for the nCounter® system (Geiss et al., 2008). 
Moving forward with the micro-device validation, the focus of this Chapter was to explore 
the feasibility of molecular analysis using advanced analytical platforms. The protein 
content was determined and cytokine of interest was identified using state-of-the-art 
tandem mass spectrometry. The relative quantification of microbiopsy samples using 
quantitative reverse-transcriptase PCR and digital gene expression profiling using a 48- 
MAQC human gene set was also examined. Finally, cDNA library preparation from 
microbiopsy samples for future discovery experiments using new-generation sequencing 
technology was also explored.  
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 Materials and Methods 7.2
 Protein extraction from microbiopsy sample 7.2.1
Microbiopsy sample collection from a volunteer was performed according to protocol 
described in Section 2.1.6. Up to ten microbiopsies were collected from the volar forearm 
of a volunteer. Each microbiopsy was opened up and tissue sample was removed from the 
chamber using a disposable 30-gauge syringe needle. This procedure was done under a 
Stemi 2000C stereo microscope (Carl Zeiss Microscopy GmbH, Germany). Microbiopsy 
tissue samples were pooled into a nuclease-free 1.5 ml microcentrifuge tube containing 
100 µl of in-house RIPA buffer (50 mM Tris pH 7.5, 1% Triton X-100, 0.5% deoxycholate, 
0.1% sodium dodecyl sulphate, 150 mM sodium chloride, 10 mM sodium fluoride, 1x 
protease inhibitors, 0.5 mM 4- benzenesulfonyl fluoride hydrochloride, 1 mM sodium 
pyrophosphate, 0.5 mM sodium vanadate) provided by the TRI Proteomics Core Facility. 
The microbiopsy tissue samples together with the RIPA buffer were kept on ice throughout 
the extraction process. The pooled samples were incubated in the RIPA buffer for 30 
minutes to no more than an hour. The tissue samples were disrupted by passing the 
samples through a 100-µl pipette tip. The tissue samples were then subjected to 
sonication to lyse the samples further. The samples was put into the FXP10MH Sonicator 
(Unisonics Australia, Australia) for 1 minute and cooled on ice. This sonication step was 
repeated after the sample was chilled and until the sample was lysed completely.  The 
sample was centrifuged at 16,873 x g (maximum speed) for 5 minutes at 4oC. The 
supernatant containing the extracted proteins was collected without disrupting the pellet. 
 Protein extraction from COS cells 7.2.2
Adherent monkey kidney tissue derived COS cells were rinsed with sterile phosphate 
buffered saline (PBS). The cells were detached using 0.5% trypsin at 37oC for 5 minutes. 
Fresh Gibco® RPMI medium (Life Technologies, USA, #11875-093) was added to further 
detach adhering cells. Equal volume of 0.4% Trypan Blue (Life Technologies, USA, 
#15250061) was mixed into 20 µl of suspension cells for cell counting. Ten-fold serial 
dilution was performed, and cells were pelleted for protein extraction using 100 µl of RIPA 
buffer. 
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 Protein quantification 7.2.3
The quantity of protein in the pooled microbiopsy sample was determined using Pierce 
Micro BCA Protein Assay Kit (Thermo Fisher Scientific Inc., Australia, #23235). Protein 
standards (BSA) and working reagents were prepared according to the manufacturer’s 
instructions. Microplate procedure was followed to determine the concentration of the 
extracted proteins from microbiopsy tissue samples.  
 Protein separation using polyacrylamide gel electrophoresis (SDS-PAGE) 7.2.4
The SDS-PAGE acrylamide gel was made up of 4% stacking gel and 10% resolving gel. 
The gels were prepared according to the in-house recipe provided by the TRI Proteomic 
Core Facility. The gel was run with 1 x SFS running buffer (provided by the facility) at 150 
W for one hour. The Precision Plus Protein™ Dual Color Standards (Bio-Rad Laboratories, 
Inc., USA, #161-0374) was used to identify molecular mass of the targeted protein. The 
sample was premixed with 5 x SDS-Page sample buffer (10% SDS, 0.25 M dithiothreitol, 
0.2 M Tris pH 6.8, 0.1% bromophenol blue, 50% glycerol). Two separate SDS-PAGE gels 
were processed. Approximately 30 – 40 µl of the sample was run for an extended period to 
achieve a better separation of the protein. The remaining 45 µl of the sample was used to 
run a short 8 mm gel that was subsequently processed for mass spectrometry analysis. 
Triple quadrupole (QqQ) hybrid liquid chromatography mass spectrometry (LC-MS) was 
performed by the facility to identify a specific range of peptides in skin tissue. Mass 
spectrometry data was generated and analysed by the facility. 
 Quantitative reverse-transcriptase PCR (qRT-PCR) 7.2.5
Freshly excised healthy skin was collected and prepared according to procedure described 
in Section 2.1.5. The excised skin was cut into smaller pieces weighing approximately 25 
mg each. The RNA from excised healthy skin was used as standard curves for two qRT-
PCR experiments. Serial dilutions were performed to obtain varying concentrations for the 
standard curves. 
In the first experiment, two sets of single microbiopsies, pooled of two and five samples 
(n=6) were collected from the volar forearm of a volunteer as per protocol described in 
Section 2.1.6. In the second experiment, two sets of microbiopsies from the normal skin 
and a raised melanocytic naevi located on the volunteer’s forearm were collected. The 
volunteer was consented with written consent forms approved by the Metro South Human 
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Research Ethics Committee in Princess Alexandra Hospital (HREC/13/QPAH/551) and 
The University of Queensland Human Research Ethics Committee (Approval number: 
2013001551).  
The samples were processed for RNA as per protocol described in Sections 2.3.1 and 
2.3.2. On-column Dnase digestion was incorporated in the isolation protocol using RNase-
Free DNase Set (QIAGEN GmbH, Germany, #79254). The RNA samples from the excised 
skin samples were then quantified and assessed for quality as per protocol described in 
Sections 2.3.3 and 2.3.4. RNA from microbiopsy samples were not quantified with Qubit® 
assay but quality assessment was carried out together with the RNA samples from the 
excised skin. Four microliters from each microbiopsy samples were used for cDNA 
synthesis. Total RNA from the excised skin was included in the cDNA synthesis procedure 
as a no amplification control. First-strand cDNA was synthesized by reverse transcription 
using SensiFAST™ cDNA Synthesis Kit (Bioline, UK, #BIO-65053). A three- to five-points 
standard curve was prepared using cDNA from the excised skin. SYBR® Green-based 
(SensiFAST™ Probe No-ROX Kit, Bioline, UK, #BIO-86005) qRT-PCR was used to 
determine the quantity of microbiopsy samples in this experiment. PCR master mix was 
prepared according to supplied instructions. Forward and reverse primers were used in the 
PCR amplification of RPLPO housekeeping gene were: F-5’-
ATCAACGGGTACAAACGAGTC-3’ and R-5’-CAGATGGATCAGCCAAGAAGG-3’ (Sigma-
Aldrich,USA) (Minner and Poumay, 2009). Forward and reverse primers were used in the 
PCR amplification of tyrosinase gene were: F-5’- TCTTCTCCTCTTGGCAGATTGT-3’ and 
R-5’-CAGTAAGTGGACTAGCAAATCCTTC-3’ (Sigma-Aldrich,USA) (Gkalpakiotis et al., 
2010). The PCR cycling conditions were set at 95oC for 2 minutes for initial denaturation, 
followed by a 40-cycled template denaturation at 95oC for 5 seconds, primer annealing at 
60 - 65oC for 10 seconds and primer extension for 5 – 20 seconds at 72oC. qRT-PCR was 
performed in technical duplicates in both experiments. The result was analysed using 
Rotor-Gene 6000 Series Software 1.7 (Corbett Life Science, QIAGEN GmbH, Germany). 
Any sample that was not amplified properly during qRT-PCR was excluded from the 
analysis. 
 Gene expression analysis via nCounter® assay 7.2.6
The recommended sample and starting material for this gene expression assay is 100 ng 
of total RNA. The aim of this experiment was to validate if unamplified microbiopsy RNA 
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samples and amplified cDNA sample (100 ng) using Whole Transcriptome Amplification kit 
could be used for nCounter® Customer Assay Evaluation (CAE) Kit (NanoString® 
Technologies Inc., USA, # GXA-CAE-12). The amplified cDNA sample used was 
generated from the previous experiment described in Chapter 4, Figure 4.15.    
Two microbiopsy samples were obtained from a volunteer and incubated in 100 µl of 
Extraction Buffer from Arcturus® PicoPure® RNA Isolation kit (Life Technologies, USA, # 
KIT0204) for 30 mins at 42oC. Post incubation, the sample was kept on ice to prevent 
degradation of RNA samples. Unpurified RNA samples can be analysed using nCounter® 
assays as advised by the manufacturer. Given that RNA samples can be lost during the 
column purification, downstream processing using the Arcturus® PicoPure® RNA Isolation 
kit was not performed. Two to five microliters of each sample were used to quantify the 
concentration of cDNA and RNA samples using the Qubit® DNA BR and RNA BR assays 
(refer to Sections 2.2.3 and 2.3.3), respectively. Dilutions were made to each sample to 
make up 100 ng of starting material for the experiment. Further dilutions were made to 
diluted RNA samples to achieve 10 ng, 5 ng and 1 ng.  
Overnight hybridisation of capture probes and reporter probes at 65oC were carried out 
according to manufacturer’s instructions. The samples were then transferred to the 
nCounter® Prep Station where excess probes were removed and the probe/target 
complexes were aligned and attached to the nCounter® cartridge. This was an automated 
sample processing step by the Prep Station. Digital data were acquired by the nCounter® 
Digital Analyzer where 48 color-coded barcodes unique to their respective target molecule 
were counted and tabulated. The data was normalised by the positive controls included in 
the assay using nSolver Analysis software version 1.1 (NanoString® Technologies Inc., 
USA) 
 cDNA library preparation for Illumina® sequencing platforms 7.2.7
Two pooled microbiopsy samples were collected from each volunteer (n=2). The 
volunteers were consented under the same Human Ethics Study as described in Section 
7.2.4. Total RNA was isolated from the samples using Nucleospin RNA XS Kit (Macherey-
Nagel GmbH & Co. KG, Germany, #740902.10) according to the manufacturer’s 
instructions. Total RNA (7 ng) from a lesional sample with RNA Integrity Number (RIN) 
number of 8.5 was included in the experiment to compare the cDNA library of the 
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microbiopsy samples. Integrity and quality of the microbiopsy samples were analysed 
according to the protocol described in Section 2.3.4. However, the RIN number of the 
samples could not be determined. Therefore, the microbiopsy samples were treated as 
medium to low quality samples in this experiment. The Ribo-Zero Magnetic Kit 
(Epicentre®, USA, #MRZH116) was used to remove ribosomal RNA (rRNA) according to a 
modified protocol from Clontech Laboratories, Inc. The samples were first subjected to 
fragmentation and conversion to single-stranded cDNA. The samples were then purified 
using SPRI AMPure Beads and amplified into RNA-Seq libraries. The generated cDNA 
libraries were then purified and assessed for quality following Agilent’s High Sensitivity 
DNA Kit’s protocol (Agilent Technologies, USA, #5067-4626). The preparation of cDNA 
libraries were carried out according to the manufacturer’s instructions. 
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 Results and Discussion 7.3
 Targeted mass spectrometry approach for peptide identification 7.3.1
Total protein was isolated independently from two individual microbiopsy samples in a 
preliminary experiment. One sample had approximately 1.45 µg of total protein and the 
other was below the detection limit of the kit. A series of ten-fold serial dilutions (102, 103, 
104, 105, and 106 cells) were included in the experiment to estimate the cell count obtained 
from a microbiopsy sample. It was calculated that the microbiopsy extracted approximately 
102 to 103 cells from the tissue. The estimated cell count was slightly lower than what was 
observed in Figure 4.4 of Chapter 4. However, this is of no surprise given that sample 
variation is common with microbiopsy sampling as observed in the volunteer studies 
(Chapter 4). 
Figure 7.3: Schematics of protein handling and analysis. 
Microbiopsy sample was collected in microcentrifuge tube containing in-house RIPA buffer (a). 
Total protein is isolated from microbiopsy samples (b) and quantified using microplate 
procedure of Pierce Micro BCA Protein Kit (c). The protein masses were separated using SDS-
Page (d) and digested (e) for targeted tandem MS analysis (f). The MS spectra was analysed 
for identification and relative quantification of the cytokines (g). Figure modified with permission 
from (Gillette and Carr, 2013) Copyright 2013, Nature Publishing Group. 
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The identification of selected cytokines using the microbiopsy technology was performed 
for a collaborative project. The general work flow of this experiment is illustrated in Figure 
7.3. The total protein was extracted from single, and pooling of two and five microbiopsy 
samples, respectively. Post protein quantification suggested insufficient protein for all three 
samples to perform downstream MS/MS analysis. The experiment was repeated with a 
pooled sample of ten microbiopsies. The total protein extracted was approximately 4 µg. 
Half of the total extracted protein sample was used for SDS-Page gel analyses and the 
other half was given to a proteomic core facility for tandem mass spectrometry analysis. A 
total of 27 cytokines were screened, and of which 22 were identified using 0.2 µg of total 
protein (Table 9). Relative quantification of six cytokines (CD56, CXCL2, CD11c, CD103, 
IL36g and Periostin) was performed (Table 10).  
The mass-charge-ratio (m/z) of the parent protein was analysed in Q1 while transitions 
were analysed in Q3. Ion with the highest intensity signal is known as the ‘quantifier’ while 
additional ions are known as qualifier. Compound identification was calculated based on 
the quantifier/qualifier ratio. The ‘area’ represents the signal intensity of the fragment ions. 
Table 10 shows the list of peptides that were semi-quantitated using the parent mass. 
Comparison in relative quantity of identified cytokines within the sample was limited by the 
lack of isotopically-labelled internal standards of known quantities. Precision and 
confidence in peptide identification were confounded as a consequence of the absence of 
internal standards. This preliminary analysis supported the possibility of microbiopsy 
samples for screening of relevant proteomic biomarkers for skin diseases.   
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Table 9: List of proteins detected from a pooled microbiopsy sample. 
Accession 
number 
Protein name Gene 
name 
P38570 Integrin alpha-E (CD103) ITGAE 
A2VCQ7 EGFR protein EGFR 
P01579 Interferon gamma  (IFN-g) IFNG 
P01584 Interleukin-1 beta (IL1B) IL1B 
P01730 T-cell surface glycoprotein (CD4) CD4 
P05231 Interleukin-6 (IL6) IL6 
P08571 Monocyte differentiation antigen CD14 (CD14) CD14 
P08575 Receptor-type tyrosine-protein phosphatase C 
 
PTPRC 
P09693 T-cell surface glycoprotein CD3 gamma chain (CD3) CD3G 
P10966 T-cell surface glycoprotein CD8 beta chain (CD8) CD8B 
P11215 Integrin alpha-M (CD11b) ITGAM 
P11836 B-lymphocyte antigen CD20 (CD20) MS4A1 
P13591 Neural cell adhesion molecule 1 (CD56) NCAM1 
P19875 C-X-C motif chemokine 2 (CXCL2) CXCL2 
P20702 Integrin alpha-X (CD11c) ITGAX 
P51671 Eotaxin  CCL11 
P59665 Neutrophil defensin 1 DEFA1 
Q15063 Periostin POSTN 
Q6UZ82 Monocyte chemoattractant protein-1 MCP1 
Q9NZH8 Interleukin-36 gamma (IL36g) IL36G 
Q9UBH0 Interleukin-36 receptor antagonist protein (IL36Ra) IL36RN 
Q9UJ71 C-type lectin domain family 4 member K (CD207) CD207 
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Table 10: Relative quantification of identified peptides. 
Protein name Peptide Q1 
m/z 
Quantifier Qualifier 
Q3 
m/z 
Area Q3 
m/z 
Area 
Neural cell 
adhesion molecule 
1 (CD56) 
GLGEISAASEFK 604.8 510.3 2722 470.3 1627 
C-X-C motif 
chemokine 2 
(CXCL2) 
ATLSAAPSNPR 542.8 570.3 33860 515.3 19806 
Integrin alpha-X 
(CD11c) 
FGAALTVLGDVNGDK 738.9 1017.5 1015 773.5 809 
Integrin alpha-E 
(CD103) 
VQNITQVGSVTK 637.4 248.2 3577 228.1 1925 
Interleukin-36 
gamma (IL36g) 
IMDLYGQPEPVKPFLFYR 738.4 245.1 11879 696.9 8167 
Periostin AAAITSDILEALGR 700.9 214.1 1531 1074.6 1391 
 
 High sensitivity total RNA quantification via qRT-PCR 7.3.2
Quantitative mRNA profiling of single cells has been established by a few groups 
(Stahlberg and Bengtsson, 2010, Bengtsson et al., 2008, Taniguchi et al., 2009). RNA 
quantification using Qubit® HS RNA assay had not been successful for every microbiopsy 
sample. Even though mRNA is only 1-3% of total RNA, an accurate estimation of sample 
quantity can be performed using tissue-specific housekeeping genes. RPLP0 was 
validated as one of the most stable housekeeping genes in keratinocytes, which is the 
most abundant cell type in skin (Minner and Poumay, 2009). Relative quantification of the 
microbiopsy samples was performed using standard curves with known quantities.  
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The integrity and quality of RNA for standard curves was 6.9 (RIN). The RIN of the 
microbiopsy samples ranged from 5.5 to 6.6 with an average of 6.18 ± 0.43. The 
calculated cDNA quantity per reaction by the software was comparable to the actual input 
of known quantities. The cDNA starting material for the standard curves were 25 ng, 2.5 
ng and 0.25 ng, and the average calculated quantity were 24.48 ± 0.37, 2.62 ± 0.37 and 
0.25 ± 0.02 ng, respectively.  The mRNA expression level of RPLP0 of the microbiopsy 
samples were within standard curves 2 and 3 (Figure 7.4). The average cDNA of single 
microbiopsies were 0.73 ± 0.58 ng (n=2) and the two-pooled samples were 0.61 ± 0.31 ng 
(n=2). The cDNA quantity of a five-pooled sample was 2.07 ± 0.18 ng (n=1).  The other 
pooled sample with five microbiopsies did not amplify properly during qRT-PCR and was 
excluded in the analysis. Calculations showed that average total RNA from single, two-
pooled and five-pooled microbiopsies were 7.99 ± 7.83 ng, 6.66 ± 4.18 ng and 22.8 ng, 
respectively.  RNA from the single microbiopsy was within the range reported in Chapter 4 
while the average per microbiopsy for pooled samples was slightly lower (5.16 ± 4.33 ng). 
Figure 7.4: Detection and quantification of RPLP0 in microbiopsies. 
Amplification plot shows three-point standard curves to quantify housekeeping RPLP0 gene in 
two sets of microbiopsy samples collected from normal skin area. The microbiopsy groups 
include single, pooled of two and five samples. The average fluorescence curve of the 
standards and the samples are represented in this plot. The inset on the bottom right shows the 
efficiency curve of the standards.  
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The starting cDNA quantified by Qubit® were similar to the calculated quantity reported by 
the software. The mRNA expression level of RPLP0 of the microbiopsy samples ranged 
from 0.032 to 0.80 ng (Figure 7.5). The R2 and PCR efficiency were similar between both 
runs (R2= 0.99924 vs. 0.99684, efficiency= 0.85 vs. 0.81). Total RNA from the raised 
melanocytic naevus (8.91 ± 0.31 ng) was higher than the normal skin region (1.41 ± 0.08 
ng). Presence of tyrosinase was assessed to validate if melanocytes were contained in the 
microbiopsy samples. Positive tyrosinase was detected in the microbiopsy collected from 
the melanocytic naevus but not from the normal skin. This is plausible given that one can 
expect more melanocytes within a melanocytic naevus than in a non-melanocytic region. 
Complete data of the qRT-PCR experiments were reported in Appendix 2. 
Figure 7.5: Detection and quantification of RPLP0 and tyrosinase genes in 
microbiopsies. 
Amplification plot shows five-point standard curves to quantify housekeeping RPLP0 and 
tyrosinase genes in two sets of microbiopsy samples collected from normal skin area and a 
melanocytic naevi. The average fluorescence curve of the standards and the samples are 
represented in this plot. The inset on the bottom right shows the efficiency curve of the 
standards. 
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 Detection limits of NanoString® technologies using microbiopsy samples 7.3.3
It was presented in a scientific report by Bhargava et al. that technical variations were 
observed in low input libraries regardless of the amplification methods (Bhargava et al., 
2014). They reported a reduction in transcriptome coverage when the amount of sample 
was progressively reduced from 1 ng to 100 pg to 50 pg to 25 pg. It was anticipated that 
genes expressing low levels might be below detectable limit when amount of sample input 
was lower than recommended. In this experiment, the mRNA input was decreased to the 
range of a single microbiopsy sample size (1 to 10 ng). There were 42 out of 48 human 
Figure 7.6: Multiplex gene expression count using NanoString® technology. 
Digital counting of 48 human gene expression of each sample group (n=2) was acquired and 
tabulated. The raw count data was normalised with positive controls using nSolver software. 
The number of normalised count is shown on the y-axis and the name of genes that was 
evaluated is represented on the x-axis. The dotted black line represents the limit for detectable 
expression of gene. 
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MAQC genes (87.5%) that were above the detection threshold (black dotted line) when the 
recommended quantity of 100 ng of RNA was used (Figure 7.6). The number of 
detectable genes decreased from 42 to 22 (45.8%) to 10 (20.8%) when the samples were 
reduced from 100 ng to 10 ng to 5 ng. Only three out of 48 genes (6.25%) were detected 
in 1 ng and microbiopsy samples. Forty-seven genes (97.9%) were identified in the cDNA 
sample (100 ng) from a microbiopsy that was subjected to whole transcriptome 
amplification.  
The MAQC genes were segregated into four different categories based on their expression 
profiles in 100 ng of mRNA (Figure 7.7). The number of gene expression counts 
decreased when the starting sample was reduced regardless of the expression profiles of 
the genes. These trends were consistent across genes that are highly expressed (Figure 
7.7a), expressed in high to med (Figure 7.7b) and med to low (Figure 7.7c) levels. The 
expression counts were more variable in genes that were expressed in low levels across 
all samples (Figure 7.7d).  
This experiment indicated that gene expression profiling of single, non-amplified 
microbiopsy samples was not feasible with NanoString® nCounter® gene expression 
assay. So to use this approach, additional microbiopsies would need to be pooled or 
amplified. The other option would be to use the single cell assay kit, which utilized an 
amplification step.  
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 Generation of indexed cDNA library 7.3.4
Clontech SMARTer Stranded RNA-Seq Kit was selected for producing cDNA libraries as it 
was designed to generate full transcriptome coverage and was suitable for samples of 
both high and low RNA integrity. In addition, this kit provided a streamlined library 
preparation workflow to produce compatible indexed cDNA libraries for Illumina 
sequencing platforms.  
Figure 7.7: Comparison of microbiopsy and sample input in varying concentrations 
across different levels of gene expression. 
The bar charts show comparisons of microbiopsy and starting material of varying concentrations 
(n=2) per test group, including 1 ng, 5 ng, 10 ng and 100 ng across representative genes of 
different expression levels. The genes are categorised into four groups: high (a), high to med 
(b), med to low (c) and low expression levels genes. 
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Complimentary DNA libraries were detected within 150 to 1000 bp for both microbiopsy 
samples. The cDNA library product of my samples did not have a distinct peak but were 
observed as double humps in both samples (Figure 8). It has been suggested in a NGS 
community forum that this was a consequence of excess amplification of the cDNA library 
during PCR and can result in high duplicate rates post sequencing (Jelsoft Enterprises 
Ltd., 2014). The cDNA library product from the lesion appeared to be insufficiently 
fragmented given the presence of a broad range peak at high molecular mass (Figure 7.8, 
black arrowhead). The kit is designed to generate RNA-seq libraries at a final 
concentration of greater than 7.5 nM and all of the microbiopsy samples were of the right 
final concentration, ranging from 7.76 to 61.68 nM.  
 
Figure 7.8: cDNA library synthesis validation. 
Bioanalyzer High Sensitivity DNA data of cDNA samples from two sets of pooled microbiopsy 
samples and actinic keratosis lesion. Serial dilutions of the lesional cDNA (n=1) were tested 
from lowest to highest concentration in the analysis. Successful cDNA library synthesis was 
marked by a distinct peak bridging 150 to 1000 base pairs as indicated by the dotted black 
lines. Black arrowhead indicates sample of high molecular mass. 
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 Conclusions 7.4
The aim of this Chapter was to explore cutting edge molecular technologies to 
characterise microbiopsy samples. Proteomics is a rapidly growing area of research that 
could be used to investigate a number of dermatological conditions. The average 
microbiopsy samples were found to contain 0.93 ± 0.74 µg. These samples were 
successfully analysed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
and 22 cytokines have been identified. 
Another state-of-the-art technology available in the market to study skin disease signature 
is the digital analysis of gene expression profiles by NanoString® Technologies Inc. qRT-
PCR was used to provide a more accurate quantification of the total RNA in microbiopsy 
samples by profiling the skin-specific RPLP0 housekeeping gene. The presence of 
melanocytes in microbiopsy samples was confirmed with positive tyrosinase expression in 
qRT-PCR. The suggested starting mRNA sample for this kit is 100 ng. The percentage of 
detectable genes decreased by 41.7% when the amount of starting mRNA was reduced 
from 100 to 10 ng. Only three out of 48 genes were detected with microbiopsy and 1 ng 
sample input, i.e. the percentage of detectable genes in these samples was decreased by 
81.25% when compared to the recommended starting mRNA.  
Complementary DNA libraries were successfully generated using SMARTer® Stranded 
RNA-Seq Kit. Even though the library products were not of ideal quality, this can be easily 
corrected by further optimisation of the protocol for processing microbiopsy samples. The 
success in generating cDNA libraries of the microbiopsy samples opens up opportunity for 
a wide variety of prospective studies. This Chapter provided a good snapshot of 
downstream omics technologies that can be analysed with microbiopsy samples. 
Technical variations are one of the most important issues to address for small sample 
input.  It is yet to be validated how much technical variation one can expect from 
microbiopsy samples and the accuracy of biological information the microbiopsy sample 
represents. The future molecular validation work for this device will be to compare it 
against single cell and conventional tissue biopsy in various omics technologies. This will 
provide clarity to the relevance of biological information from the microbiopsy sample when 
compared to single cell and whole lesions.  
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 Chapter 8
General Discussion, Conclusions and Future Directions 
Current sampling approaches adopted in clinical and research practice are confounded by 
the need for local anaesthetic and suture, along with possible risks of infection and pain 
experienced by patients during the process. There is a clear need for an alternative 
method to enable minimally invasive sampling in the field of dermatology to fill the gap for 
both clinical and research use. As discussed previously, there are many fabrication 
methods available, but not all were suitable in this context mainly due to the cost of 
operation and the feasibility of using this process in a laboratory environment.   
Three strategies were put in place to approach this research project. 1) To identify a 
feasible fabrication method suitable for use in the laboratory settings that will enable 
reproducible fabrication of the microbiopsy at low operational cost. Laser cutting was 
ultimately chosen as the fabrication technique to produce the microbiopsy devices. 2) To 
characterise and optimise the microbiopsy prototypes, and benchmark it to the 
conventional biopsy as the gold standard. 3) To explore and validate the functionalities of 
this device for molecular analysis in various downstream omics technologies and assays. 
The overall development process of the microbiopsy platform is illustrated in Figure 8.1. 
This Chapter addresses the pros and cons of current sampling approaches, followed by 
factors influencing the choice of fabrication methods and microneedle material. The testing 
models employed during the device optimisation stage, and the advantage and 
considerations of these models will also be addressed. Finally, possible improvements to 
the current device and potential applications of this device in dermato-oncology and 
research settings, and future plans for integration with existing technology/platforms are 
proposed. 
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Figure 8.1: Developmental process of the microbiopsy device.  
The flowchart highlights the process of developing the device, starting from conceptual design 
by 3D CAD modelling, followed by prototype construction, characterisation and optimisation, to 
the functionality assessment of the microbiopsy. Red text: requires further characterisation, Blue 
text: functionality assays completed. 
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 Comparisons of current sampling approaches 8.1
Current sampling approaches for genetic analysis include blood, saliva and cheek swabs. 
The issue with blood sampling (phlebotomy) is the invasive and painful nature of the 
procedure, which has resulted in needle phobia in people. This condition has been 
reported to affect treatment compliance in patients with chronic disease such as diabetes 
when multiple monitoring of glucose level per day is required.  
Saliva collection, in contrast, is non-invasive and does not risk needle-stick injuries.  An 
added benefit of this sampling method is that samples can be self-collected by patients. As 
a result, this was perceived as a more appealing approach for sample collection. Even 
though many salivary biomarkers were comparable to that of blood or urine samples, this 
approach is limited by inconsistency in results and several methodological concerns during 
sampling process (Koh and Koh, 2007). Examples of these issues include risk of cross 
contamination by blood and environmental exposure, and stability problems contributed by 
storage duration. Buccal cell collection using either cheek swabs or cytobrushes is a 
simple and quick technique, which is also commonly used for non-invasive sampling of 
DNA. The downside of using these samples was the lower quality of DNA compared to 
whole saliva sample (Rogers et al., 2007).  Molecular samples extracted from frozen 
microbiopsy samples that were stored at -70oC for over 12 months were shown to be of 
relatively good quality. This advocated that the storage duration had minimal impact on the 
quality of microbiopsy samples. This highlights another advantage of microbiopsy 
sampling over saliva collection. Microbiopsy sampling also has the capacity for repeated 
sampling and longitudinal studies. The time taken to collect multiple samples is moreover 
significantly reduced with microbiopsy devices when compared to blood or saliva 
sampling.  
The use of sample from all the sampling techniques discussed earlier is limited to only 
DNA analysis. Due to the specificity of the sample location obtained by the microbiopsy, 
DNA, RNA and protein studies can be used for somatic profiling at both transcriptional and 
translational level relating to the disease. The samples from blood, saliva or buccal cells, 
with respect to skin, can only be used for germline mutation profiling. Microbiopsy-based 
sampling approach collects a few cells with minimal to no pain and damage to site of 
application. This signifies that collection can be made repeatedly and molecular changes 
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in an individual can be monitored over time. The usefulness of this approach can also be 
extended to the monitoring of toxic chemicals and sun exposure in high risk people.  
 Fabrication of the microbiopsy device 8.2
There are many microneedles (MN) methods developed in recent years due to the 
advances in rapid prototyping technologies, and the appeal of minimally invasive 
procedures. Scalability for mass production is an issue relevant to these technologies due 
to high cost of production contributed by the requirement for cleanroom facilities, 
expensive equipment and the engagement of services to handle hazardous chemical 
waste. Therefore, the goal of the project was to design a device that was minimally 
invasive, but also easy to use, low-cost and has scalable potential. 
Traditionally, the production of MN was achieved by hand pulling glass pipettes. Not only 
was this process expensive and time consuming, the resulting MNs demonstrated poor 
fracture properties. Microfabrication techniques, also known as MEMS(originally used for 
the production of microprocessors) was effectively employed by Henry et al. to 
microfabricate MN for drug delivery purpose (Henry et al., 1998). Even though these 
microfabrication processes for making silicon MN has the potential for scaling, but the cost 
of production remains prohibitive compared to commonly used materials. This is because 
the processes are highly specialised, complex and multistep (Ziaie et al., 2004).  
The choice of using stainless steel in our design was supported by the lower fabrication 
cost, while equally effective skin penetration (Verbaan et al., 2008). Medical apparatus 
made out of metal, particularly stainless steel, have a long standing history in medical use. 
This was also the other benefit for using stainless steel as the regulatory path to approval 
will be considerably cut down.  
Fabrication techniques compatible with stainless steel are electroplating and laser cutting. 
Electroplating supports a wide array of geometrical designs (including hollow solid MNs), 
but suffers from poor resolution. On top of that, MN produced by this method has poor 
fracture resistance and are relatively thin walled (Gittard et al., 2010). The choice of using 
laser cutting was influenced by the speed and accuracy of the technique, generating 
relatively good resolution for sub-millimetre objects. We have demonstrated that laser 
cutting was easy to operate, and a low-cost and scalable operation. 
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 Microbiopsy characterisation and optimisation 8.3
There are several areas to further improve the functions of the microbiopsy. One is to 
enable direct imaging and immunohistochemistry analysis. To image the sample with the 
current device, one will have to unfold the cutting tip to gain access to the tissue. During 
this process, the histological structure of the tissue will be disrupted and often makes 
image analysis difficult as images from multiple areas needs to be combined to represent 
the sample. Microbiopsies made of transparent polymer or silicon can resolve this issue. 
Emerging fabrication technologies like two-photon polymerisation have the potential to 
mass manufacture microbiopsy devices of high resolution made of transparent polymer 
material without the high cost of maintaining the operation. The presence of blood can 
sometimes pose as a confounding factor in certain analysis when only tissue samples are 
required. A possible solution would be to coat the microbiopsy’s cutting tip with a 
hydrophobic film to allow extraction of tissue without contaminating the sample with blood.  
The depth of microbiopsy penetration was characterised in the human and mouse skin 
models, which each model showing advantages and limitations. For example, in the 
mouse skin and excised human skin, cross-sectional analysis of histological sections for 
accurate measurement of the application site was possible. The drawback of the mouse 
model is that the skin is thinner, and the probability of the microbiopsy cutting tip 
penetrating the skin completely is high. Hence, characterising the penetration depth of 
microbiopsy application will not be ideal using the mouse model. There are important 
considerations for using human explants. For example, the surface tension of excised 
human skin can vary depending on how much it was stretched during the experiment. This 
can potentially affect the way the device penetrates the skin and how deep it can infiltrate. 
Therefore, it is important to have an applicator that helps to flatten the skin surface and 
maintain a mechanically reproducible application site.  
The functionality of the microbiopsy device was also compared in healthy and diseased 
skin such as in actinic keratoses where the stratum corneum is significantly thickened due 
to the hyperkeratotic condition. Varying amount of tissue collected was observed 
throughout the collection period even though the same batch of cutting tips was used. The 
number of successful collection can vary from four out of five to two out of five on different 
AK lesions. It was believed that the severity of the hyperkeratosis had affected the 
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outcome. This was no different to healthy skin models as every individual may have 
difference in thickness of their stratum corneum. The access of a consistent model may 
provide more rapid and accurate manner by eliminating structural variability in those 
models. One approach will be to use of computer modelling for the characterisation and 
optimisation of the microbiopsy.  
 Microbiopsy applications in dermato-oncology. 8.4
High-throughput technologies such as genomic sequencing and together with 
bioinformatics have the potential to influence the health care planning and prevention. 
These technologies provide molecular stratification of the disease to determine treatment 
pathways and the ability to optimise drug options and dosages in an individual. It is 
foreseen that the personalised medicine will play a strong role in the future of oncology. 
Personalised oncology is a new diagnostic and individualised treatment-based approach to 
address the problems of intra- and inter-tumor heterogeneity. It is conceivable that the 
development of targeted drug in the near future will make this approach commonplace,  
although relevant molecular signatures and targets must first be identified. The 
submillimeter skin microbiopsy offers a targeted sampling solution to help address these 
intra- and inter-tumor heterogeneity issues in squamous cell carcinoma (SCC) and 
melanoma.  
In today’s clinical practice, US FDA-approved signalling pathway inhibitors are used to 
target metastatic melanoma that harbours the BRAFV600E mutation. The issue is that not 
all melanomas have this mutation and many develop resistance to the drug (Nazarian et 
al., 2010). Combination inhibitors drug therapy has shown promising results.  The current 
clinical reality is that the primary melanoma lesion is excised before tumor genomic profile 
is extracted. One cannot define the optimum combination unless possible therapeutic 
resistance has been predefined. In the future, microbiopsies can be taken from every 
clinically suspicious naevi or primary melanoma to either assess for prognosis biomarkers 
or to determine the probabilities of transformation before metastasis occurs.  
This principle can also be applied in the arena of non-melanoma skin cancer where the 
prevalence is much higher, especially in organ transplant patients (Bangash and Colegio, 
2012). Many of the sun-damaged and immunocompromised patients can present with 
numerous precancerous actinic keratoses (AK), where some of which will progressively 
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become SCC. The task to select a few most suspicious lesions out of this many for biopsy 
and histopathology can be daunting. It can also be cosmetically challenging when AK is 
present on areas like the face. The microbiopsy-based sampling approach could yield 
molecular signatures to detect presence of neoplastic transformation without the need for 
conventional biopsy. Crucially, this improvement in patient care is only possible if there are 
validated biomarkers and development of new targeted therapies.  
 Microbiopsy applications in the research arena 8.5
The skin provides easily access for research in many areas, yet many of these research 
are limited by a common confounding factor – the lack of a suitable sampling tool that will 
enable repeated sampling over time. One example is the research in the field of molecular 
skin pathology. A repeated collection from multiple lesions in an animal model or a given 
patient, which was previously unfeasible, is now possible with the microbiopsy device. This 
enables researchers to study the molecular mechanisms of disease more closely, as it 
progresses. This also suggests that the outstanding question of how valuable molecular 
profiling is to the treatment process can now be answered with the device.  
Mutations of the oncogenes can provide clues for prediction of the disease course while 
the immune system inexorably plays an important role in the suppression of skin cancer. 
By combining oncogene mutations, expression and immune profiling, one can obtain 
comprehensive overview of the processes leading to disease progression and predict the 
efficacy of small molecules used during immunotherapy. This area of research may be 
necessary for stratifying skin cancer, predicting risk of disease and determining the 
effectiveness of the therapy. Given today’s rapid advances in nanomedicine and 
bioengineering, this approach can theoretically be carried out with a single microbiopsy.  
The capacity of the microbiopsy device to sample viable cell from the skin enabled a 
unique approach for in vivo live cell-based assay that has, to the best of my knowledge, 
not been performed by any research group. This means new paradigms for analysing 
products that can be topically delivered to the skin. For example, the functionality and 
toxicology of a particular vaccine, drug or chemical can now be performed on human 
volunteers. Current testing systems are either done using cell lines, on explants (excised 
skin) or in animal models, but the most relevant model remains to be the human volunteer. 
Furthermore, current techniques (e.g. microdialysis and suction blistering) that are 
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considered minimally invasive still carry higher risks of infection compared to the 
microbiopsy due to the deeper and wider surface area of sampling.   
Biobanking involves the collection and storage of biological samples in a biorepository to 
support research studies. It is now considered an important and valuable research tool for 
the validation and translation of research into medical diagnoses and treatment. The 
challenges in biobanking sampling are the ethical concerns, and balancing the rights of 
individuals versus the interests of the research society. The pitfalls associated with 
conventional biopsy have resulted in potential donors turning away from sample donations. 
It is foreseen that microbiopsies will become a functional option for biobanking of all skin 
diseases to move forward clinical and translational medicine in dermatology. 
The microbiopsy device has a unique application in the area of vector-borne diseases. 
Pilot field testing has been conducted in Ethiopia and Ghana for detection of skin/blood 
parasites causing visceral leishmaniasis and river blindness. These parasites are spread 
by blood-feeding vectors such as sand flies and black flies. In the study of its transmission, 
a method called xenodiagnosis is traditionally performed by exposing infected individuals 
to insectary-reared vectors to determine the infectivity of the host. The application of this 
technique to mass screen large rural communities in impoverished countries like Ethiopia 
and Ghana is limited due to logistical and ethical complications. Serendipitously, it was 
discovered that the cutting tip of the microbiopsy resembles the mouthparts of the vector-
of-interest. Hence, the microbiopsy could substitute the vector by mimicking the 
transmission during blood feeding. The pilot study showed promising results of 
microbiopsy application in this area of research wherein only one out of eight subjects had 
a false positive outcome.  This alternate method helps to improve logistic capacity, and 
increase patient compliance, particularly in rural areas, and also minimises any potential 
experimental variability.  
  Smart-integration of microbiopsy  8.6
The existing problem observed with the microbiopsy device is the sample handling 
procedure. The microbiopsy’s cutting tip containing the biopsy sample is typically removed 
from the applicator plunger by a clean pair of forceps. This handling process introduces 
the risks of samples contamination. To reduce this risk, direct handling of the cutting tip 
should be avoided. One approach to overcome this is to integrate the microbiopsy 
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sampling tool into micro-total analysis systems (Asiello and Baeumner, 2011). These 
systems are established using isothermal nuclei acid amplification technology platform. 
Combining the sample preparation and miniaturising amplification reactions prevents risk 
of contamination, requires fewer manual steps and can significantly reduce the use of 
expensive reagents. This type of isothermal microsystems is portable and can be useful 
for rapid on-site diagnosis of pathogens and parasites, particularly in field conditions in 
rural countries. These systems have the potential for streamlining near patient diagnosis 
and treatment planning in a clinical setting. There are existing systems with and without 
sample preparation integrations but none works for whole tissue. The microbiopsy device 
fills the technology gap in dermatology research that has the potential to be translated into 
a diagnostic device in the future. 
Biosensing is another conceivable future application of microiopsy. One of the most 
common biosensor is used for glucose monitoring in diabetes patients. Biosensor offers 
real-time and label-free measurement and detection of biological elements. This 
technology is not new and rapid advanced have been made since the 1990s to detect a 
variety of biological materials (Cornell et al., 1997). An example of biosensor that made out 
to the market is the Medtronic MiniMed. This device has an integrated insulin pump that 
accurately detects, monitor and maintain optimal glucose level by controlled delivery of 
insulin to meet the body’s needs. It is anticipated that moving forward, the next-generation 
of microbiopsy technology would have an integrated miniaturized diagnostic component 
where direct diagnosis is detected on the microbiopsy device. An analogy of such a 
diagnostic device is the pregnancy test kit, where sample collection and diagnostic 
information is integrated. It is envisioned that consumers as the end-users would be able 
to purchase these devices easily off-the-shelves in a pharmacy.  
 Conclusions 8.7
Fabrication of these devices using laser cutting techniques is quick and of low operation 
cost with scalable potential, making it a commercially viable alternative to current biopsy 
tools. This device fills the need for an alternative sampling approach that is minimally-
invasive for both research and clinical settings. More importantly, it is a simple and easy-
to-use device that can be easily adopted in clinics or used by patients themselves. Given 
its pain-free and suture-free application, the microbiopsy can improve patient care and 
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compliance for early detection of skin diseases. Adequate amounts of nucleic acids were 
successfully obtained from human tissues, and together with current amplification 
technologies, this platform can essentially be applied to any downstream molecular 
analysis application. The potential of this device is not limited to bedside testing of 
common skin diseases, but also the diagnosis of infectious diseases in the field. It is 
foreseen that the microbiopsy can enable elaboration of molecular profiling to facilitate 
early detection of diseases and aid in the identification of therapeutic targets. The 
anticipated long-term benefits of using microbiopsies in the research and clinical settings 
are earlier and more accurate detection of neoplastic skin diseases, enabling targeted skin 
cancer therapy.  
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Appendices 
Appendix 1 – p53/Rb Pathway Mutation PCR Array Genotype Call (n=4) 
Position Gene COSMIC ID nt change AA change 
AKSFS15-
L1 NA 
AKSFS15-
L1 A 
AKSFS15-
L1 MB2 
AKSFS15-
L1 MB3 
AKSFS15-
L1 MB4 
A01 ATM 21826 c.2572T>C p.F858L - - - - - 
A02 ATM 12951 c.7325A>C p.Q2442P - - - - - 
A03 ATM 20404 c.7328G>A p.R2443Q - - - - - 
A04 ATM 21642 c.9022C>T p.R3008C - - - - - 
A05 ATM 21626 c.9023G>A p.R3008H - - - - - 
A06 ATM 21624 c.9139C>T p.R3047* - - - - - 
A07 CDKN2A 13653 c.128G>T p.S43I - - - - - 
A08 CDKN2A 12743 c.143C>T p.P48L - - - - - 
A09 CDKN2A 12484 c.322G>A p.D108N - - - - - 
A10 CDKN2A 13520 c.322G>C p.D108H - - - - - 
A11 CDKN2A 13489 c.322G>T p.D108Y - - - - - 
A12 CDKN2A 12481 c.329G>A p.W110* - - - - - 
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B01 CDKN2A 12547 c.330G>A p.W110* + + + + + 
B02 CDKN2A 12476 c.341C>T p.P114L - - - - - 
B03 CDKN2A 12479 c.358G>T p.E120* - - - - - 
B04 RB1 887 c.1654C>T p.R552* - - - - - 
B05 RB1 888 c.1666C>T p.R556* - - - - - 
B06 RB1 861 c.1981C>T p.R661W - - - - - 
B07 TP53 11073 c.1024C>T p.R342* - - - - - 
B08 TP53 11582 c.395A>G p.K132R - - - - - 
B09 TP53 10801 c.404G>A p.C135Y - - - - - 
B10 TP53 10647 c.404G>T p.C135F - - - - - 
B11 TP53 43708 c.422G>A p.C141Y - - - - - 
B12 TP53 43609 c.437G>A p.W146* - - - - - 
C01 TP53 10727 c.438G>A p.W146* - - - - +/- 
C02 TP53 10905 c.451C>T p.P151S - - - - - 
C03 TP53 10790 c.455C>T p.P152L - - - - - 
C04 TP53 6815 c.461G>T p.G154V - - - - - 
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C05 TP53 10670 c.469G>T p.V157F - - - - - 
C06 TP53 10690 c.473G>A p.R158H - - - - - 
C07 TP53 10714 c.473G>T p.R158L - - - - - 
C08 TP53 11148 c.476C>T p.A159V - - - - - 
C09 TP53 10739 c.481G>A p.A161T - - - - - 
C10 TP53 10808 c.488A>G p.Y163C - - - - - 
C11 TP53 11084 c.517G>A p.V173M - - - - - 
C12 TP53 43559 c.517G>T p.V173L - - - - - 
D01 TP53 10648 c.524G>A p.R175H - - - - - 
D02 TP53 10687 c.527G>A p.C176Y - - - - - 
D03 TP53 10645 c.527G>T p.C176F - - - - - 
D04 TP53 10768 c.535C>T p.H179Y - +/- +/- - + 
D05 TP53 10889 c.536A>G p.H179R - - - - - 
D06 TP53 43635 c.536A>T p.H179L - - + - - 
D07 TP53 10733 c.574C>T p.Q192* - - - - - 
D08 TP53 10742 c.578A>G p.H193R - - - - - 
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D09 TP53 11066 c.578A>T p.H193L - - - - - 
D10 TP53 11089 c.584T>C p.I195T - - - - - 
D11 TP53 10705 c.586C>T p.R196* - - - - - 
D12 TP53 43947 c.614A>G p.Y205C - - - - - 
E01 TP53 10654 c.637C>T p.R213* - - - - - 
E02 TP53 43687 c.641A>G p.H214R - - - - - 
E03 TP53 10667 c.646G>A p.V216M - - - - - 
E04 TP53 10758 c.659A>G p.Y220C - - - - - 
E05 TP53 10725 c.701A>G p.Y234C - - - - - 
E06 TP53 10731 c.707A>G p.Y236C - - - - - 
E07 TP53 10834 c.711G>A p.M237I - - - - - 
E08 TP53 11059 c.713G>A p.C238Y - - - - - 
E09 TP53 10777 c.715A>G p.N239D - - - - - 
E10 TP53 10812 c.722C>T p.S241F - - +/- - - 
E11 TP53 10646 c.725G>A p.C242Y - - - - - 
E12 TP53 10810 c.725G>T p.C242F - - - - - 
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F01 TP53 10941 c.730G>A p.G244S - - - - - 
F02 TP53 11524 c.730G>T p.G244C - - - - - 
F03 TP53 10883 c.731G>A p.G244D - - - - - 
F04 TP53 6932 c.733G>A p.G245S - - - - - 
F05 TP53 11081 c.733G>T p.G245C - - - - - 
F06 TP53 43606 c.734G>A p.G245D - - - - - 
F07 TP53 11196 c.734G>T p.G245V - - - - - 
F08 TP53 10656 c.742C>T p.R248W - - - - - 
F09 TP53 10662 c.743G>A p.R248Q - - - - - 
F10 TP53 6549 c.743G>T p.R248L - - - - - 
F11 TP53 10817 c.747G>T p.R249S - - - - - 
F12 TP53 10771 c.749C>T p.P250L - - - - - 
G01 TP53 10988 c.772G>A p.E258K - - - - - 
G02 TP53 10867 c.797G>A p.G266E - - - - - 
G03 TP53 10891 c.814G>A p.V272M - - - - - 
G04 TP53 10659 c.817C>T p.R273C - - - - - 
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G05 TP53 10660 c.818G>A p.R273H - - - - - 
G06 TP53 10779 c.818G>T p.R273L - - - - - 
G07 TP53 10893 c.824G>A p.C275Y - - - - - 
G08 TP53 10701 c.824G>T p.C275F - - - - - 
G09 TP53 10939 c.832C>T p.P278S - - +/- - - 
G10 TP53 10863 c.833C>T p.P278L - - + - - 
G11 TP53 43714 c.836G>A p.G279E - - - - - 
G12 TP53 10728 c.839G>A p.R280K - - - - - 
H01 TP53 10724 c.839G>C p.R280T - - - - - 
H02 TP53 10704 c.844C>T p.R282W - +/- - - +/- 
H03 TP53 10722 c.853G>A p.E285K - - - - - 
H04 TP53 10726 c.856G>A p.E286K - - - - - 
H05 TP53 10856 c.880G>T p.E294* - - - - - 
H06 TP53 10710 c.892G>T p.E298* - - - - - 
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Position Gene COSMIC ID nt change AA change 
AKSFS30-
L2 NA 
AKSFS30-
L2 A 
AKSFS30-
L2 MB 1 
AKSFS30-
L2 MB 2 
AKSFS30-
L2 MB 3 
A01 ATM 21826 c.2572T>C p.F858L - - - - - 
A02 ATM 12951 c.7325A>C p.Q2442P - - - - - 
A03 ATM 20404 c.7328G>A p.R2443Q - - - - - 
A04 ATM 21642 c.9022C>T p.R3008C - - - - - 
A05 ATM 21626 c.9023G>A p.R3008H - - - - - 
A06 ATM 21624 c.9139C>T p.R3047* - - - - - 
A07 CDKN2A 13653 c.128G>T p.S43I - - - - - 
A08 CDKN2A 12743 c.143C>T p.P48L - - - - - 
A09 CDKN2A 12484 c.322G>A p.D108N - - - - - 
A10 CDKN2A 13520 c.322G>C p.D108H - - - - - 
A11 CDKN2A 13489 c.322G>T p.D108Y - - - - - 
A12 CDKN2A 12481 c.329G>A p.W110* - - - - - 
B01 CDKN2A 12547 c.330G>A p.W110* - - - - - 
B02 CDKN2A 12476 c.341C>T p.P114L - - - - - 
B03 CDKN2A 12479 c.358G>T p.E120* - - - - - 
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B04 RB1 887 c.1654C>T p.R552* - - - - - 
B05 RB1 888 c.1666C>T p.R556* - - - - - 
B06 RB1 861 c.1981C>T p.R661W - - - - - 
B07 TP53 11073 c.1024C>T p.R342* - - - - - 
B08 TP53 11582 c.395A>G p.K132R - - - - - 
B09 TP53 10801 c.404G>A p.C135Y - - - - - 
B10 TP53 10647 c.404G>T p.C135F - - - - - 
B11 TP53 43708 c.422G>A p.C141Y - +/- +/- - +/- 
B12 TP53 43609 c.437G>A p.W146* - - - - - 
C01 TP53 10727 c.438G>A p.W146* - - - - +/- 
C02 TP53 10905 c.451C>T p.P151S - - - - - 
C03 TP53 10790 c.455C>T p.P152L - - - - - 
C04 TP53 6815 c.461G>T p.G154V - - - - - 
C05 TP53 10670 c.469G>T p.V157F - - - - - 
C06 TP53 10690 c.473G>A p.R158H - - - - - 
C07 TP53 10714 c.473G>T p.R158L - - - - - 
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C08 TP53 11148 c.476C>T p.A159V - - - - - 
C09 TP53 10739 c.481G>A p.A161T - - - - - 
C10 TP53 10808 c.488A>G p.Y163C - - - - - 
C11 TP53 11084 c.517G>A p.V173M - - - - - 
C12 TP53 43559 c.517G>T p.V173L - - - - - 
D01 TP53 10648 c.524G>A p.R175H - - - - - 
D02 TP53 10687 c.527G>A p.C176Y - - - - - 
D03 TP53 10645 c.527G>T p.C176F - - - - - 
D04 TP53 10768 c.535C>T p.H179Y - + +/- +/- +/- 
D05 TP53 10889 c.536A>G p.H179R - - - - - 
D06 TP53 43635 c.536A>T p.H179L - +/- +/- +/- - 
D07 TP53 10733 c.574C>T p.Q192* - - - - - 
D08 TP53 10742 c.578A>G p.H193R - - - - - 
D09 TP53 11066 c.578A>T p.H193L - - - - - 
D10 TP53 11089 c.584T>C p.I195T - - - - - 
D11 TP53 10705 c.586C>T p.R196* - - - - - 
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D12 TP53 43947 c.614A>G p.Y205C - - - - - 
E01 TP53 10654 c.637C>T p.R213* - - - - - 
E02 TP53 43687 c.641A>G p.H214R - - - - - 
E03 TP53 10667 c.646G>A p.V216M - - - - - 
E04 TP53 10758 c.659A>G p.Y220C - - - - - 
E05 TP53 10725 c.701A>G p.Y234C - - - - - 
E06 TP53 10731 c.707A>G p.Y236C - - - - - 
E07 TP53 10834 c.711G>A p.M237I - - - - - 
E08 TP53 11059 c.713G>A p.C238Y - - - - - 
E09 TP53 10777 c.715A>G p.N239D - - - - - 
E10 TP53 10812 c.722C>T p.S241F - - +/- - - 
E11 TP53 10646 c.725G>A p.C242Y - - - - - 
E12 TP53 10810 c.725G>T p.C242F - - - - - 
F01 TP53 10941 c.730G>A p.G244S - - - - - 
F02 TP53 11524 c.730G>T p.G244C - - - - - 
F03 TP53 10883 c.731G>A p.G244D - - - - - 
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F04 TP53 6932 c.733G>A p.G245S - - - - - 
F05 TP53 11081 c.733G>T p.G245C - - - - - 
F06 TP53 43606 c.734G>A p.G245D - - - - - 
F07 TP53 11196 c.734G>T p.G245V - - - - - 
F08 TP53 10656 c.742C>T p.R248W - - - - - 
F09 TP53 10662 c.743G>A p.R248Q - - - - - 
F10 TP53 6549 c.743G>T p.R248L - - - - - 
F11 TP53 10817 c.747G>T p.R249S - - - - - 
F12 TP53 10771 c.749C>T p.P250L - - - - - 
G01 TP53 10988 c.772G>A p.E258K - - - - - 
G02 TP53 10867 c.797G>A p.G266E - - - - - 
G03 TP53 10891 c.814G>A p.V272M - - - - - 
G04 TP53 10659 c.817C>T p.R273C - - - - - 
G05 TP53 10660 c.818G>A p.R273H - - - - - 
G06 TP53 10779 c.818G>T p.R273L - - - - - 
G07 TP53 10893 c.824G>A p.C275Y - - - - - 
207 
 
G08 TP53 10701 c.824G>T p.C275F - - - - - 
G09 TP53 10939 c.832C>T p.P278S - + - - - 
G10 TP53 10863 c.833C>T p.P278L - +/- - - - 
G11 TP53 43714 c.836G>A p.G279E - - - - - 
G12 TP53 10728 c.839G>A p.R280K - - - - - 
H01 TP53 10724 c.839G>C p.R280T - - - - - 
H02 TP53 10704 c.844C>T p.R282W - +/- - - - 
H03 TP53 10722 c.853G>A p.E285K - - - - - 
H04 TP53 10726 c.856G>A p.E286K - - - - - 
H05 TP53 10856 c.880G>T p.E294* - - - - - 
H06 TP53 10710 c.892G>T p.E298* - - - - - 
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Position Gene COSMIC ID nt change AA change 
VH006-
RJW-L1 
NA 
VH006-
RJW-L1 A 
VH006-
RJW-L1 
MB1 
VH006-
RJW-L1 
MB2 
VH006-
RJW-L1 
MB4 
A01 ATM 21826 c.2572T>C p.F858L - - - - - 
A02 ATM 12951 c.7325A>C p.Q2442P - - - - - 
A03 ATM 20404 c.7328G>A p.R2443Q - - - - - 
A04 ATM 21642 c.9022C>T p.R3008C - - - - - 
A05 ATM 21626 c.9023G>A p.R3008H - - - - - 
A06 ATM 21624 c.9139C>T p.R3047* - - + - - 
A07 CDKN2A 13653 c.128G>T p.S43I - - - - - 
A08 CDKN2A 12743 c.143C>T p.P48L - - - - - 
A09 CDKN2A 12484 c.322G>A p.D108N - - - - - 
A10 CDKN2A 13520 c.322G>C p.D108H - - - - - 
A11 CDKN2A 13489 c.322G>T p.D108Y - - - - - 
A12 CDKN2A 12481 c.329G>A p.W110* - - - - - 
B01 CDKN2A 12547 c.330G>A p.W110* - - - - - 
B02 CDKN2A 12476 c.341C>T p.P114L - - - - - 
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B03 CDKN2A 12479 c.358G>T p.E120* - +/- - - - 
B04 RB1 887 c.1654C>T p.R552* - - - - - 
B05 RB1 888 c.1666C>T p.R556* - - - - - 
B06 RB1 861 c.1981C>T p.R661W - - - - - 
B07 TP53 11073 c.1024C>T p.R342* - - - - - 
B08 TP53 11582 c.395A>G p.K132R - - - - - 
B09 TP53 10801 c.404G>A p.C135Y - - - - - 
B10 TP53 10647 c.404G>T p.C135F - - - - - 
B11 TP53 43708 c.422G>A p.C141Y - +/- - +/- - 
B12 TP53 43609 c.437G>A p.W146* - - - - - 
C01 TP53 10727 c.438G>A p.W146* - +/- - +/- + 
C02 TP53 10905 c.451C>T p.P151S - - - - - 
C03 TP53 10790 c.455C>T p.P152L - - - - - 
C04 TP53 6815 c.461G>T p.G154V - - - - - 
C05 TP53 10670 c.469G>T p.V157F - - - - - 
C06 TP53 10690 c.473G>A p.R158H - - - - - 
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C07 TP53 10714 c.473G>T p.R158L - - - - - 
C08 TP53 11148 c.476C>T p.A159V - - - - - 
C09 TP53 10739 c.481G>A p.A161T - - - - - 
C10 TP53 10808 c.488A>G p.Y163C - - - - - 
C11 TP53 11084 c.517G>A p.V173M - - - - - 
C12 TP53 43559 c.517G>T p.V173L - - - - - 
D01 TP53 10648 c.524G>A p.R175H - - - - - 
D02 TP53 10687 c.527G>A p.C176Y - - - - - 
D03 TP53 10645 c.527G>T p.C176F - - - - - 
D04 TP53 10768 c.535C>T p.H179Y - + - +/- +/- 
D05 TP53 10889 c.536A>G p.H179R - - - - - 
D06 TP53 43635 c.536A>T p.H179L - +/- - - +/- 
D07 TP53 10733 c.574C>T p.Q192* - - - - - 
D08 TP53 10742 c.578A>G p.H193R - - - - - 
D09 TP53 11066 c.578A>T p.H193L - - - - - 
D10 TP53 11089 c.584T>C p.I195T - - - - - 
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D11 TP53 10705 c.586C>T p.R196* - - - - - 
D12 TP53 43947 c.614A>G p.Y205C - - - - - 
E01 TP53 10654 c.637C>T p.R213* - - - - - 
E02 TP53 43687 c.641A>G p.H214R - - - - - 
E03 TP53 10667 c.646G>A p.V216M - - - - - 
E04 TP53 10758 c.659A>G p.Y220C - - - - - 
E05 TP53 10725 c.701A>G p.Y234C - - - - - 
E06 TP53 10731 c.707A>G p.Y236C - - - - - 
E07 TP53 10834 c.711G>A p.M237I - - - - - 
E08 TP53 11059 c.713G>A p.C238Y - - - - - 
E09 TP53 10777 c.715A>G p.N239D - - - - - 
E10 TP53 10812 c.722C>T p.S241F - - - - - 
E11 TP53 10646 c.725G>A p.C242Y - - - - - 
E12 TP53 10810 c.725G>T p.C242F - - - - - 
F01 TP53 10941 c.730G>A p.G244S - - - - - 
F02 TP53 11524 c.730G>T p.G244C - - - - - 
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F03 TP53 10883 c.731G>A p.G244D - - - - - 
F04 TP53 6932 c.733G>A p.G245S - - - - - 
F05 TP53 11081 c.733G>T p.G245C - - - - - 
F06 TP53 43606 c.734G>A p.G245D - - - - - 
F07 TP53 11196 c.734G>T p.G245V - - - - - 
F08 TP53 10656 c.742C>T p.R248W - - - - - 
F09 TP53 10662 c.743G>A p.R248Q - - - - - 
F10 TP53 6549 c.743G>T p.R248L - - - - - 
F11 TP53 10817 c.747G>T p.R249S - - - - - 
F12 TP53 10771 c.749C>T p.P250L - - - - - 
G01 TP53 10988 c.772G>A p.E258K - - - - - 
G02 TP53 10867 c.797G>A p.G266E - - - - - 
G03 TP53 10891 c.814G>A p.V272M - - - - - 
G04 TP53 10659 c.817C>T p.R273C - - - - - 
G05 TP53 10660 c.818G>A p.R273H - - - - - 
G06 TP53 10779 c.818G>T p.R273L - - - - - 
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G07 TP53 10893 c.824G>A p.C275Y - - - - - 
G08 TP53 10701 c.824G>T p.C275F - - - - - 
G09 TP53 10939 c.832C>T p.P278S - - +/- - - 
G10 TP53 10863 c.833C>T p.P278L - +/- - +/- +/- 
G11 TP53 43714 c.836G>A p.G279E - - - - - 
G12 TP53 10728 c.839G>A p.R280K - - - - - 
H01 TP53 10724 c.839G>C p.R280T - - - - - 
H02 TP53 10704 c.844C>T p.R282W - - +/- +/- - 
H03 TP53 10722 c.853G>A p.E285K - - - - - 
H04 TP53 10726 c.856G>A p.E286K - - - - - 
H05 TP53 10856 c.880G>T p.E294* - - - - - 
H06 TP53 10710 c.892G>T p.E298* - - - - - 
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Position Gene COSMIC ID nt change AA change 
VH009-
AKH-L1 
NA 
VH009-
AKH-L1 A 
VH009-
AKH-L1 
MB1 
VH009-
AKH-L1 
MB2 
VH009-
AKH-L1 
MB3 
A01 ATM 21826 c.2572T>C p.F858L - - - - - 
A02 ATM 12951 c.7325A>C p.Q2442P - - - - - 
A03 ATM 20404 c.7328G>A p.R2443Q - - - - - 
A04 ATM 21642 c.9022C>T p.R3008C - - - - - 
A05 ATM 21626 c.9023G>A p.R3008H - - - - - 
A06 ATM 21624 c.9139C>T p.R3047* - - - - - 
A07 CDKN2A 13653 c.128G>T p.S43I - - - - - 
A08 CDKN2A 12743 c.143C>T p.P48L - - - - - 
A09 CDKN2A 12484 c.322G>A p.D108N - - - - - 
A10 CDKN2A 13520 c.322G>C p.D108H - - - - - 
A11 CDKN2A 13489 c.322G>T p.D108Y - - - - - 
A12 CDKN2A 12481 c.329G>A p.W110* - - - - - 
B01 CDKN2A 12547 c.330G>A p.W110* - - - - - 
B02 CDKN2A 12476 c.341C>T p.P114L - - - - - 
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B03 CDKN2A 12479 c.358G>T p.E120* - - - - - 
B04 RB1 887 c.1654C>T p.R552* - - - - - 
B05 RB1 888 c.1666C>T p.R556* - - - - - 
B06 RB1 861 c.1981C>T p.R661W - - - - - 
B07 TP53 11073 c.1024C>T p.R342* - - - - - 
B08 TP53 11582 c.395A>G p.K132R - - +/- - - 
B09 TP53 10801 c.404G>A p.C135Y - +/- + - - 
B10 TP53 10647 c.404G>T p.C135F - - - - - 
B11 TP53 43708 c.422G>A p.C141Y - +/- + - +/- 
B12 TP53 43609 c.437G>A p.W146* - - + - - 
C01 TP53 10727 c.438G>A p.W146* - +/- + - - 
C02 TP53 10905 c.451C>T p.P151S - - - - - 
C03 TP53 10790 c.455C>T p.P152L - - - - - 
C04 TP53 6815 c.461G>T p.G154V - - - - - 
C05 TP53 10670 c.469G>T p.V157F - - - - - 
C06 TP53 10690 c.473G>A p.R158H - - + - - 
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C07 TP53 10714 c.473G>T p.R158L - - - - - 
C08 TP53 11148 c.476C>T p.A159V - - - - - 
C09 TP53 10739 c.481G>A p.A161T - - - - - 
C10 TP53 10808 c.488A>G p.Y163C - - - - - 
C11 TP53 11084 c.517G>A p.V173M - - +/- - - 
C12 TP53 43559 c.517G>T p.V173L - - - - - 
D01 TP53 10648 c.524G>A p.R175H - - - - - 
D02 TP53 10687 c.527G>A p.C176Y - - + - - 
D03 TP53 10645 c.527G>T p.C176F - - - - - 
D04 TP53 10768 c.535C>T p.H179Y - +/- + - +/- 
D05 TP53 10889 c.536A>G p.H179R - - - - - 
D06 TP53 43635 c.536A>T p.H179L - + + - - 
D07 TP53 10733 c.574C>T p.Q192* - - - - - 
D08 TP53 10742 c.578A>G p.H193R - - - - - 
D09 TP53 11066 c.578A>T p.H193L - - - - - 
D10 TP53 11089 c.584T>C p.I195T - - + - - 
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D11 TP53 10705 c.586C>T p.R196* - - - - - 
D12 TP53 43947 c.614A>G p.Y205C - - - - + 
E01 TP53 10654 c.637C>T p.R213* - - +/- - - 
E02 TP53 43687 c.641A>G p.H214R - - - - - 
E03 TP53 10667 c.646G>A p.V216M - - - - - 
E04 TP53 10758 c.659A>G p.Y220C - - - - - 
E05 TP53 10725 c.701A>G p.Y234C - - - - - 
E06 TP53 10731 c.707A>G p.Y236C - - - - - 
E07 TP53 10834 c.711G>A p.M237I - - - - - 
E08 TP53 11059 c.713G>A p.C238Y - - - - - 
E09 TP53 10777 c.715A>G p.N239D - - - - - 
E10 TP53 10812 c.722C>T p.S241F - +/- +/- - - 
E11 TP53 10646 c.725G>A p.C242Y - - - - - 
E12 TP53 10810 c.725G>T p.C242F - - - - - 
F01 TP53 10941 c.730G>A p.G244S - - - - - 
F02 TP53 11524 c.730G>T p.G244C - - - - - 
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F03 TP53 10883 c.731G>A p.G244D - - - - - 
F04 TP53 6932 c.733G>A p.G245S - - - - - 
F05 TP53 11081 c.733G>T p.G245C - - - - - 
F06 TP53 43606 c.734G>A p.G245D - - - - - 
F07 TP53 11196 c.734G>T p.G245V - - - - - 
F08 TP53 10656 c.742C>T p.R248W - - - - - 
F09 TP53 10662 c.743G>A p.R248Q - - - - - 
F10 TP53 6549 c.743G>T p.R248L - - - - - 
F11 TP53 10817 c.747G>T p.R249S - - - - - 
F12 TP53 10771 c.749C>T p.P250L - - - - - 
G01 TP53 10988 c.772G>A p.E258K - - - - - 
G02 TP53 10867 c.797G>A p.G266E - - - - - 
G03 TP53 10891 c.814G>A p.V272M - - - - - 
G04 TP53 10659 c.817C>T p.R273C - - - - + 
G05 TP53 10660 c.818G>A p.R273H - +/- +/- - - 
G06 TP53 10779 c.818G>T p.R273L - - - - - 
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G07 TP53 10893 c.824G>A p.C275Y - - - - - 
G08 TP53 10701 c.824G>T p.C275F - - - - - 
G09 TP53 10939 c.832C>T p.P278S - +/- +/- - - 
G10 TP53 10863 c.833C>T p.P278L - + - - - 
G11 TP53 43714 c.836G>A p.G279E - - - - - 
G12 TP53 10728 c.839G>A p.R280K - - - - - 
H01 TP53 10724 c.839G>C p.R280T - - - - - 
H02 TP53 10704 c.844C>T p.R282W - +/- + - +/- 
H03 TP53 10722 c.853G>A p.E285K - - - - - 
H04 TP53 10726 c.856G>A p.E286K - - + +/- - 
H05 TP53 10856 c.880G>T p.E294* - - - - - 
H06 TP53 10710 c.892G>T p.E298* - - - - - 
 
220 
 
Appendix 2 – Real-time PCR results summary 
Real-time PCR experiment 1 
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Real-time PCR experiment 2 
 
 
222 
 
Appendix 3 – Ethics Approval and Publications 
• HREC-09-QPAH-162 approval letter 
• HREC-11-QPAH-442 approval letter 
• HREC-11-QPAH-363 approval letter 
• HREC-11-QPAH-236 approval letter 
• HREC-12-QPAH-217 approval letter 
• HREC-12-QPAH-082 approval letter 
• HREC-12-QPAH-251 approval letter 
• HREC-13-QPAH-551 approval letter 
• UQ HREC 2008001342 approval letter 
• Lin LL, Prow TW, Raphael AP, Harrold III RL, Primiero CA., Ansaldo AB, Soyer HP. 
2013. Microbiopsy engineered for minimally invasive and suture-free sub-millimetre 
skin sampling. F1000Res, 2, 120. 
• Banan P, Lin LL, Lambie D, Prow TW, Soyer HP.  2013. Effects of ex vivo skin 
microbiopsy on histopathologic diagnosis in melanocytic skin lesions. JAMA 
Dermatol, 149, 1107-9. 
• McClenahan P, Lin LL, Tan JM, Flewell-Smith, Schaider H, Jagirdar K, Atkinson V, 
Lambie D, Prow TW, Sturm RA, Soyer HP. 2014. BRAFV600E mutation status of 
involuting and stable nevi in dabrafenib therapy with or without trametinib. JAMA 
Dermatol, 150, 1079-82. 
• Tan JM, Lin LL, Lambie D, Flewell-Smith R, Jagirfdar K, Schaider H, Sturm RA, Prow 
TW, Soyer HP. 2015. BRAF Wild-Type Melanoma in Situ Arising In a BRAF V600E 
Mutant Dysplastic Nevus. JAMA Dermatol. 
223 
 
• Soyer HP, Lin LL, Prow TW. A plea for bio-banking of all equivocal melanocytic 
proliferations. JAMA Dermatology. 2013 Sep 1;149(9):1023-4. 
• Prow TW, Lin LL, Soyer HP. The opportunity for microbiopsies for skin cancer. Future 
Oncology. 2013 Sep;9(9):1241-3. 
















F1000Research
Open Peer Review
, Emory University USAJack Arbiser
, San GallicanoMarco Ardigò
Dermatological Institute Italy
, Newcastle University UKNeil Rajan
Discuss this article
 (1)Comments
3
2
1
METHOD ARTICLE
   
Microbiopsy engineered for minimally invasive and suture-free
 sub-millimetre skin sampling [v2; ref status: indexed, 
http://f1000r.es/1h7]
Lynlee L Lin,     Tarl W Prow, Anthony P Raphael, Robert L Harrold III, Clare A Primiero,
 Alexander B Ansaldo, H Peter Soyer
Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, QLD 4012,
Australia
Abstract
We describe the development of a sub-millimetre skin punch biopsy device for
minimally invasive and suture-free skin sampling for molecular diagnosis and
research. Conventional skin punch biopsies range from 2-4 mm in diameter.
Local anaesthesia is required and sutures are usually used to close the wound.
Our microbiopsy is 0.50 mm wide and 0.20 mm thick. The microbiopsy device
is fabricated from three stacked medical grade stainless steel plates tapered to
a point and contains a chamber within the centre plate to collect the skin
sample. We observed that the application of this device resulted in a 0.21 ±
0.04 mm wide puncture site in volunteer skin using reflectance confocal
microscopy. Histological sections from microbiopsied skin revealed 0.22 ± 0.12
mm wide and 0.26 ± 0.09 mm deep puncture sites. Longitudinal observation in
microbiopsied volunteers showed that the wound closed within 1 day and was
not visible after 7 days. Reflectance confocal microscope images from these
same sites showed the formation of a tiny crust that resolved by 3 weeks and
was completely undetectable by the naked eye. The design parameters of the
device were optimised for molecular analysis using sampled DNA mass as the
primary end point in volunteer studies. Finally, total RNA was characterized.
The optimised device extracted 5.9 ± 3.4 ng DNA and 9.0 ± 10.1 ng RNA. We
foresee that minimally invasive molecular sampling will play an increasingly
significant role in diagnostic dermatology and skin research.
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Introduction
Skin biopsy is one of the most essential techniques in dermatol-
ogy for accurate diagnosis of neoplastic or inflammatory skin 
diseases through histopathological assessment. This technique 
is performed under local anaesthetic by trained medical person-
nel, normally a dermatologist, to remove a skin sample 2–4 mm 
in diameter (Figure 1) that is then preferably sent to a dermato-
pathologist for histopathological diagnosis. Pathological exami-
nation using skin biopsies often complements and/or confirms 
diagnosis of common neoplastic or inflammatory skin diseases1. 
This technique is usually performed using a punch biopsy tool or a 
scalpel. The wound is then either sutured or left to heal.
An excisional biopsy, a common alternative in neoplastic skin con-
ditions, is performed when the entire tumour is needed for histo-
pathological examination, or when melanoma is suspected. This 
depends on the size and location of the lesion and can be performed 
using a larger 4–6 mm diameter punch biopsy, a deep shave biopsy, 
or with a fusiform excision2. These biopsy techniques coupled with 
histopathology are able to provide accurate diagnosis of the disease 
occurrence and progression, however the downsides of these tech-
niques are that they require local anaesthesia and sutures in addi-
tion to the time required to carry out the procedure. Furthermore, 
samples are generally fixed with formalin that hinders molecular 
analysis. Molecular fingerprinting of skin disease has the potential 
to dramatically improve diagnostic sensitivity and open the door 
for personalised medicine3–5. To date, there have been no reports on 
biomarker profiling of lesional samples in a prospective study due 
to the lack of suitable technologies to perform multiple sampling 
over time. This is due to the iatrogenic issue of cutting out the lesion 
through biopsy precluding further study of that lesion.
This problem exists in many medical disciplines and has led to the 
evolution of experimental diagnostic devices towards miniaturised 
versions of their predecessors. This miniaturisation trend is enabled 
by several factors including improved micro-manufacturing toler-
ances, decreasing costs and increasing availability. One of the earli-
est micro-devices developed to obtain biopsy samples was patented 
by Krulevitch et al.6. They patented microbiopsy/precision cutting 
devices fabricated by conventional machining, silicon micromachin-
ing, precision machining and injection moulding. Over the years, 
there have been many similar patents that report a variety of such 
microbiopsy devices. The unifying theme is that these patents all de-
scribe micro-biopsy devices for breast or intestinal tissue sampling7–10 
and importantly none were engineered for skin or skin lesions.
Our group has developed a new microbiopsy platform technol-
ogy that enables the collection of tiny pieces of skin using a 
micro-medical device that is minimally invasive and does not re-
quire local anaesthesia (IP Australia Appl. Num. 2012901490, filed 
on 16/04/2012). There are situations when conventional biopsies 
are not appropriate. Skin disease may present with multiple lesions 
and/or in a cosmetically sensitive area. The microbiopsy device has 
the potential to fill a void in dermatology where conventional bi-
opsies are not feasible or could do more harm than good. We have 
      Changes from Version 1
We have replaced the word “painless” to “minimally invasive” 
throughout the manuscript. We have removed the statement 
regarding leg complications. We have included additional data on 
the quality of DNA comparing conventional shave biopsy sample 
and the microbiopsy sample that was taken from the same lesion 
and the method to obtain this data has been provided under the 
‘Materials and Methods’. We have emphasized in the ‘Discussion’ 
that unlike the conventional biopsy, the microbiopsy sample cannot 
be used for histological assessment. We have also addressed in the 
‘Discussion’ the importance for using high quality RNA samples in 
whole transcriptome approaches and future directions for this novel 
device. 
See referee reports
Figure 1. Size comparison of needle, biopsy devices and biopsy 
comparisons. A conventional biopsy punch is shown on the left, 
an 18 gauge syringe needle in the centre and the inner chamber 
of our microbiopsy device on the right Panel (a) our microbiopsy 
device chamber is 0.15 mm in width with an outer width of 0.25 mm. 
The top row of Panel (b) contains a conventional 3 mm biopsy site 
and tissue, whereas the bottom panels show microbiopsied skin 
and tissue.
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RCM was also used to perform in vivo examination of the skin 
after microbiopsy. RCM images were collected through the 
microscope head, integrated with a water immersion objec-
tive, at a near-infrared wavelength of 785 nm. Blocks consist-
ing of 7 × 7 mm mosaics of stitched RCM images and 2 µm to 
200 µm vertical z-stacks were acquired at the microbiopsy sam-
pling site. Dermatoscopic images were collected with a Canon 
Power Shot G10 digital camera (Canon, Japan) and a dermatoscope 
attachment (Dermlite©, 3Gen, USA).
Microbiopsy site visualisation histology
Microbiopsied tissue was embedded (Optimal cutting temperature 
compound, Sakura Finetek, USA) and cryosectioned (CM1850, 
Leica Microsystems Pty Ltd, Australia). The 10 µm thick sections 
were fixed with 100% cold methanol for 10 minutes, air dried and 
stained with haematoxylin and eosin (Varistain Gemini ES, Thermo 
Fisher Scientific Inc., USA) to visualize the microbiopsy sites.
Nuclear labelling and confocal microscopy
The microbiopsy extracted tissue was incubated with DRAQ5 
(BioStatus Limited, UK) at 10 µM in PBS for 30 minutes at room 
temperature. Confocal microscopy images were taken with a Zeiss 
510 META confocal microscope (Carl Zeiss Microscopy GmbH, 
Germany). A 3D projection was then created from the z-stacks 
(2 µm steps) of confocal images using Imaris (Bitplane Scientific 
Software, Switzerland). ImageJ (NIH, USA) was used to estimate 
the nuclei in microbiopsy samples. 
DNA isolation
DNA was extracted from the microbiopsy samples using QIAamp 
DNA Micro purification kits (QIAGEN GmbH, Germany) using a 
protocol modified to accommodate the unique microbiopsy sample. 
The microbiopsy was removed from the applicator housing after ap-
plication. The presence of a tissue sample was quickly confirmed by 
opening the microbiopsy device and visualizing with a stereo micro-
scope (Carl Zeiss Microscopy GmbH, Germany). The opened device 
was then immersed in 180 µl lysis buffer (Buffer ATL, QIAGEN 
GmbH, Germany) in the presence of proteinase K (20 µl) in a 1.5 ml 
tube. Fifteen seconds of pulse-vortexing was applied to ensure that the 
sample was well-mixed. The sample was then placed in a thermomixer 
(Eppendorf, Australia) at 56°C with shaking at 800 rpm overnight. The 
tube containing the device was briefly centrifuged for 10 seconds to re-
move the solution adhering to the cap of the tube before transferring the 
lysate into a new tube. The tube containing the device was centrifuged 
again at 6000 g for 30 seconds to remove any lysate adhering to the 
device. The lysates were combined and the remaining procedure fol-
lowed the manufacturer supplied instructions.
observed that microbiopsy sampling does not interfere with down-
stream histopathological diagnosis11. The data presented herein 
describe the fabrication, optimisation and early steps toward the vali-
dation of a novel microbiopsy device for use in vivo.
Materials and methods
Microbiopsy device fabrication
The microbiopsy devices used in our studies were fabricated by laser 
cutting plates of stainless steel. The in-house fabrication of microbi-
opsy devices involves laser cutting of two-dimensional designs on 
0.05 mm thick medical grade stainless steel (304, Mastercut Tech-
nologies, Australia) at 95% power, 30% frequency and speed of 0.9 
using a 20 W laser marking system (LaserPro S290, GCC, Taiwan). 
All of the 2D microbiopsy components were assembled into 3D 
devices, and sterilized using a glass bead sterilizer (Steri Inotech 
350, Sigma-Aldrich, USA) at 250°C for 30 seconds or submerged 
in 70% ethanol for 1 min and air-dried prior to use. The microbiopsy 
device was then fitted into a spring-loaded applicator.
Microbiopsy device imaging
A bench top scanning electron microscope (SEM) (JCM-6000 Neo-
scope, JEOL, USA) was used to acquire high-resolution images of 
the microbiopsy device. The roughness amplitude of the microbi-
opsy chamber was obtained by measuring the average distances of 
the edge to a regression-fitted straight line using MatLab (Math-
works, Australia).
Microbiopsy and conventional biopsy sample collection
Microbiopsy samples were either obtained in vivo from healthy 
volunteers (HREC/12/QPAH/082, Metro South Human Research 
Ethics Committee, Centres for Health Research, Princess Alex-
andra Hospital) or ex vivo from excised actinic keratosis (AK) le-
sions. The skin of a healthy volunteer was swabbed with alcohol 
and the microbiopsy applied. Conventional biopsies e.g. punch 
(Figure 1b) or shave biopsies, were performed with informed 
consent from patients (HREC/08/QPAH/207 for healthy skin or 
HREC/11/QPAH/477 for AK lesions) prior to being microbiopsied. 
Samples were collected in sterile RNase and DNase free 1.5 ml mi-
crocentrifuge tubes containing either RNALater (Life Technolo-
gies, USA) or pH 7.0 phosphate buffered saline (PBS) on ice within 
20 minutes after tissue removal from patients. All samples placed 
in RNALater were kept overnight at 4°C and then stored at -80°C.
Measurement of pain score
Volunteer pain scores were evaluated with Metro South Human 
Research Ethics Committee, Princess Alexandra Hospital approval 
(HREC/12/QPAH/082). Each of the 20 volunteers (Table 1) was pre-
sented with an assessment form to grade his/her expected pain score 
based on a numerical rating 10-point Likert scale, 0 as having no 
pain and 10 as pain as bad as they can imagine before the start of the 
experiment. Each microbiopsy application was performed one min-
ute apart and the pain score recorded immediately after application. 
Five minutes after the final microbiopsy application, the volunteers 
were asked to rate the level of pain for each microbiopsy site.
Reflectance confocal microscopy
Microbiopsy sites were visualized with a reflectance confo-
cal microscope (RCM, Vivascope 1500 Multilaser, Lucid, Inc., 
USA) in volunteers or in excised skin (HREC/12/QPAH/217). 
Table 1. Volunteer summary. Volunteers for microbiopsy classified 
by age, ethnic group, gender and Fitzpatrick skin type.
Ethnic 
group
Fitzpatrick 
skin type22
Gender Age (as of 
study year)
Number of 
participants
Caucasian II–III M 23–44 8
Caucasian I–II F 22–39 6
Asian IV M 27–33 4
Asian III F 27 2
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3 mm punch biopsy and more than 5 times smaller than an 18 GA 
syringe needle (Figure 1a). Figure 1b demonstrates the size differ-
ences between a conventional 3 mm punch biopsy (top panels) and 
our microbiopsy (bottom panels).
Channel width optimisation
We conducted a volunteer study in 20 healthy individuals to deter-
mine the optimal channel width and application velocity for this 
device. Extracted DNA mass was chosen to be the primary indica-
tor for sample-to-sample comparisons. Interestingly, we observed 
tissue collection (4.5 ± 1.5 ng DNA) around the rough edges of 
a microbiopsy device without a chamber (Figure 2a–b, channel 
width of 0 mm). After applying the microbiopsy, the device was 
opened up and visualized under a dissecting microscope. Suc-
cessful collection was achieved when tissue was evident within or 
around the device and unsuccessful if no tissue was present. Tissue 
was collected from all volunteers (n=20) when a 0.15 mm channel 
width microbiopsy device was used. Only 13 successful collections 
were achieved from 20 applications when a 0.20 mm channel width 
microbiopsy device was used. This indicated that the collection rate 
decreased from 100% to 65% when channel width was increased 
by 0.05 mm. The device without a channel (0 mm channel width) 
captured tissue around the edges of the tapered plates in all replicates 
(n=20). This experiment showed that a channel width of 0.15 mm 
obtained the highest average amount of DNA (5.9 ± 3.4 ng), which 
was significantly higher than 0.25 and 0.30 mm channel widths 
(p < 0.0001). There was no significant difference in the total DNA 
extracted between 0–0.20 mm channel widths (Figure 2a). 
Application velocity optimisation
Microbiopsy application velocity was evaluated by us-
ing defined applicator springs to achieve velocities between 
0–20.2 m/s (Figure 2d). Only negligible amounts of DNA were re-
covered when the device was applied at less than 9.2 m/s. How-
ever, there was a 7.5-fold increase (0.8 ± 0.8 to 6.0 ± 3.0 ng) in 
DNA recovered when the application velocity was increased from 
9.2 m/s to 16.6 m/s (p < 0.0001). An additional increase to 20.2 m/s 
increase in application velocity did not result in significant increases 
in DNA collection.
Pain scale assessment
There was no change in the level of pain reported when 
microbiopsies with varying channel widths were applied 
(Figure 2c). The level of pain significantly increased and variation 
increased when microbiopsies were applied at increasing velocities 
(Figure 2e). All of the volunteers had a pain score of 0 at 5 minutes 
after the final microbiopsy application (data not shown). The vol-
unteers scored pain between 0 to 10 with an average score of 
1.5 ± 1.1, when the 0.15 mm channel width microbiopsy was 
applied at 20.2 m/s. 
Edge roughness optimisation
We observed DNA collection without a centre chamber 
(Figure 2a, 4.5 ± 1.4 ng from channel width 0 mm) and hypoth-
esized that surface roughness could be key to successful sample 
collection. We compared microbiopsy devices with varying rough-
ness amplitudes (RA) and observed an increasing trend in total DNA 
extracted with increasing RA (Figure 3a) (n=20 for 5.36 RA and n=5 
for 0.92 and 1.32). The SEM images of the inner chamber edge 
RNA isolation
The modified sample lysing processing described in DNA iso-
lation above was also used with the Arcturus PicoPure RNA 
Isolation Kit (Life Technologies, USA) to obtain total RNA from 
microbiopsy samples. RNA isolation of lesional samples was per-
formed using RNeasy Mini Kit (QIAGEN GmbH, Germany) ac-
cording to the RNeasy Mini Handbook (version 2010).
DNA and RNA quantification
A quantitative fluorometer-based assay (Qubit 2.0, Life Tech-
nologies, USA) was used to determine the concentration of DNA 
and RNA with the protocol provided by the manufacturer.
DNA and RNA quality control
Agilent DNA 12000 DNA kit (Agilent Technologies, USA) was 
used to determine the integrity and quality of DNA after whole 
genomic amplification of isolated DNA from microbiopsy and 
matched conventional shave biopsy samples. Agilent RNA 6000 
Nano and Pico kits (Agilent Technologies, USA) were used to de-
termine the RNA integrity number (RIN) of lesional and micro-
biopsy samples after RNA isolation. The supplied protocol was 
followed.
Whole genomic amplification
Identical amounts of total DNA (1.85 ng) for both lesional and mi-
crobiopsy samples were subjected to whole genomic amplification. 
The amplification procedure was carried according to manufactur-
er’s instructions (REPLI-g Single Cell Kit, QIAGEN, Australia).
Whole transcriptome amplification
Identical amounts of total RNA (14 ng) for both lesional and mi-
crobiopsy samples were subjected to whole transcriptome amplifi-
cation. The procedure was carried out using the supplied instruc-
tions (QuantiTect Whole Transcriptome Kit, QIAGEN, Australia). 
The cDNA obtained from the amplification process was used as a 
template in a polymerase chain reaction (PCR) reaction using hu-
man beta actin primers (forward: ATC TGG CAC ACC TTC TAC 
AAT GA; reverse: CGT CAT ACT CCT GCT TGC TGA TCC AC) 
(Integrated DNA Technologies, NSW, Australia). There was an ini-
tial denaturation for 2 minutes at 98°C, followed by 30 cycles of 
98°C for 30s (denaturation), 67°C for 30s (annealing), and 72°C for 
1 minute (extension). The cDNA and PCR products were run on a 
1% agarose gel (Bio-rad Laboratories, Inc., Australia) and visual-
ized with RedSafe (ChemBio, UK). HyperLadder 1 kb (Hyper-
Ladder I) (Bioline, UK) was used to determine the mass of cDNA 
and human beta actin amplicons.
Statistical analysis
Statistical analysis was performed using PRISM 6 for Windows 
(GraphPad Software, Inc., USA). Channel width, velocity and 
roughness amplitude data were presented as mean ± SD. Pain score 
for channel width and velocity were presented as minimum to max-
imum box-and-whiskers plot. One-way ANOVA combined with a 
Tukey’s multiple comparison post-test was performed to determine 
the statistical significance.
Results
Our microbiopsy device has a chamber volumetric size of 
0.003 mm3 that is more than 6000 times smaller than a conventional 
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Figure 2. Microbiopsy channel width and velocity optimisation. Channel width and velocity were varied to optimise the microbiopsy 
device configuration. Total DNA was used as a surrogate for sample size. Panel (a) shows the DNA extracted from device with varying 
channel width and that the maximum amount of DNA was collected with 0.15 mm channel width. Panel (b) displays high resolution scanning 
electron microscopic images showing different channel widths of the microbiopsy device. Panel (c) shows the level of pain volunteers 
reported when different channel width microbiopsies were used. Panel (d) shows the varying velocity applied and that the maximum amount 
of DNA was collected when the device was applied at 16.6 m/s. Panel (e) shows the level of pain volunteers reported when application 
velocity was varied.
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Figure 3. Microbiopsy roughness amplitude optimisation. Panel (a) shows that microbiopsy devices with higher roughness amplitude 
channels are capable of collecting more DNA. Panel (b) contains high resolution scanning electron microscopic images showing different 
channel widths and roughness of the microbiopsy device.
were used to measure the RA. These measurements ranged from rel-
atively smooth (RA 0.92) to rough (RA 5.36) (Figure 3b, side view). 
Microbiopsy site imaging
RCM was used to visualise the microbiopsy application site. RCM 
images revealed a microbiopsy site similar to the size of a small 
hair follicle in the dermal papillary post microbiopsy application 
(Figure 4a and 4b). The inset shows that microbiopsy application 
resulted in a puncture site that was approximately 0.10 × 0.50 mm 
in dimension (Figure 4b). Microbiopsy samples were stained with 
DRAQ5 (BioStatus Limited, UK) to highlight the nuclei. Confo-
cal images were used to generate a 3D model of the microbiopsy 
sample. The usual skin strata were apparent in this model. We esti-
mated that there were 1634 nuclei in Figure 4c. We observed 0.22 
± 0.12 mm wide and 0.26 ± 0.09 mm deep puncture sites in excised 
abdominal skin from 10 histological sections (Figure 4d).
Microbiopsy sample molecular characterisation
One of our goals was to compare AK lesions to microbiopsy 
samples since many of these lesions can be present in patients 
but only a few progress12 to squamous cell carcinoma and the 
molecular mechanism behind this transition is a focus of intense 
research. Microbiopsy samples were taken from freshly excised 
AKs. The RNA from these matched samples had comparable 
quality with an average RIN difference of -0.85 ± 0.85 for n=4. 
Representative Bioanalyzer (Agilent Technologies, USA) results 
for the conventional biopsy (RIN 6.50) and microbiopsy (RIN 5.10) 
are shown in Figure 5, left panel. The results showed that there are 
similarities and differences in the RNA bands, which may be due 
to the large amount of tissue sampled with conventional biopsy and 
the relatively small number of cells sampled with the microbiopsy.
The small sample size is an inherent limitation of the microbiopsy 
device. To mitigate this, a pilot experiment was conducted where 
the microbiopsy sample was subjected to whole transcriptome 
amplification for RNA analysis. We included a skin sample with 
the same amount of starting material (14 ng) as an amplification 
control in the experiment. We observed a 2000-fold increase in 
cDNA from both samples based on total RNA and cDNA meas-
urements. The cDNAs were of comparable quality and quantity 
(Figure 5, Transcriptome Amplification to cDNA). Subsequently, 
we used PCR to amplify human beta-actin mRNA. We observed 
2 identical bands at 800 bp with comparable PCR product quality 
both lanes (Figure 5, Actin PCR).
Wound healing kinetics
Immediately after microbiopsy application we observed local ery-
thema that resolved within 24 hours. The tiny excision site from the 
microbiopsy healed quickly and was invisible to the naked eye after 
24 hours (Figure 6). We used dermoscopy and RCM to monitor the 
wound healing process at regular intervals (Figure 6, center and 
right columns).
Influence of channel width and velocity of microbiopsy on DNA, 
extraction, RNA extraction and pain scores in volunteers
1 Data File
http://dx.doi.org/10.6084/m9.figshare.687063
Discussion and conclusion
Whereas conventional biopsies allow accurate diagnosis of tissue 
sampled through histopathological assessment, there is a need for an 
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Figure 5. Molecular characterization of conventional shave biopsies and microbiopsies. The left panel shows the Bioanalyzer readout from 
amplified DNA from a conventional actinic keratosis (AK) shave biopsy next to the microbiopsy DNA sample obtained from the same AK lesion. 
The middle panel shows the Bioanalyzer readout from RNA isolated from a conventional AK shave biopsy and a microbiopsy that was obtained 
from the same AK lesion.  The right panel compares the RNA quality of a shave biopsy and normal skin microbiopsy that were subjected to total 
transcriptome amplification to generate cDNA. The cDNA was then used as a template for a PCR reaction containing actin specific primers with 
an expected product at 800 bp.
Figure 4. Site of microbiopsy and microbiopsy content. Panels (a) and (b) are reflectance confocal microscopy mosaics of a microbiopsy 
site, see the hair follicles featured in the centre and on the right hand side of the images for size comparison (bar indicates 0.5 mm in a 
and b). Panel (c) shows a 63x magnification, 3D rendering of the microbiopsy tissue with a nuclear counter stain (orange) derived from 
a confocal microscopy z-stack of the sample within the microbiopsy device. The stratum corneum (SC), viable epidermis (VE), dermal-
epidermal junction (DEJ) and superficial dermis (DER) are labeled. This microbiopsy contained an estimated 1634 nuclei. Haematoxylin and 
eosin stained section of human skin after microbiopsy application shows a 0.10 mm wide and 0.25 mm deep puncture Panel (d). * indicates 
the site of microbiopsy application.
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arsenal. Recent developments in molecular inhibitors for skin 
cancer, e.g. Vemurafenib13 and Trametinib14,15, are driving a new 
need for molecular diagnostic information that cannot be gathered 
through morphologic analysis. Molecular biomarkers have been 
used to detect cancer, but are now being developed to determine 
which molecular therapeutic will be the most effective. Melanoma 
clinical biology research has resulted in genomic data identifying 
oncogenes that can be targeted by protein kinase inhibitors 
e.g. BRAF and MEK16. Diagnostic assays to detect BRAF and NRAS 
mutations are now being used to stratify skin cancer lesions17. The 
microbiopsy device has the potential to help screen multiple lesions 
for specific mutations, and to be important in discovery based 
research.
Yancovitz et al. describe intra- and inter-tumour heterogeneity 
of melanoma in the context of BRAFV600E mutations18. Hematoxylin 
and eosin stained sections of primary and metastatic lesions were 
subjected to laser capture microdissection to isolate the lesions 
of interest. They captured 30–300 cells for each lesion of interest. 
This is less than 5 times that captured with the microbiopsy de-
vice. The authors used the same DNA extraction kit as we did to 
isolate lesional DNA for analysis. These samples were then used 
to detect BRAFV600E tumour heterogeneity. Based on our analysis, 
we estimate that Yancovitz et al. isolated <1 ng of DNA in this 
study and were able to amplify BRAF exon 15 using conven-
tional PCR followed by mutation analysis. We found that we can 
reproducibly isolate 5 ng of DNA from the superficial skin and 
in another publication show the use of the microbiopsy device in 
dysplastic nevi11. This work sets the stage for future microbiopsy 
studies focused on BRAF mutational analysis in nevi in situ. The 
addition of RNA analysis to mutational studies would give ad-
ditional insights into gene expression profiles of these lesions.
Berglund et al. (2007) reported that their optimised methodology 
yielded an average 1.4 ± 0.4 µg of consistently high quality RNA 
(8.4–8.9 RIN) from 3 mm skin punch biopsies19. Another group re-
ported that they had isolated an average of 1.5 µg of RNA with 
an average RIN value of 8.1 from half of a 4 mm punch biopsy 
skin sample (n=97)20. The average total RNA yielded from the mi-
crobiopsy device is 9.0 ± 10.1 ng (n=5). Even though we isolated 
far less RNA with the microbiopsy device, our proof of concept 
study supports the hypothesis that this limitation can be addressed 
using commercial amplification kits and PCR (Figure 5) for inves-
tigating the molecular basis of skin disease. Through the course of 
these experiments we observed RNA integrity values that ranged 
between 1.2 and 7.6 with the microbiopsy. We also observed that 
these values correlated with matched conventional shave biopsies. 
In some cases the values were quite low (e.g. RIN 5.1 in Figure 5) 
and would not be considered for whole transcriptome approaches. 
Sampling for RNA analysis can be difficult and optimizing this ap-
plication for the microbiopsy is one of our priorities as we move 
forward with this technology.
Discovering non-melanoma skin cancer biomarkers and po-
tential therapeutic targets is an emerging area of research. For 
alternative technology, such as the microbiopsy, to screen multiple 
lesions through molecular diagnosis. In this proof of concept study, 
we have shown that an arrangement of stacked plates to form a 
3D microbiopsy device is capable of providing molecular samples 
from normal and diseased skin. DNA extraction from human skin 
is critical for stratifying lesions in terms of mutational status. This 
type of characterization is becoming more and more relevant as 
targeted signalling inhibitors are being added to the therapeutic 
Figure 6. Wound healing kinetics of microbiopsy site. The 
left column shows dermoscopic images of the microbiopsy site 
over time. The middle and right column are mosaics and at 30x 
magnification reflectance confocal microscopy (RCM) images, 
respectively, of the microbiopsy site.
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example, Dang et al. (2006) focused on the genetic changes 
that occur in AK to squamous cell carcinoma (SCC) for pro-
spective development of new diagnostic tools and therapeu-
tic approaches. They reported that 7 out of 14 genes in 10 AK, 
10 SCC and 20 normal skin samples related to cell adhesion, com-
munication, metabolism and respiration were significantly dysreg-
ulated in AK and SCC (p < 0.05)21. The microbiopsy device has 
the potential to help facilitate longitudinal studies within a single 
lesion.
Application of the relatively small microbiopsy device does not 
require local anaesthesia or sutures and therefore no set up for a 
minor clinical procedure is necessary. Observations from our vol-
unteer study suggest that collecting multiple microbiopsies within 
in a short period is feasible. We envision that microbiopsy devices 
will become a routine clinical and research device in dermatology 
allowing the dermatologist to obtain targeted lesion data for mo-
lecular stratification.
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Letters
RESEARCH LETTER
Effects of Ex Vivo SkinMicrobiopsy
onHistopathologic Diagnosis
inMelanocytic Skin Lesions
Currently,histopathologicanalysis represents thepractical ref-
erence standard for the diagnosis of melanocytic skin le-
sions.However, thereare limitationsparticularly related to the
morphologic nature of thehistopathologic interpretation and
the influenceof theclinical informationon the finaldiagnosis.1
Toprovide lesional tissue frommelanocytic proliferations for
molecular analysiswithout jeopardizing the conventional his-
topathologicdiagnosis,we inventedaminiaturizedbiopsyde-
vicewith a totalwidthof 0.35mm, containing a sample cham-
ber 0.15 mmwide. This device penetrates approximately 250
μm in healthy skin (ie, superficial dermis) to collect approxi-
mately 1600 cells.2 Thismicrobiopsydevice canbeusedwith-
out local anesthetic, and there is noneed for a suture. Our hy-
pothesis is that the minimal skin damage caused by the
microbiopsy does not interfere with the subsequent histo-
pathologic diagnosis.
Methods | Five patients scheduled for suspicious pigmented
lesion removal at the dermatology department of the Prin-
cess Alexandra Hospital, a public tertiary hospital in Bris-
bane, Australia, were recruited.
Consent was obtained from all
participants with approval from
The University of Queensland/
Princess Alexandra Hospital Human Research Ethics Com-
mittees. Clinical images of the lesions were taken before sur-
gery and immediately after excision. Each excised lesion was
bisected, and 5 microbiopsy specimens were applied ex vivo
to one of the halved lesions. The microbiopsy site locations
were documented, and the specimens were labeled accord-
ingly. All specimens were sectioned in the hospital’s pathol-
ogy laboratory according to routine protocol.
Results | All sections were examined by a dermatopathologist
(D.L.) for the histopathologic diagnosis, with special empha-
sis on the microbiopsy defect. The mean (SD) size of the mi-
crobiopsy defect was 113 (50) μm wide and 146 (37) μm deep
(n = 4). These defects are comparable, albeit not identical, to
processing artifacts in nonmicrobiopsied specimens ranging
from 20 to 2100 μmwide and 70 to 600μmdeep. Histopatho-
logicdiagnoses inbothhalves,whileexaminedseparately,were
exactly the same in all lesions. Diagnoses included com-
pound nevus, junctional lentiginous nevus, compound dys-
plastic nevus, junctional dysplastic nevus, and solar lentigo.
From the 5 lesions included in the study, 2 are displayed
herein clinically and histopathologically. Patient 1 was an 88-
year-oldmanwith ahistoryofmetastaticmelanoma,whohad
adeepshaveexcisionofanewnevus identifiedonhis left flank.
One of themicrobiopsy defects identifiedwithin themelano-
cytic region was 132 × 74 μm in size (Figure 1). The diagnosis
was a compound dysplastic nevus. Patient 2 was a 56-year-
oldwomanwithhistoryofnonmelanomaskincancer,whopre-
sented with a changing nevus on her left scapula. One of the
microbiopsy defects found outside the lesional region was
145 × 201μmand reached the superficial dermis (Figure 2). Di-
agnosis of this lesion was junctional lentiginous nevus.
Discussion | Over the years, many microdevices have been de-
veloped to obtain tissue samples,3-5 but interestingly enough
noneof thesemicrodevices are specifically engineered for skin
lesions. Because of the new exciting developments of tar-
geted molecular therapies in patients with melanoma,6 there
is aneed for aminimally invasivebiopsydevice enabling small
tissuecollectionwithminimaladverseeffects toperformdown-
streammolecular diagnosis of melanocytic skin lesions.
Thesizeofmicrobiopsydefectsmeasured in this studywas
comparable to other artifacts more or less commonly seen in
routine sectioned specimens. The potential diagnostic diffi-
culties for the dermatopathologist encountered with the his-
topathologic assessment of amicrobiopsiedmelanocytic skin
lesion can easily be overcome by orderingmultiple levels. All
5 melanocytic lesions included in this study were not diffi-
cult to assess, and therefore the diagnostic process was not
hamperedby themicrobiopsy-induced artifacts; however, on
the basis of the size of the microbiopsy artifacts, we foresee
that the diagnostic process, even in equivocal cases, will not
be influenced. The data from this study support the hypoth-
esis thatminimal skindamagecausedby themicrobiopsydoes
not affect the histopathologic diagnosis.
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magnification; and F, the site at high
magnification.
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BRAFV600EMutation Status of Involuting and Stable Nevi
in Dabrafenib TherapyWith orWithout Trametinib
Phil McClenahan, BSc; Lynlee L. Lin, BSc; Jean-Marie Tan, MB, BCh, BAO (hons);
Ross Flewell-Smith, BCom, BEng; Helmut Schaider, MD; Kasturee Jagirdar, MSc;
Victoria Atkinson, MBBS, FRACP; Duncan Lambie, BDSc, MBBS, FRCPA;
Tarl W. Prow, BS, MSc, PhD; Richard A. Sturm, PhD; H. Peter Soyer, MD, FACD
M elanocytes, likemanyotherhumancells, express theBRAF gene. However, mutation of BRAF in melano-cytesoccurs athigh frequency inmelanocytic prolif-
erationssuchasnevi (70%-82%)andmelanomas (50%-60%).1,2
Mutation of BRAF results in a defect of the mitogen-activated
protein kinase (MAPK) pathway causing oncogenic prolifera-
tion and avoidance of apoptosis.3 Most frequently, BRAFmu-
tations occur at the V600E position (74%-90%), and the next
most common mutation occurs at V600K (16%-29%)4; to-
gether, these sites account for 95% of all BRAFmutations.
Initial breakthrough treatments were made with vemu-
rafenib, a selective inhibitorofBRAFV600E-mutatedkinase.The
inhibition of BRAFV600E initially induces tumor growth arrest
and partial or complete tumor regression in metastatic
melanoma.5GiventhefrequencyofBRAFV600Emutations inbe-
nign nevi,2 it is also not surprising that changes have been ob-
served in existing melanocytic nevi and that new nevi appear
during BRAFV600E inhibitor therapy.6,7 Recently, a study of 42
patients treated with vemurafenib for a mean duration of 6.7
months described a high level of dermoscopic change in pre-
existing lesions such as color changes, appearance and disap-
pearanceofglobules,dermoscopic islandpigmentation,and in-
creases insizeofnevi.8Newprimarymelanomashavealsobeen
reportedduring theearlystagesofvemurafenib treatment,aris-
ing from new erupting melanocytic proliferations or rapidly
changing existing nevi.9 Zimmer et al,9 Dalle et al,7 and Perier-
Muzet et al8 report that these newprimarymelanomas arising
during vemurafenib therapy are BRAFwild type.
Hereinwedescribeanexampleofnevusvolatility andpro-
pose the molecular involvement in a patient undergoing
BRAFV600E inhibition therapy and who participated in a ne-
vus surveillance study. All patients in the surveillance study
provided written consent, and the study followed the Decla-
ration ofHelsinki protocols andwas approvedby thePrincess
Alexandra Hospital human research ethics committee.
Report of a Case
While participating in a nevus surveillance study, 1 of the pa-
tients, a man in his 30s who had been diagnosed 5 years ear-
lier as having a superficial melanoma (Clark level 3, Breslow
IMPORTANCE Recent advances in targeting BRAFV600E mutations, which occur in roughly
50% of melanomas and 70% of benign nevi, have improved response rates and survival in
patients with melanoma. With increased survival, the importance of other comorbidities
increases and requires consideration in long-termmanagement. This case report discusses
dynamic dermoscopic nevus changes that occur during dabrafenib therapy and offers some
conclusions regarding BRAFmutations and the changes.
OBSERVATIONS Aman in his 30s had beenmonitored with whole-body dermoscopy at
roughly 7-month intervals as part of a nevus surveillance study. Fourteenmonths after his
initial visit, metastases were found, and the patient entered a clinical trial of dabrafenib with
or without trametinib therapy. Continued dermoscopic monitoring for the next 12 months
revealed that approximately 50% of the existing acquiredmelanocytic nevi involuted, while
the remaining nevi did not change. Biopsy findings from 1 unchanged and 1 involuted nevus
showed BRAFwild type in the unchanged nevus, BRAFV600E mutation in the involuting
nevus, and nomalignant histopathologic characteristics in either one.
CONCLUSIONS AND RELEVANCE Our observations indicate that a previously suggested
hypothesis regarding involuting nevi in BRAF inhibitor therapy is correct: Nevi that involute
while a patient is undergoing BRAF V600E inhibitor therapy possess the BRAF V600E
mutation, while others that grow or remain unchanged are wild type. However larger-scale
trials are required to gather conclusive data and create a more complete clinical picture.
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index 0.64mm), developedmetastases in the pancreas, liver,
and mesenteric lymph nodes. Two months later, he was en-
rolled in a clinical trial of dabrafenib with or without tra-
metinib therapy. Dabrafenib is aBRAF inhibitor similar to ve-
murafenib, and it was being tested with trametinib, a MEK
(MAPK kinase) inhibitor that targets the same MAPK path-
way. The trial was blinded and still ongoing at the time of the
present report, and so it is unknown whether this patient’s
treatment regimen included trametinib.
The patient presented with Fitzpatrick skin type III,
dark brown hair, and green eyes. He underwent imaging
with a FotoFinder system (FotoFinder Systems GmbH) of all
nevi larger than 2 mm on the back and larger than 5 mm on
the rest of the body. No significant changes were observed
dermoscopically throughout. Ten nevi larger than 5 mm
were identified on the body, while 25 nevi larger than 2 mm
were identified on the back, for a total of 31 nevi included in
our analysis. There were 2 globular, 15 reticular, and 14
nonspecific/homogeneous nevi.
Full-bodyanddermoscopic imagingwasconducted5times
over the next 27months at roughly 7-month intervals, and no
significant dermoscopic changes were identified by assess-
ment of imaged nevi at the 7- or 14-month visits. However, at
the 21-month visit, 6 months after he commenced participa-
tion in the BRAF inhibitor trial, assessment revealed signifi-
cantdermoscopic changes 16nevi (51%of total) (Figure 1). The
nevi changes predominantly involved involution and a de-
crease in pigmentation and size. In addition, in concurrence
with other reports,6 flattening of raised nevi was also ob-
served. By dermoscopic pattern, 4 reticular, 10 homoge-
neous, and 2 globular nevi showed signs of involution. There-
fore, 71%of theunspecificand26%of the reticularnevi showed
signs of involution, while both raised globular nevi de-
creased in pigmentation and flattened.
By the time of final imaging at 27 months’ surveillance
(12 months into the BRAF inhibitor trial), the nevi had gen-
erally not further changed, but 5 nevi had continued to
involute: 3 reticular and 2 homogeneous nevi. Again, no
increase in pigmentation was observed in any lesions, and
no new nevi were observed. The patient had an otherwise
excellent systemic response to the targeted therapy and an
excellent partial response to the point of almost a complete
response, with the exception of a small unchanged node
near the pancreas that was seen on computed tomographic
imaging.
There are a number of external and endogenous factors
influencing changes and appearance of nevi over time. These
include UV radiation exposure, hormonal changes associated
with pregnancy,10 and targeted melanoma therapies such as
selective BRAFV600E inhibitors.6 As unchanged and changed
nevi were at times adjacent at the same body site, UV expo-
sure was not considered to be a major influencing factor, and
Figure 1. Surveillance of Involuting Nevi During BRAFV600E Inhibitor Therapy and Clinical Image of Back
A F
B
C
D
E
Baseline 7 Months 14 Months 21 Months 27 Months
A-C, Three nevi have undergone involution 7months after initiation of
BRAFV600E inhibitor therapy. D and E, The other 2 nevi remain unchanged.
Excisional shave biopsies and numerous ex vivomicrobiopsies were performed
on nevi C and E. Images to the left of the vertical red line were obtained before
the patient commenced participation in the BRAF inhibitor trial; images to the
right of the line were obtained after he entered the trial. F, Clinical image of the
back shows nevi locations: white arrow indicates biopsied involuting nevus;
white circles indicate involuting nevi; black arrow indicates biopsied unchanged
nevus; black circles indicate unchanged nevi.
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Figure 2. Histopathologic Images andMolecular Sequencing Charts for BRAFV600E Status of 1 Involuting Nevus
and 1 Noninvoluting Nevus
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A-D, Workup of an involuting nevus.
E-H, Workup of a noninvoluting
nevus. C and G, Dermoscopic images
showmicrobiopsy sites 1 through 5
(scale bar = 1 mm); site 6 in each
panel is a control biopsy site adjacent
to the nevus. D and H, Molecular
analysis charts for microbiopsy sites
shown in panels C and G,
respectively. A and E, Histopathologic
images of the nevi, neither of which
shows any histopathological criteria
for melanoma (scale bars = 200 μm;
boxes enclose areas shown at higher
magnification in panels B and F). The
involuted nevus in panel A is a
benign, predominantly junctional
nevus with few discrete nests of
nonpigmented nevus cells at the
dermal-epidermal junction; subtle
lymphatic infiltration around
suprapapillary vascular plexus; and
no obvious signs of fibrosis or
regression; sequencing (D) reveals
that the nevus is heterogeneous for
BRAFV600Emutation at sites 1 and 5.
The noninvoluted nevus in panel E is
a benign lentiginous melanocytic
nevus with elongated pigmented rete
ridges and slightly increased numbers
of melanocytes at the
dermal-epidermal junction; small
junctional nests of melanocytes are
also present; and sequencing (H)
reveals no presence of BRAFV600E
mutation. B and F, Greater
magnifications of the boxed areas of
panels A and E, respectively (scale
bars = 200 μm).
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pregnancy cannot be considered in our male patient. There-
fore to sample molecular markers, specifically BRAF muta-
tion status of changed and unchanged nevi, we used a newly
described microbiopsy device.11-13
Diagnostic shave excisions were performed on 1 invo-
lutednevusand1unchangednevus (Figure 1). Thehistopatho-
logic diagnosis for the involuted lesion was a predominantly
junctional compound nevus without significant inflamma-
tion or fibrosis, and the unchanged lesion was characterized
as a junctional nevuswith a lentiginousmelanocytic pattern.
Microbiopsy specimens were taken from 6 locations on both
of theexcisednevi (Figure 2).DNAsamples extracted frommi-
crobiopsy specimens were subjected to polymerase chain re-
actionamplificationusingselectedforwardandreverseprimers
to flank the BRAF exon 15 and NRAS exon 2 mutation
hotspots.14Molecular sequencingof the samples forBRAFand
NRAS mutations were performed after extraction of ampli-
fied products from the DNA gel. Sequencing revealed hetero-
geneousBRAFV600Emutation inthe involutingnevusandBRAF
wild type in the unchanged nevus, while both lesions were
NRASwild type.
Discussion
The involutionofnevi inBRAFV600E inhibitor therapyhasbeen
reported, but herein we report findings that support the
hypothesis6 that thesenevi areBRAFV600E positive. This is re-
lated to decreased MAPK activity due to BRAF inhibition. In
contrast to reports in vemurafenib-treated patients of in-
creased size and pigmentation in some nevi and the appear-
ance of new BRAFwild-type melanoma through paradoxical
BRAF activation,15 we observed no increase in pigmentation
of nevi or suspect changes in our patient. Because we could
not knowwhether our dabrafenib-treatedpatientwas also re-
ceivingtrametinib,conclusionsregardingthecombinationregi-
men cannot be drawn. However, our long-term monitoring
prior to andduring therapy combinedwith confirmationof in-
voluting nevi possessing BRAFV600E mutation adds another
component to the dermoscopic changes in long-term therapy
withBRAFV600E inhibitors. Larger-scale and longer-term trials
will give a broader and more accurate description of specific
medication effects required for dermatologic follow-up.
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BRAFWild-TypeMelanoma In Situ Arising In a BRAFV600E
Mutant Dysplastic Nevus
Jean-Marie Tan, MB, BCh, BAO (Hons); Lynlee L. Lin, BSc; Duncan Lambie, BDSc, MBBS, FRCPA;
Ross Flewell-Smith, BCom, BEng; Kasturee Jagirdar, MSc; Helmut Schaider, MD; Richard A. Sturm, PhD;
Tarl W. Prow, BS, MSc, PhD; H. Peter Soyer, MD, FACD
I nitiation of malignant melanocytic proliferation throughactivationof themitogen-activatedproteinkinase (MAPK)pathwaymost commonly involves themutation ofmutu-
ally exclusive BRAF or NRAS.1 Constitutive activation of the
MAPK pathway drives subsequent expression of a variety of
oncogenes resulting in a transformedphenotype secondary to
cell growthpromotion.2BRAFmutational frequency inmela-
noma is commonly a substitution of valine by glutamic acid
at codon 600 (V600E),3 accounting for 74% to 90% of BRAF
mutations in thismalignantneoplasm.4TheBRAFV600Emu-
tation has also been detected in 73% to 82% of melanocytic
nevi, implicating this genemutation in the initiation ofmela-
nocytic neoplasia.1,2
The role of the BRAFmutation in the current genetic ba-
sis ofmelanomadevelopment andprogression is basedon the
Clarkmodel formelanomaprogression,5 corresponding to the
proposedmorphologic changes fromabenignnevus to a dys-
plastic nevus to amelanoma.6 Thus, an alternative divergent
molecularpathwaygeneticmodelhasbeenproposed forBRAF
or NRAS wild-type melanomas, developing possibly by acti-
vationof cell-cycle regulatory genes serving independent on-
cogenic function.2Wehereindescribe thephenotypic charac-
teristicsandhighlight themolecular complexityofamelanoma
in situ arising within a dysplastic nevus via dermoscopy-
targeted sampling and genotyping using a miniaturized bi-
opsy device.
Report of a Case
This study was approved by the Princess Alexandra Hospital
human research ethics committee. Thepatient providedwrit-
ten informed consent in accordance with the Declaration of
Helsinki.
Aman in his 50swith Fitzpatrick skin type II and a family
historyofmelanomapresentedwitha5 × 3-mmirregularlypig-
mentedmelanocytic lesion onhis left lower back detected on
routineskinexamination.Thepatientunderwent imagingwith
the FotoFinder system (FotoFinder Systems Inc) of all nevi
larger than 5 mm and also those between 2 and 5 mm on the
back as part of a study on nevus morphology.7 The total nevi
count was 42, with 36 nevi on the back and 6 nevi on the rest
IMPORTANCE The BRAF V600Emutation accounts for themajority of BRAFmutations found
in cutaneous melanoma and is also commonly found in nevi. We used dermoscopy-targeted
sampling and amicrobiopsy device coupled with DNA sequence analysis to highlight BRAF
V600E heterogeneity within a multicomponent melanocytic proliferation. This sampling
technique demonstrates the prospect of in vivo application in a clinical setting.
OBSERVATIONS Aman in his 50s with Fitzpatrick skin type II presented with an irregularly
pigmentedmelanocytic lesion on his back that met melanoma-specific dermoscopic criteria,
and diagnostic shave excision of the lesion was performed. Histopathologic analysis revealed
amelanoma in situ arising in a dysplastic nevus. Dermoscopy-targetedmicrobiopsy
specimens were taken across the lesion, and genotyping was carried out on extracted DNA
samples for BRAF and NRASmutations. Themelanoma in situ showed only BRAFwild-type
results, while the dysplastic nevus showed both BRAFwild-type and BRAF V600Emutations.
Sequencing in all DNA samples revealed NRASwild-type genotype.
CONCLUSIONS AND RELEVANCE Dermoscopy-targeted sampling and genotyping of a
melanoma in situ arising in a dysplastic nevus revealed a phenotype-genotype paradox that
confounds the exclusive significance of BRAF and NRASmutations in melanoma
pathogenesis. Further studies are required to investigate the importance of other candidate
genes linked tomelanomagenesis.
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of the body; 35 of 36 of the nevi on the back measured be-
tween2and5mm.Thepatient’s germlineMC1Rgenotypewas
wild-type.
Dermoscopy unveiled a pigmented macule with multi-
component pattern (Figure 1A, Figure 2A, and Figure 3A)—a
normal reticularpatternonthe left sideof the lesion, somecon-
fluent blue areas at the center of the lesion, and a well-
circumscribed areameasuring 1 × 1mmand characterized by
anatypical pigmentnetworkanda few irregular streakson the
right side of the lesion at the 4-o’clock corner. The lesionmet
the 3-point checklist criteria for a melanoma with the pres-
enceof 2 features in that it hadasymmetry andanatypical pig-
ment network. It also showedmelanoma-specific local crite-
ria (atypical pigment network and irregular streaks), and so a
diagnostic shave excision of the lesion was performed.
Theexcised lesionwasevaluatedby2 independentboard-
certified dermatopathologists (D.L. and H.P.S.). Histopatho-
logic findingsof the left sideof the lesionwere consistentwith
adysplastic nevus characterizedby elongatedpigmented rete
ridges, discrete nests ofmelanocytes, and few singlemelano-
cytesmostly along thedermoepidermal junction correspond-
ing with the typical pigment network seen on dermoscopy
(Figure 1). Similar morphologic findings were present at the
center of the lesion with evidence of amplemelanophages in
thepapillarydermis accounting for the subtleblueareasnoted
ondermoscopy (Figure2).Histopathologic analysisof the right
sideof the lesion revealed features suggestiveof anearlymela-
noma in situ characterized by an increased number of atypi-
Figure 1. Dermoscopy and Hematoxylin-Eosin–Stained Histopathology
Images Corresponding to the Left Side of the Subject Lesion
A
B
C
1 mm
200 µm
100 µm
A, Circled area of the dermoscopy image reveals a normal reticular pattern
without any dermoscopic criteria suggestive for melanoma; dermoscopy-
targetedmicrobiopsy samples were taken from this circled area; vertical line
corresponds to the site of the specimen shown in panel B. B, Photomicrograph
of the histologic specimen reveals a rather conventional dysplastic nevus; boxed
area corresponds to themagnified area shown in panel C. C, Higher
magnification of the boxed section displays elongated pigmented rete ridges,
discrete nests of melanocytes, and few single melanocytes, mostly along the
dermoepidermal junction; a microbiopsy defect can be seen in this frame
(arrowhead).
Figure 2. Dermoscopy and Hematoxylin-Eosin–Stained Histopathology
Images Corresponding to the Center of the Subject Lesion
A
B
C
200 µm
1 mm
100 µm
A, Circled area of the dermoscopy image reveals a slightly more pigmented
typical pigment network and subtle blue areas; dermoscopy-targeted
microbiopsy samples were taken from this circled area; vertical line corresponds
to the site of the specimen shown in panel B. B, Photomicrograph of the
histologic specimen reveals a dysplastic nevus without any remarkable
histopathologic findings; boxed area corresponds to themagnified area shown
in panel C. C, Higher magnification of the boxed section exhibits a slightly
increased number of melanophages in the papillary dermis, most probably
reflecting the subtle bluish pigmentation at the center of the lesion.
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cal melanocytes at all levels of the epidermis corresponding
to the well-circumscribed area at the 4-o’clock corner arising
in an otherwise conventional predominantly junctional dys-
plastic nevus (Figure 3).
We used a new miniaturized biopsy device to sample le-
sional tissue for molecular analysis.8 This sampling tech-
nique has been shown not to cause significant disruption to
the lesionarchitectureandthuswouldnotcompromise thehis-
topathologic assessment.9,10 First, a transparent plate with a
pinhole was coupled with a dermoscope to visualize the de-
sired area for sampling. The dermoscope was removed once
the areawas identified through the pinhole, leaving the plate
in contactwith the lesion and rendering the area for sampling
accessible to the biopsy device microneedle. The microbi-
opsy device applicator was then aligned with the pinhole al-
lowing for targeted samplingof the tissue. Threedermoscopy-
guided microbiopsy specimens were taken from each of the
described dermoscopic areas in the excised lesion using this
technique (Figure 4A).
Samples ofDNAwere extracted from themicrobiopsy tis-
sue specimens using the QIAamp DNAMicro Kit followed by
whole genomic amplification carried outwith REPLI-g Single
Cell Kit according tomanufacturer’s protocols (QIAGEN). The
quality and integrity of amplifiedDNAwasvalidatedusing the
Bioanalyzer DNA 12000 kit (Agilent Technologies Inc). Gene-
specific forward and reverse primers flanking BRAF exon 15
and NRAS exon 2 mutation hotspots were used for poly-
merase chain reaction.10,11 Sanger sequencing was then car-
ried out on the DNA amplified products for BRAF and NRAS
mutationdetection,withBRAFV600Emutationdetectioncon-
firmedusing aMALDI-TOFmass spectrometry assay (eFigure
in the Supplement).
Themicrobiopsy-extractedDNAsamples fromthe left side
and center of the lesion revealed BRAFV600E heterogeneity,
while no BRAF V600E mutation was found in any of the
samples taken fromthemelanoma in situ (Figure4B).Ofnote,
molecular sequencingof allmicrobiopsy specimensacross the
lesion revealed noNRASmutation at codon 61. Thus, somatic
genomicprofiling andmolecular landscapingof this lesion re-
vealed theparadoxical findingofamelanomainsituwithBRAF
wild-typeDNAarising in adysplasticnevusheterogeneous for
the BRAF V600Emutation.
Discussion
Wedescribe herein the use of aminiaturized biopsy device to
evaluate a melanoma in situ with a BRAF wild-type DNA se-
quencedevelopingwithin a heterogeneousBRAFV600Emu-
tant dysplastic nevus. A dermoscope was used as a targeting
tool to improvethesamplingofdistinctdermoscopicareas from
within this multicomponent lesion. We observed that all
samples from themelanoma in situ were concordantly BRAF
wild-type, whereas the BRAF V600E mutation was detected
in the other 2 dermoscopic areas within the same melano-
cytic lesion.
Mutation of the BRAF gene in melanoma arising within
nevi was recently studied using DNA extraction of 1 or mul-
tiple laser-capture-microdissected, formalin-fixed, paraffin-
embedded, 5-μm-thick histologic sections that were hema-
toxylin-eosin stainedand thensubjected toSanger sequencing
and immunohistochemical analysis.11 This study observed 5
cases (about11%)ofBRAFwild-typesuperficial spreadingmela-
noma adjacent to a BRAF V600E mutated nevus, which was
not statistically significant. Additionally, the investigators
foundmelanoma-associated nevi to be either strictly dermal
or compound type, leading Tschandl et al11 to conclude that
theirphenotypic andgenotypic findingsdidnotmirror the tra-
ditional model of stepwise tumor progression. In compari-
son,wewere able to demonstrate this phenomenon in a thin-
ner melanoma using dermoscopy-targeted sampling with a
microbiopsy device coupledwithDNA sequence analysis, ac-
centuating the potential role of this minimally invasive tech-
Figure 3. Dermoscopy and Hematoxylin-Eosin–Stained Histopathology
Images Corresponding to the Right Side of the Subject Lesion
A
B
C
200 µm
1 mm
100 µm
A, Circled area of the dermoscopy image displays a 1 × 1-mmwell-circumscribed
area with an atypical broadened pigment network and irregular streaks at the
4-o’clock corner; dermoscopy-targetedmicrobiopsy samples were taken from
this circled area; vertical line corresponds to the site of the specimen shown in
panel B. B, Photomicrograph of the histologic specimen reveals features
suggestive of an early evolving melanoma in situ arising within a dysplastic
nevus. C, Higher magnification of the boxed section shows architectural
disarray with predominantly single atypical melanocytes at all levels of the
epidermis.
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nique in providing insight into intralesional heterogeneity in
melanocytic lesions in vivo.12Moreover, thephenotypic char-
acteristics of our melanocytic lesion fits with the Clark clini-
copathologic model in that the melanoma developed within
a dysplastic nevus,6 though this is undermined by the para-
dox in our lesion’s genetic signature.
Although histopathologic criteria have traditionally been
the practical reference standard in melanoma diagnosis and
staging, recent discovery of tumors harboring different onco-
genicmutationshas implicated theexistenceofmolecular sub-
groupsofmelanoma.2Theevaluationofearly cutaneousmela-
nomas in particular would benefit from a shift toward an
integratedphenotype-genotypemelanomaclassification sys-
tem, insteadof usingmorphologic criteria alone, because this
enables future development of melanoma-specific biomark-
ers toaid inmelanomadetection independentofdisease stage.
Othercandidategenes linkedtomelanomagenesis suchascKIT,
GNAQ,GNA11,RAC1,TERT,PTEN,andNF113 remain tobestud-
ied in the lesion described herein.
Similarly,BRAF andNRAS genemutations have been used
asgeneticmarkers instudiesattemptingto integrategeneticand
morphologic features to improvemelanoma classification.14,15
However, thehighconcordance rate (80.4%)ofBRAFmutation
betweenmelanomaand its associatednevus counterpart dem-
onstrated by Tschandl et al11 as well as the occurrence ofBRAF
wild-type melanoma arising in a BRAF V600E mutated nevus
suggest that other molecular signatures are involved in mela-
nomadevelopment. Onemay argue that our findingsmight re-
sult from themicroneedle deviating from the exact desired lo-
cation despite an attempt to improve sampling accuracy using
a dermoscope, as well as the remote possibility that the mi-
croneedle did not sample melanocytes and so consequently
yielded the wild-type sequence. Nonetheless, conventional
methods such as laser-capture microdissection also present a
probability of not sampling BRAF-mutantmelanocytes.
Conclusions
Our observation supports other reports on the limitations of
currentmelanomabiomarkers in deconstructing themolecu-
lar events responsible for tumorigenesis. Further large-scale
studiesare required to investigate thesignificanceofothercan-
didategenes linkedtomelanomagenesis.Translationofamini-
mally invasive invivomicrobiopsydevice insampling formela-
noma-specific biomarkers may have a prospective role in the
nextphaseofmelanomadiagnosis, risk stratification, andper-
sonalized therapeutics.
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Figure 4. Three Sampled Sectors of the Subject Lesion and Their Corresponding BRAFV600EMutation Status
C C CA A A A A A A A A A A A A A A A AT T T T T TG G G G G G
Codon 600 Codon 600 Codon 600
Area I Area II Area III
I II III
A
B
A, Dermoscopy image specifying the
locations where microbiopsy samples
were taken from each dermoscopic
area (circles) of the subject lesion
with the aid of a dermoscope; area I
corresponds to Figure 1; area II, to
Figure 2; and area III, to Figure 3. B,
Representative chromatograms
corresponding to areas I, II, and III of
the lesion, as shown in panel A; BRAF
V600Emutation was detected in
areas I and II (highlighted as A/T in
the boxed areas); conversely, no
mutation was detected in area III.
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A Plea for Biobanking of All Equivocal
Melanocytic Proliferations
H. Peter Soyer, MD, FACD; Lynlee L. Lin, BSc; Tarl W. Prow, PhD
In 2005, in an editorial in the Archives of Dermatology (now
JAMADermatology), wemade a plea for a combined diagnos-
tic approach tohistopathologic anddermoscopic evaluation.1
Weconcludedoureditorialwith the followingstatement1 (p211):
Histopathology, as every other purelymorphologicmethod,
is limited by methodologic drawbacks and sometimes by prac-
titioners’ personal limitations.Todayweareon the edgeofanew
biology in histopathology, and one can foresee that our beloved
classic morphology will soon be replaced by new technologies.
In themeantime, a combinedmorphologic approach linkingder-
moscopy and histopathology might be helpful for pathologists
to come tomore reliable diagnostic conclusions for patients and
their physicians.
And it is encouraging to see that indeed there is an increased
awareness by colleagues dealing with problematic and bor-
derline melanocytic proliferations that has led to a more re-
fined clinicodermoscopic and pathologic approach in the in-
terpretation of these lesions.
In the present editorial, we take the opportunity to make
anotherplea,namely, aplea forbiobankingofall equivocalme-
lanocytic proliferations. This plea is based on our interpreta-
tionof thepioneering studybyMalvehyandcolleagues2 in this
issue of JAMA Dermatology.
This original morphologic
study combining expertise in
dermoscopy and dermatopa-
thology will doubtless lead to a redefinition of the way tradi-
tional gross pathologic procedures are carried out for equivo-
cal pigmented skin lesions. We commend the authors of this
seminal, albeit contested, work, and we agree with them that
highlyspecializedprovidersof skinpathologicanalysiswill em-
bracemore advanced sampling technologies that usedermos-
copy guidance in the future, thus reflecting the paradigmatic
shift fromconventional surgicalpathologicanalysis tomolecu-
larpathologicanalysis, inorder toremaincompetitiveand,most
importantly, do themost good for our patients.
Why Biobanking?
The new credo of personalizedmedicine has already reached
dermato-oncology, and more and more of our patients with
melanomaareno longer asking about their prognosis or about
an estimated survival time but whether their melanoma is a
BRAF melanoma. Whereas this specific query can be an-
swered rather easily by performing, for example, the cobas
4800BRAFV600MutationTest (Roche)on formalin-fixedpar-
affin-embedded samples, there is a growing need for frozen
tissue samples for thosemolecular andgenetic tests thatmight
be available by the time today’s primary melanomametasta-
sizes in 5 or 10 years’ time. There is no doubt that biobanking
is one of the central tools for clinical and translational
medicine.3 The challenge is, of course, to organize the bio-
bank samplingwithminimaldisruption to thebusydailyprac-
ticeofdealingwithpatientswithmelanomasandclinically sus-
picious pigmented skin lesions. Malvehy and colleagues2
correctly note that their sophisticated protocol for biobank
sampling has been developed for “experienced research cen-
ters.” Of interest is a recent publication by Caenazzo and
colleagues4 on the ethical issues of balancing the rights of the
individual and the interest of society in biobanking research
on oncological residualmaterial. Biobank research cannot be
conducted without considering arguments for obtaining the
donors' consent.Theauthorsdescribedthetypeofconsent that
“would be appropriate in this context, considering the ethi-
cal principles of donation, solidarity, protection of the do-
nors' rights and the requirements of scientific progress.”4 The
authors concluded that an important ethical aspect in regard
to the role of biobanking is the need to encourage sample
donation.
Dermoscopy, Dermatopathology, and Targeted Sampling
The “ex vivo dermoscopic-oriented sampling of melanoma”
protocol has been designed in close collaboration by a group
of dermatologists and dermatopathologists, all of them with
great expertise in dermoscopy, with the specific aim of not
jeopardizing the conventional histopathologic diagnosis.
The protocol includes conservation of the thickest part of
the lesion for measuring the Breslow index. The authors
nicely showed that by creating a “dermoscopic melanoma
map” they were able to successfully sample the nonthickest
part of the lesion and also avoided sampling areas that con-
tain dermoscopic melanoma-specific features whose
absence could interfere with the dermatopathologist’s ability
to render a conclusive diagnosis. Unfortunately, their tar-
geted sampling protocol excludes small melanomas, dermo-
scopically equivocal lesions, and other melanocytic lesions
for which they suspect that the histopathologic evaluation
may prove difficult. The authors fear that insufficient mate-
rial will be provided for the pathological assessment and that
this may lead to clinical and medicolegal consequences.5
Also, the issue of shave biopsies or saucerizations was not
mentioned at all. Only completely excised lesions can be
included. All these exclusion criteria are, in our estimation,
serious limitations for the purpose of “biosampling” even in
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a highly specialized melanoma center because as many sus-
picious melanocytic skin proliferations as possible should be
biosampled. However, one can imagine that, inspired by this
original and authentic work by Malvehy and colleagues,2
several dermatology and/or pathology teams worldwide will
come up with their own solutions and protocols for molecu-
lar sampling of suspicious melanocytic proliferations.
Microbiopsies forMolecular Sampling
Recently, we have developed a submillimeter skin punch bi-
opsy device forminimally invasive and suture-free skin sam-
pling that extracts approximately 1500 keratinocytes and 5 to
10 ng DNA and RNA for molecular diagnosis in dermatology
and dermato-oncology (L. L. Lin, BSc; T. W. Prow, PhD; A. P.
Raphael, PhD; R. L. Harrold III, MD; C. A. Primiero, BSc; A. B.
Ansaldo, BE; H. P. Soyer, MD, FACD; unpublished data; May
2013). Our microbiopsy device is 0.50 mmwide and 0.15 mm
thickandresults ina0.21 ± 0.04-mm-widepuncturesite invol-
unteer skin as measured using reflectance confocal micros-
copy. In a research letter in this issue of JAMA Dermatology,
we have demonstrated theminimal impact that the choice of
microbiopsysitehasonthehistopathologicdiagnosisofagiven
melanocytic proliferation.6 The size of microbiopsy defects
measured in this study was comparable to those of other ar-
tifactsmoreor less commonly seen in routine sectioned speci-
mens, and the inherent diagnostic difficulties for the derma-
topathologistencounteredwiththehistopathologicassessment
of amicrobiopsiedmelanocytic skin lesion can easily be over-
come by ordering of multiple levels.
Synopsis and Utopia
Microbiopsy devices have already been developed for breast
and intestinal tissue on the basis of the step change advances
in micromanufacturing and in molecular and genetic testing.
The ingenious outcomes are meaningful analyses that can be
obtained nowadays even froma few cells.We foresee thatmi-
crobiopsieswill become a feasiblemolecular sampling option
forbiobankingofequivocalmelanocyticproliferations, andbe-
cause of the simplicity of the sampling procedure, a multi-
tude of melanocytic lesions can be biobanked easily in due
course. In addition, the use of these samples can be maxi-
mized with nucleic acid amplification followed by whole ge-
nome and transcriptome sequencing that will be made open
source, thereby creating a sort of virtual biobank in the cloud
in the spirit of theubiquitousbigdata concept. If only 1or a few
expert laboratories in collaborationwith a fewmelanomacen-
tersdoesthis,ourpatientswillbenefit throughopensourcedata
analysis linking the microbiome, virome, genome, transcrip-
tome, and thenoncodingRNAworldwith the clinical andder-
moscopicphenotypes. Suchanapproachwill probably change
our understanding of the enigmatic and so often fateful na-
ture of melanocytic proliferations to the better. One possible
outcomemaybe amolecular profile assigned to a specific der-
moscopic morphology, ie, a molecular imaging profile, that
could give us insight into themolecular pathologic character-
istics of a lesion using just dermoscopy imaging. Biobanking
ofmelanomasandequivocalmelanocyticproliferationswill lose
its research status soon and become a standard of care in der-
mato-oncology as an integral part of personalizedmedicine.
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High-throughput sequencing and bioinformat-
ics are laying bare the molecular mechanisms 
of disease [1,2]. This rapidly expanding founda-
tion of knowledge is supporting the evolution 
of targeted molecular medicine in oncology. 
Although targeted molecular medicine is at a 
relatively early stage, the future of oncology 
will likely have a strong personalized treatment 
component [3–5]. We have recently developed the 
first submillimeter skin microbiopsy device to 
be used in patients and foresee this technology 
enabling personalized dermato-oncology [6,7].
Personalized oncology is a recent diagnos-
tic and treatment-based clinical approach that 
addresses the issues of intra- and inter-tumor 
heterogeneity within the scope of personalized 
medicine [3–5]. If we look at recent reports on 
inter- and intra-tumor heterogeneity of squa-
mous cell carcinoma/melanoma it is conceiv-
able that targeted drug development will make 
individualized care commonplace, but this can 
only happen by first identifying the molecu-
lar signatures and targets within lesions [8,9]. 
Mutations can cause changes in cell signaling 
and molecular interactions that result in trans-
formation. The resulting uncontrolled prolif-
eration results in an unstable genome that can 
give rise to the evolution of unique transformed 
cell clones within a given lesion, also known as 
intratumor hetero geneity. This is well known in 
melanoma, but there is also evidence that sup-
ports the hypothesis that this can occur in non-
melanoma skin cancer [10]. Similar circumstances 
can lead to intertumor heterogeneity, such as two 
melanomas with different mutations in the same 
person. This facet of cancer biology has direct 
consequences for tumor diagnostic markers and 
the clinical thera peutic outcome. The concept of 
personalized dermato-oncology is predicated on 
the capacity to identify and treat based on the 
presence of a validated biomarker [5]. 
One example of this principle in dermato-
oncology can be found in melanomas with the 
BRAF V600E mutation, reviewed in [4] and [11]. 
Not all melanomas have this mutation, but if one 
does, then vemurafenib, a US FDA-approved 
specific signaling pathway inhibitor, can be used 
to target the metastases of the particular mela-
noma harboring the BRAF V600E mutation [12]. 
Today’s clinical reality is that the primary mela-
noma lesion is excised before the BRAF status is 
known and that information is used to treat the 
metastatic tumors. In the future, a microbiopsy 
could be taken from every naevi, clinically more 
or less suspicious, and a prognostic biomarker 
can be assessed to determine the likelihood of 
transformation and the precursor or even the 
primary lesion treated before metastasis occurs. 
As a rule, skin cancer is currently identified 
by morphological assessment. This can be as 
simple as looking at a lesion with the trained 
eye of a dermatologist or using dermoscopy, a 
non invasive diagnostic technique that enables an 
experienced clinician to perform direct micro-
scopic examination of the surface and architec-
ture of a given skin lesion or histopathologic 
examination following excision of the lesion 
[13]. The latter represents the current diagnostic 
gold standard. In both scenarios, the derma-
tologist or dermato pathologist require there to 
be cancer already present and cannot visually 
identify the crucial molecular signatures that can 
be used to determine whether one or the other 
highly specific signaling inhibitors will be ben-
eficial. This is one case that supports the use of 
a tiny molecular sampling device coupled with 
validated biomarkers for melanoma.
Nonmelanoma skin cancer is far more preva-
lent, especially in organ transplant patients [14], 
and more costly compared with melanoma, 
albeit with a much lower incidence of mortal-
ity. Sun-damaged and/or transplant patients 
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can present with many precancerous actinic 
keratoses, some of which will progress into an 
overt squamous cell carcinoma. Selecting a few 
of the many lesions that are most suspicious for 
biopsy and histopathology can be a daunting 
task. There are also significant cosmetic chal-
lenges that cannot be ignored because actinic 
keratoses are present on sun-exposed areas, such 
as the face. In this arena, a tiny biopsy device 
could yield molecular signature data capable of 
being used to assess the presence of transformed 
cells or the potential for neoplastic transform-
ation. However, this improvement in patient care 
is dependent on validated biomarkers and the 
development/approval of new targeted therapies.
“With a microbioposy-based approach 
to collect just a few cells from a lesion 
repeatedly over time, without destroying 
that lesion, a new dimension of 
biological replication is now possible.”
Thus, the clinical promise of microbiopsy 
is early detection, risk assessment and to aid 
therapeutic selection. Recently, we developed a 
microbiopsy device for rapid, minimally inva-
sive and suture-free sampling and we foresee 
several research applications in dermatology 
far beyond dermato-oncology. The challenge 
is to define informative molecular signatures, 
similar in principle to the morphological signa-
tures elaborated in conventional histopathology 
nearly a century ago, in order for this approach 
to effectively diagnose melanoma/skin cancer 
with a higher diagnostic accuracy [15]. We envi-
sion that the future adoption of the microbiopsy 
will be guided by the use of the device in the 
clinical research arena. We are using the term 
‘biomarker’ as a relatively broad descriptor for 
one or more molecular signatures from only 
the primary lesion that can be used to iden-
tify whether a disease is present, predict clini-
cal outcome or predict the response to targeted 
molecular therapies – that is, diagnostic, prog-
nostic or therapeutic biomarkers. This field is 
more mature in other areas of oncology, but is 
relatively young in dermato-oncology, with the 
main driver being improved survival in mela-
noma. However, the significant cost and com-
mon drug resistance over time are important 
sources of controversy [16]. 
The microbiopsy approach is currently used in 
other oncology specialities, such as breast cancer 
[17], but not for skin cancer, where conventional 
biopsies range from 2 to 4 mm. This size range is 
key for enabling histopathological diagnosis. The 
outstanding question is of the value of molecu-
lar profiling in the treatment cycle. Oncogene 
mutations are clues that can help predict the 
disease course. The immune system function is 
inexorably tied to the suppression of skin can-
cer and the usefulness of immunotherapy [14]. 
Therefore, this area of research could become 
essential for predicting risk, stratifying skin can-
cer and therapeutic effectiveness. The combina-
tion of oncogene mutations, expression profiles 
and immune-profiling may give a comprehensive 
overview of what processes are likely to occur and 
predict the likelihood of successful small mol-
ecule therapy. This could, in theory, all be car-
ried out with a single microbiopsy given the rapid 
advances in nanomedicine and bioengineering.
Mutational analysis can be performed on DNA 
or RNA, both have the capacity to be amplified 
with high fidelity [18]. Immune status can be 
assessed with very small protein samples with 
cytometric bead arrays or indirectly character-
ized by examining RNA expression profiles. One 
example is the positive correlation of CXCL8 
with melanoma progression [19]. There are many 
research publications with putative biomarker 
lists for both melanoma and nonmelanoma skin 
cancers. The significant challenge is to standard-
ize profiles in a similar way to histopathological 
analysis of lesion morphology. 
“We foresee microbiopsy-enabled 
elaboration of molecular profiling for 
early skin cancer diagnosis/prognosis 
and the identification of therapeutic 
targets as the future of 
dermato-oncology research.”
Research is moving at a hurried pace towards 
the goal of molecular diagnosis. Conceptually, 
one of the stumbling blocks is that the transfor-
mation from a functional skin cell to an anarchic 
cancer cell is a continuum. The use of a micro-
biopsy approach will open new doors for research 
in the field of molecular skin pathology. Paradox-
ically, we seem to know genetic markers for rare 
diseases, but not common ones. Therefore, stud-
ies on common skin cancers could reveal critical 
information for diagnostics, prognostics and tar-
geted therapeutics. With a microbioposy-based 
approach to collect just a few cells from a lesion 
repeatedly over time, without destroying that 
lesion, a new dimension of biological replica-
tion is now possible. Collecting cells from many 
lesions in an animal model or a given patient 
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is also possible. These new avenues of research 
enable scientists to look even more closely at the 
molecular mechanisms of disease as it unfolds. 
However, smaller samples require sensitive assays 
and selective targeting. The application of our 
device captures approximately 1600 keratino-
cytes, from which 5 ng of RNA or DNA can 
be isolated. This is more than the picograms of 
genetic material isolated from single cells, but 
less than the micrograms of genetic material we 
isolate from convention biopsies.
It is also important to note that environ-
mental factors, such as sunlight exposure and 
micro biome, can play significant roles in cancer. 
Sun-damaged skin is the fertile soil for the for-
mation of actinic keratoses. The transformation 
of this precursor lesion into a squamous cell car-
cinoma could be tied to bacteria/viruses living 
on the skin. The skin produces antimicrobial 
peptides that have been shown to have altered 
expression levels in squamous cell carcinomas 
compared with actinic keratoses or normal skin 
[20]. The biodiversity of the skin microbiome 
could also be investigated with a microbiopsy-
based approach.
Conclusion
We have developed a skin microbiopsy device for 
quick, simple, minimally invasive and suture-free 
sampling for neoplastic and inflammatory skin 
diseases. We foresee microbiopsy-enabled elabo-
ration of molecular profiling for early skin cancer 
diagnosis/prognosis and the identification of ther-
apeutic targets as the future of dermato-oncology 
research. The long-term benefits of using micro-
biopsies in the laboratory and clinic are projected 
to be earlier detection of neoplastic skin diseases, 
more accurate prognosis estimates and targeted 
skin cancer therapy without all the nuisances 
related to conventional skin biopsies.
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